

GNE.3230R1C58

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Appellant : Goddard, et al.
Appl. No. : 10/063,584
Filed : May 3, 2002
For : SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME
Examiner : Rachel Kapust Hunnicutt
Group Art Unit : 1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 27, 2005

(Date)


AnneMarie Kaiser, Reg. No. 37,649

ON APPEAL TO THE BOARD OF PATENT APPEALS AND INTERFERENCES
APPELLANT'S BRIEF

Mail Stop Appeal Brief – Patents
COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Applicants appeal the rejection of Claims 1-5 in the above-captioned patent application. These claims were rejected in a Final Office Action dated December 28, 2004. Additional arguments were made and additional references were cited by the Examiner in an Advisory Action dated April 12, 2005. Applicants filed a Notice of Appeal April 27, 2005. Applicants file concurrently herewith an Amendment After Final Office Action, and a request for a 1-month extension of time.

I. REAL PARTY IN INTEREST

Pursuant to 37 C.F.R. 41.37(c)(1), Appellants hereby notify the Board of Patent Appeals and Interferences that the real party in interest is the assignee of record for this application, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.

08/02/2005 EFLORES 00000113 10063584

01 FC:1402

500.00 DP

BEST AVAILABLE COPY

Appl. No. : 10/063,584
Filed : May 3, 2002

II. RELATED APPEALS AND INTERFERENCES

A Notice of Appeal has been filed in the related Application No. 10/063578. Appellants are unaware of any other related appeals or interferences.

III. STATUS OF THE CLAIMS

The above-captioned application was filed with Claims 1-6. Claim 6 was canceled in an Amendment and Response to Office Action mailed November 3, 2004. Claims 1-5 were finally rejected by the Examiner in a final Office Action mailed December 28, 2004. Appellants file concurrently herewith an Amendment After Final Office Action amending Claim 1. Accordingly, Claims 1-5 are the subject of this appeal. The claims attached hereto as Appendix A reflect the claims as amended by the Amendment After Final Office Action filed concurrently herewith.

IV. STATUS OF AMENDMENTS

Appellants filed an "Amendment and Response to Final Office Action" on March 14, 2005, submitting the claims with no additional amendments, and offering additional evidence in support of Appellants' arguments. In an Advisory Action mailed April 12, 2005, the Examiner indicated that the proposed amendment and affidavit or other evidence would be entered for purposes of appeal. Appellants file concurrently herewith an Amendment After Final Office Action amending Claim 1.

V. SUMMARY OF THE CLAIMED SUBJECT MATTER

The claimed subject matter relates to isolated antibodies which specifically bind to the polypeptide having SEQ ID NO: 74. As amended, independent Claim 1 reads:

1. An isolated antibody that specifically binds to the polypeptide of SEQ ID NO: 74.

Various aspects of the claimed antibody are described in the specification at, for example, paragraphs [0024], [0225],[0238]-[0248], and [0361]-[0405]. SEQ ID NO: 74 is disclosed in the Sequence Listing appended to the application.

VI. GROUND S OF REJECTION TO BE REVIEWED ON APPEAL

The Examiner has rejected Claims 1-5 under 35 U.S.C. §101, stating that the claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility.

The Examiner has also rejected Claims 1-5 under 35 U.S.C. §112, first paragraph. The Examiner asserts that since the claimed invention is not supported by either a specific or substantial asserted utility or a well-established utility, one skilled in the art clearly would not know how to use the claimed invention.

VII. APPELLANTS' ARGUMENT

A. Utility Rejection

The first issue before the Board is whether Appellants have asserted at least one "specific, substantial, and credible utility." *See* Examination Guidelines ("Utility Guidelines"), 66 Fed. Reg. 1092 (2001). Appellants have asserted that the claimed antibodies to the polypeptide of SEQ ID NO: 74 (the PRO1335 polypeptide) are useful as diagnostic tools for cancer, particularly for stomach, lung, rectal, and skin cancer. This asserted utility is specific, substantial, and credible.

Briefly stated, Appellants' asserted utility is based on the disclosure in Example 18 of the instant application that the mRNA encoding the PRO1335 polypeptide is more highly expressed in normal stomach, lung, rectal, and skin tissue compared to stomach, lung, rectal, and melanoma tumor, respectively. It is well-established that there is a reasonable correlation between changes in mRNA level for a particular gene and a corresponding change in the level of expression of the encoded polypeptide, such that increasing or decreasing the amount of mRNA for a particular gene leads to a corresponding increase or decrease in the amount of the encoded protein. Thus, one of skill in the art would be more likely than not to believe that, like the PRO1335 mRNA, the PRO1335 protein is more highly expressed in normal stomach, lung, rectal, and skin tissue compared to stomach, lung, rectal, and melanoma tumor, respectively. This differential expression of PRO1335 polypeptide is useful for distinguishing stomach, lung, rectal, or melanoma tumor tissue from its normal tissue counterpart. Therefore, the claimed antibodies to

Appl. No. : 10/063,584
Filed : May 3, 2002

the PRO1335 polypeptide have a specific, substantial and credible utility as diagnostic tools for cancer, particularly stomach, lung, rectal, and skin cancer, as is explained in more detail below.

1. Utility – Legal Standard

A “specific utility” is defined as utility which is “specific to the subject matter claimed,” in contrast to “a general utility that would be applicable to the broad class of the invention.” See *M.P.E.P.* § 2107.01 I. For example, it is generally not enough to state that a nucleic acid is useful as a diagnostic tool without also identifying the condition that is to be diagnosed.

The requirement of “substantial utility” defines a “real world” use, and derives from the Supreme Court’s holding in *Brenner v. Manson*, 383 U.S. 519, 534 (1966) stating that “[t]he basic *quid pro quo* contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility.” In explaining the “substantial utility” standard, *M.P.E.P.* § 2107.01 cautions, however, that Office personnel must be careful not to interpret the phrase “immediate benefit to the public” or similar formulations used in certain court decisions to mean that products or services based on the claimed invention must be “currently available” to the public in order to satisfy the utility requirement. “Rather, any reasonable use that an Appellant has identified for the invention that can be viewed as providing a public benefit should be accepted as sufficient, at least with regard to defining a ‘substantial’ utility.” *M.P.E.P.* § 2107.01 (emphasis added).

Indeed, the Guidelines for Examination of Applications for Compliance With the Utility Requirement, set forth in *M.P.E.P.* § 2107 II(B)(1) gives the following instruction to patent examiners: “If the Appellant has asserted that the claimed invention is useful for any particular practical purpose ... and the assertion would be considered credible by a person of ordinary skill in the art, do not impose a rejection based on lack of utility.”

Finally, in assessing the credibility of the asserted utility, the *M.P.E.P.* states that “to overcome the presumption of truth that an assertion of utility by the Appellant enjoys” the PTO must establish that it is “more likely than not that one of ordinary skill in the art would doubt (i.e., ‘question’) the truth of the statement of utility.” *M.P.E.P.* § 2107.02 III A.

Appl. No. : 10/063,584
Filed : May 3, 2002

2. Utility – Burden of Proof

It is well established that a specification which contains a disclosure of utility which corresponds in scope to the subject matter sought to be patented “must be taken as sufficient to satisfy the utility requirement of § 101 for the entire claimed subject matter unless there is reason for one skilled in the art to question the objective truth of the statement of utility or its scope.” *In re Langer*, 503 F.2d 1380, 1391, 183 U.S.P.Q. 288, 297 (C.C.P.A. 1974). Thus “the PTO has the initial burden of challenging a presumptively correct assertion of utility in the disclosure.” *In re Brana*, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d 1436 (Fed. Cir. 1995). Only after the PTO provides evidence showing that one of ordinary skill in the art would reasonably doubt the asserted utility does the burden shift to the Appellant to provide rebuttal evidence sufficient to convince such a person of the invention’s asserted utility. *Id.*

3. Utility – Standard of Proof

Compliance with 35 U.S.C. § 101 is a question of fact. *Raytheon v. Roper*, 724 F.2d 951, 956, 220 U.S.P.Q. 592, 596 (Fed. Cir. 1983). The evidentiary standard to be used throughout *ex parte* examination in setting forth a rejection is a preponderance of the evidence, or “more likely than not” standard. *In re Oetiker*, 977 F.2d 1443, 1445, 24 U.S.P.Q.2d 1443, 1444 (Fed. Cir. 1992). This is stated explicitly in the M.P.E.P.:

[T]he Appellant does not have to provide evidence sufficient to establish that an asserted utility is true “beyond a reasonable doubt.” Nor must the Appellant provide evidence such that it establishes an asserted utility as a matter of statistical certainty. Instead, evidence will be sufficient if, considered as a whole, it leads a person of ordinary skill in the art to conclude that the asserted utility is more likely than not true. M.P.E.P. at § 2107.02, part VII (emphasis in original, citations omitted).

The Court of Appeals for the Federal Circuit has stated that the standard for satisfying the utility requirement is a low one:

The threshold of utility is not high: An invention is “useful” under section 101 if it is capable of providing some identifiable benefit. *See Brenner v. Manson*, 383 U.S. 519, 534, 86 S.Ct. 1033, 16 L.Ed.2d 69 (1966); *Brooktree Corp. v. Advanced Micro Devices, Inc.*, 977 F.2d 1555, 1571 (Fed. Cir. 1992) (“To violate § 101 the claimed device must be totally incapable of achieving a useful result”); *Fuller v. Berger*, 120 F. 274, 275 (7th Cir.1903) (test for utility is whether invention “is incapable of serving any beneficial end”). *Juicy Whip, Inc. v. Orange Bang, Inc.*, 185 F.3d 1364, 1366, 51 U.S.P.Q. 2d 1700 (Fed. Cir. 1999) (emphasis added).

Appl. No. : 10/063,584
Filed : May 3, 2002

The low threshold for satisfying the utility requirement is reflected in the standard set by the Federal Circuit for invalidating a patent based on a lack of utility: “[T]he fact that an invention has only limited utility and is only operable in certain applications is not grounds for finding lack of utility. Some degree of utility is sufficient for patentability. Further, the defense of non-utility cannot be sustained without proof of total incapacity.” *Envirotech Corp. v. Al George, Inc.*, 730 F.2d 753, 762, 221 U.S.P.Q. 473 (Fed. Cir. 1984) (emphasis added, citations omitted).

Because the standard for satisfying the utility requirement is so low, requiring total incapacity for a finding of no utility, the M.P.E.P. cautions that:

Rejections under 35 U.S.C. 101 have been *rarely* sustained by federal courts. Generally speaking, in these *rare* cases, the 35 U.S.C. 101 rejection was sustained [] because the Appellant ... asserted a utility that could only be true if it violated a scientific principle, such as the second law of thermodynamics, or a law of nature, or was wholly inconsistent with contemporary knowledge in the art. M.P.E.P. § 2107.02 III B., citing *In re Gazave*, 379 F.2d 973, 978, 154 U.S.P.Q. 92, 96 (C.C.P.A. 1967) (underline emphasis in original, italic emphasis added).

4. *Appellants Asserted a Specific, Substantial and Credible Utility that is Sufficient to Satisfy the Utility Requirement of § 101*

The claimed subject matter relates to antibodies which specifically bind to the polypeptide having SEQ ID NO: 74. The polypeptide of SEQ ID NO: 74 (referred to as “PRO1335 polypeptide”) is encoded by the polynucleotide of SEQ ID NO: 73 (also referred to as DNA62812-1594). *Specification* at ¶¶ [0099-0100]. Appellants have asserted that the claimed antibodies are useful as diagnostic tools for cancer, particularly stomach, lung, rectal, and skin cancer.

In “Example 18: Tumor Versus Normal Differential Tissue Expression Distribution” Appellants disclose that the mRNA encoding PRO1335 polypeptide is more highly expressed in normal stomach, lung, rectal, and skin tissue compared to stomach, lung, rectal, and melanoma tumor, respectively. *Specification* at ¶¶ [0529-0530] and accompanying tables. As explained in paragraph [0530], the differential expression of the PRO1335 mRNA was detected using the well-established technique of quantitative PCR amplification of cDNA libraries isolated from different human normal and tumor tissue samples. To ensure that equivalent amounts of nucleic acid were used in each reaction, the cDNA for β -actin was used as a control.

The specification teaches that identification of the differential expression of a PRO polypeptide-encoding nucleic acid in one or more tumor tissues as compared to one or more

Appl. No. : 10/063,584
Filed : May 3, 2002

normal tissues of the same tissue type “renders the molecule useful diagnostically for the determination of the presence or absence of tumor in a subject suspected of possessing a tumor.” *Specification* at ¶ [0530]. Similarly, Appellants disclose that PRO polypeptides “may also be used diagnostically for tissue typing, wherein the PRO polypeptides of the present invention may be differentially expressed in one tissue as compared to another, preferably in a diseased tissue as compared to a normal tissue of the same tissue type.” *Specification* at ¶ [0336]. Likewise, Appellants disclose the use of antibodies to PRO polypeptides as diagnostic tools:

[A]nti-PRO antibodies may be used in diagnostic assays for PRO [polypeptide], e.g., detecting its expression (and in some cases, differential expression) in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases. *Specification* at [0407].

Taken together, the specification clearly discloses the use of the claimed antibodies as diagnostic tools for cancer, particularly stomach, lung, rectal, and skin cancer. This utility is substantial, as one of skill in the art will recognize that the diagnosis of cancer is a “real world” use; it is specific, as the diagnosis of stomach, lung, rectal, and skin cancer is not a utility that applies to the broad class of antibodies; and it is credible, as it not a utility “that could only be true if it violated a scientific principle, ...or a law of nature, or [is] wholly inconsistent with contemporary knowledge in the art.” M.P.E.P. § 2107.02 III B., citing *In re Gazave*, 379 F.2d 973, 978, 154 U.S.P.Q. 92, 96 (C.C.P.A. 1967). Because Appellants’ specification contains a disclosure of utility which corresponds in scope to the claimed subject matter, the asserted utility “must be taken as sufficient to satisfy the utility requirement of § 101 for the entire claimed subject matter unless there is reason for one skilled in the art to question the objective truth of the statement of utility or its scope.” *In re Langer*, 503 F.2d 1380, 1391, 183 U.S.P.Q. 288, 297 (C.C.P.A. 1974). Therefore, the burden of establishing a *prima facie* case of lack of utility rests with the PTO. See, *In re Brana*, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d 1436 (Fed. Cir. 1995) (“the PTO has the initial burden of challenging a presumptively correct assertion of utility in the disclosure”).

5. *The Examiner’s Unsupported Arguments*

To establish a *prima facie* showing that the claimed subject matter lacks utility, the Examiner must “provide[] evidence showing that one of ordinary skill in the art would

Appl. No. : 10/063,584
Filed : May 3, 2002

reasonably doubt the asserted utility.” *In re Brana*, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d 1436 (Fed. Cir. 1995). The Examiner has filed a first Office Action, final Office Action, and an Advisory Action during the prosecution of the instant application. None of these papers provide any evidence that one of ordinary skill in the art would reasonably doubt the asserted utility.

In the first Office Action, dated August 3, 2004, the Examiner rejected the pending claims, stating “Claims 1-6 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility.” *First Office Action* at 3. The Examiner stated that “[t]he antibodies of the current invention bind to polypeptides comprising SEQ ID NO: 74. However, there is no utility for a polypeptide comprising SEQ ID NO: 74.” *Id.* The Examiner rejected several of the disclosed utilities for the claimed antibodies, including therapeutic uses of the antibodies, stating that “the specification does not disclose any diseases or conditions known to be associated with the encoded protein. Further research would be required to identify a disease in which the encoded protein is involved.” *Id.* at 3-4. The Examiner did not address the asserted utility of a diagnostic tool for cancer.

In a final Office Action dated December 28, 2004, the Examiner maintained her rejection of the pending claims “for the reason of record.” The Examiner stated that Appellants’ arguments made in an Amendment and Response to Office Action filed November 3, 2004, were fully considered, but were not persuasive. First, the Examiner argued that the data of Example 18 and a declaration entered to support the data were insufficient because they did not indicate how high the levels of expression were, how reproducible and reliable the results were, whether the results were statistically significant, or the nature or number of samples used. *Final Office Action* at 4. The Examiner also argued that one cannot determine if the observed “amplification” is due to an increase in chromosomal copy number or an increase in transcription rates. *Id.* The Examiner concluded that the disclosure “does not enable the skilled artisan to differentiate amongst expression levels in order to diagnose any disease.” *Id.*

The Examiner also argued that paragraph 4 of the second Grimaldi declaration (originally submitted as Exhibit 2) was not persuasive because unlike the genes discussed in the references cited in the declaration “The PRO1335 gene, ... has *not* been associated with tumor formation or the development of cancer, nor has it been shown to be predictive of such. Similarly, ... no translocation of PRO1335 is known to occur. ... No mutation or translocation of PRO1335 has

Appl. No. : 10/063,584
Filed : May 3, 2002

been associated with stomach, lung, rectal, or skin cancer.” *Final Office Action* at 4. The Examiner concluded that “[i]n the absence of any of the above information” the disclosure was insufficient to satisfy the requirements of § 101.

Finally, the Examiner stated that whether or not increased levels of PRO1335 mRNA correlate with increased levels of PRO1335 protein is not an issue. The Examiner stated that the declarations and cited references “do not establish a substantial utility for the claimed PRO1335 nucleic acid molecules. As stated above, the specification does not provide sufficient guidance to the skilled artisan to diagnose or treat any disease. Thus, there would be no specific utility for antibodies which bind to PRO1335 proteins.” *Final Office Action* at 5.

In response to the final Office Action, Appellants submitted an Amendment and Response to Final Office Action, mailed March 14, 2005, which included additional arguments and references in support of their initial Amendment. The Examiner issued an Advisory Action on April 12, 2005.

In the Advisory Action, the Examiner essentially repeated her previous unsupported arguments, stating that Appellants had not taught what kind of tumors could be diagnosed, the baseline levels of expression, or provided numerical values for the levels of overexpression and underexpression. The Examiner argued that “[m]erely stating that the nucleic acid is ‘more highly expressed’ is simply an invitation to experiment,” and one of skill in the art would not know how to use the claimed invention to diagnose tumors. *Advisory Action* at 2.

In response to Appellants’ arguments, declarations, and references stating that in general, there is a positive correlation between changes in mRNA and changes in the level of the encoded polypeptide, the Examiner cited Chen *et al.* (*Molecular and Cellular Proteomics*, 1:304-313 (2002)) for the first time. The Examiner argued that Chen *et al.* teach “that correlation between protein levels and mRNA expression in lung adenocarcinomas varies depending upon the protein.” *Advisory Action* at 2. Based on Chen, the Examiner concluded that “without further testing it cannot be assumed that mRNA levels correlate to protein levels.” *Id.*

6. **The Examiner has not established a Prima Facie case that Claims 1-5 lack Utility**

The above arguments do not satisfy the Examiner’s burden to “provide[] evidence showing that one of ordinary skill in the art would reasonably doubt the asserted utility.” *In re*

Appl. No. : 10/063,584
Filed : May 3, 2002

Brana, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d 1436 (Fed. Cir. 1995). The Examiner has the burden of presenting “countervailing facts and reasoning sufficient to establish that a person of ordinary skill would not believe the Appellant’s assertion of utility.” *M.P.E.P.* at §2107.02 III.A., *citing in re Brana*, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d 1436 (Fed. Cir. 1995) (“Only after the PTO provides evidence showing that one of ordinary skill in the art would reasonably doubt the asserted utility does the burden shift to the Appellant to provide rebuttal evidence”) (emphasis added). With the exception of the *Chen et al.* reference cited for the first time in the Advisory Action, the Examiner’s assertions are not supported by any facts or evidence, and as is explained below, *Chen* does not support the Examiner’s position. Therefore there is simply no evidence in the record to support her assertion that the disclosure “does not enable the skilled artisan to differentiate amongst expression levels in order to diagnose any disease.” Absent some evidence to support her assertions, the Examiner has failed to establish a *prima facie* showing that one of skill in the art would reasonably doubt the asserted utility, and the Board should accept Appellants’ disclosed utility as sufficient.

a. The data in Example 18 are sufficient to establish the asserted utility

Appellants turn first to the Examiner’s arguments challenging the reliability of the data reported in Example 18. The Examiner argues that Example 18 and the first declaration of Mr. Grimaldi are insufficient to overcome the utility rejection of the pending claims because they do not teach how high the expression level is, what the level of reproducibility or reliability of the data is, whether the results are statistically significant, or the nature or number of samples that were used. *Final Office Action* at 4; *Advisory Action* at 2. The Examiner also argues that one cannot determine if the observed “amplification” is due to an increase in chromosomal copy number or an increase in transcription rates. *Final Office Action* at 4. The Examiner concludes that the disclosure would not enable one of skill in the art to differentiate amongst expression levels to diagnose any disease. *Id.* None of these unsupported arguments are sufficient to establish a *prima facie* case that one of skill in the art would reasonably doubt the asserted utility.

The gene expression data in Example 18 of the specification show that the mRNA associated with protein PRO1335 was more highly expressed in normal stomach, lung, rectal, and skin tissue compared to stomach, lung, rectal, and melanoma tumor, respectively. See *Specification* at ¶ [0530] and accompanying tables. Gene expression was analyzed using standard quantitative PCR amplification reactions of cDNA libraries isolated from different

Appl. No. : 10/063,584
Filed : May 3, 2002

human tumor and normal human tissue samples. *Id.* It is well known in the art that the number of copies of a particular cDNA in the cDNA library is determined by the number of copies of the corresponding mRNA in the sample. Therefore, the cDNA libraries can be used to determine the level of expression of the corresponding mRNA in the tissue.

Appellants have asserted that identification of the differential expression of the PRO1335 polypeptide-encoding gene in tumor tissue compared to the corresponding normal tissue renders the molecule useful as a diagnostic tool for the determination of the presence or absence of tumor. *Id.* In support of this asserted utility, Appellants submitted as Exhibit 1 to their Amendment and Response to Office Action a first Declaration of J. Christopher Grimaldi, an expert in the field of cancer biology. This declaration explains the importance of the data in Example 18, and how differential gene and protein expression studies are used to differentiate between normal and tumor tissue. *See First Grimaldi Declaration.*

In paragraphs 6 and 7, Mr. Grimaldi explains that the semi-quantitative analysis employed to generate the data of Example 18 is sufficient to determine if a gene is over- or under-expressed in tumor cells compared to corresponding normal tissue. He states that any visually detectable difference seen between two samples is indicative of at least a two-fold difference in cDNA between the tumor tissue and the counterpart normal tissue. He also states that the results of the gene expression studies indicate that the genes of interest “can be used to differentiate tumor from normal.” He explains that, contrary to the PTO’s assertions, “[t]he precise levels of gene expression are irrelevant; what matters is that there is a relative difference in expression between normal tissue and tumor tissue.” *First Grimaldi Declaration* at ¶ 7.

This declaration makes clear that since it is the relative level of expression between normal tissue and suspected cancerous tissue that is important, how high the level of expression in normal tissue is, is irrelevant. As to the Examiner’s questions about the reliability and reproducibility of the results, Appellants employed standard techniques which are well-known and accepted by those of skill in the art. Mr. Grimaldi states that if a difference is detected using these techniques, “this indicates that the gene and its corresponding polypeptide and antibodies against the polypeptide are useful for diagnostic purposes...” *Id.* Thus, it is the uncontested opinion of an expert in the field that the results are reliable enough to indicate that the claimed antibodies are useful as diagnostic tools. As to the Examiner’s concerns regarding the number

Appl. No. : 10/063,584
Filed : May 3, 2002

and types of samples used, Mr. Grimaldi states that the samples are pooled samples of normal and tumor tissue. *Id.* at ¶ 5.

The Examiner has also rejected the data because she questions the statistical significance of the data. However, Appellants are not required to prove utility to a statistical certainty, only that it is more likely than not true. *See Nelson v. Bowler*, 626 F.2d 853, 856-57, 206 U.S.P.Q. 881, 883-84 (C.C.P.A. 1980) (reversing the Board and rejecting an argument that evidence of utility was insufficient because it was not statistically significant). Therefore, whether the results are statistically significant or not is irrelevant to establishing the asserted utility. Finally, the Examiner has failed to explain the relevance of whether the reported differential expression is due to an increase in chromosomal copy number or increased transcription rates. The cause of the differential expression is not relevant to whether the difference in expression can be used to distinguish tumor from normal tissue.

The data in Example 18 and the first Grimaldi Declaration are therefore sufficient to establish the asserted utility, and the Examiner has not rebutted the presumption of utility that the Appellants' application is afforded. Mr. Grimaldi is an expert in the field who conducted or supervised the experiments at issue. His declaration is based on personal knowledge of the relevant facts at issue. Appellants' have reminded the Examiner that "Office personnel must accept an opinion from a qualified expert that is based upon relevant facts whose accuracy is not being questioned." *M.P.E.P.* § 2107 (emphasis added). In addition, declarations relating to issues of fact should not be summarily dismissed as "opinions" without an adequate explanation of how the declaration fails to rebut the Examiner's position. *See in re Alton* 76 F.3d 1168 (Fed. Cir. 1996). The Examiner has offered no reason or evidence to reject either the underlying data or Mr. Grimaldi's conclusions. Therefore, the Examiner should accept Mr. Grimaldi's opinion with regard to his statement that "any visually detectable difference seen between two samples is indicative of at least a two-fold difference in cDNA between the tumor tissue and the counterpart normal tissue" and that the genes of interest "can be used to differentiate tumor from normal."

In conclusion, Appellants submit that the evidence reported in Example 18, supported by the first Grimaldi Declaration, establish that there is at least a two-fold difference in PRO1335 cDNA between stomach, lung, rectal, and melanoma tumor tissue and the normal stomach, lung, rectal, and skin tissue, respectively. Therefore, it follows that the PRO1335 gene, polypeptide, and antibody can be used to distinguish stomach, lung, rectal, and melanoma tumor tissue from

Appl. No. : 10/063,584
Filed : May 3, 2002

their normal tissue counterparts. The Examiner has not offered any significant arguments or evidence to the contrary, and therefore has not established a *prima facie* case that one of skill in the art would reasonably doubt the asserted utility.

b. The lack of a known role for PRO1335 in tumor formation or the development of cancer does not prevent its use as a diagnostic tool for cancer

Appellants turn next to the Examiner's argument that paragraph 4 of the second Grimaldi declaration (originally submitted as Exhibit 2 with the Appellants' Amendment and Response to Office Action) was not persuasive because unlike the genes discussed in the references cited in the declaration, "[t]he PRO1335 gene, ... has *not* been associated with tumor formation or the development of cancer, nor has it been shown to be predictive of such. Similarly, ... no translocation of PRO1335 is known to occur. ... No mutation or translocation of PRO1335 has been associated with stomach, lung, rectal, or skin cancer." *Final Office Action* at 4. The Examiner concluded that "[i]n the absence of any of the above information" the disclosure was insufficient to satisfy the requirements of § 101. *Id.*

The Examiner's arguments fail to establish that one of skill in the art would doubt Appellants' asserted utility. Once again, the Examiner has failed to establish how the "absence of any of the above information" is relevant to the asserted utility. The lack of a known role for PRO1335 in tumor formation or the development of cancer does not prevent its use as a diagnostic tool for cancer. Likewise, the fact that there is no known translocation or mutation of PRO1335 is irrelevant to whether its differential expression can be used to assist in diagnosis of cancer – one does not need to know why PRO1335 is differentially expressed, or what the consequence of the differential expression is, in order to exploit the differential expression to distinguish tumor from normal tissue.

The Revised Interim Utility Guidelines promulgated by the PTO recognize that proteins which are differentially expressed in cancer have utility. (See the caveat in Example 12 which state that the utility requirement is satisfied where a protein is expressed in melanoma cells but not on normal skin and antibodies against the protein can be used to diagnose cancer.) In addition, while Appellants appreciate that actions taken in other applications are not binding on the PTO with respect to the present application, Appellants note that the PTO has issued several patents claiming differentially expressed polypeptides and antibodies to the same, or methods

Appl. No. : 10/063,584
Filed : May 3, 2002

employing such antibodies. *See, e.g.*, U.S. Patent No. 6,414,117, U.S. Patent No. 6,124,433, U.S. Patent No. 6,156,500, and U.S. Patent No. 6,562,343.

In addition, Appellants note that they did not even rely on the portion of the second Grimaldi declaration cited by the Examiner. Instead, Appellants submitted the second Grimaldi declaration in support of the assertion that changes in mRNA are positively correlated to changes in protein levels. Appellants relied on paragraph 5 of the declaration which states: "Those who work in this field are well aware that in the vast majority of cases, when a gene is over-expressed...the gene product or polypeptide will also be over-expressed.... This same principal applies to gene under-expression." *Amendment and Response to Final Office Action* at 12, quoting *Second Grimaldi Declaration* at ¶ 5. As support for this statement, Mr. Grimaldi noted that "[t]echniques used to detect mRNA, such as Northern Blotting, Differential Display, *in situ* hybridization, quantitative PCR, Taqman, and more recently Microarray technology all rely on the dogma that a change in mRNA will represent a similar change in protein. If this dogma did not hold true then these techniques would have little value and not be so widely used." *Second Grimaldi Declaration* at ¶ 5. Whether the differential expression of mRNA is due to mutations or translocations has no bearing on the portion of the Grimaldi reference relied on by Appellants. The Examiner did not even address this portion of the second Grimaldi declaration until the Advisory Action.

c. ***The sole reference cited by the Examiner does not support the rejection of the pending claims***

Appellants turn next to Examiner's final argument and the sole reference cited by the Examiner to support her rejection.¹ In the Advisory Action, the Examiner cites Chen *et al.* as support for the assertion that the correlation between protein levels and mRNA expression in lung adenocarcinomas varies depending on the protein. The authors of the Chen reference examined the relationship between mRNA levels and protein levels in 76 lung adenocarcinomas and nine non-tumor lung samples.

As an initial matter, it is important to note that a portion of Chen is clearly not relevant to Appellants' assertion that changes in the level of mRNA lead to changes in the level of the

¹ Appellants question the propriety of citing a reference for the first time in an Advisory Action since they were afforded no opportunity to respond to the cited reference. Therefore, Appellants must present their response to the cited reference for the first time here.

Appl. No. : 10/063,584
Filed : May 3, 2002

encoded polypeptide. In one experiment, Chen examined the global relationship between mRNA and the corresponding protein abundance by calculating the average mRNA and protein level of all the samples for each gene or protein, and then looked for a correlation across different genes. Based on these data, Chen reported that “no significant correlation between mRNA and protein expression was found ($r = -0.025$) if the average levels of mRNA or protein among all samples were applied across the 165 protein spots (98 genes).” *Chen* at Abstract. This measurement of a correlation across genes is not relevant to Appellants’ asserted utility, and is apparently not relied on by the Examiner.

Chen also looked at the level of mRNA of 98 individual genes and their corresponding proteins across the samples. Chen reports that 17% (28 of 165) of the protein spots, or 21.4% (21 of 98) of the genes, showed a statistically significant correlation between protein and mRNA expression. *Chen* at Abstract. It is these results that the Examiner relies on for support.

However, read in its entirety, Chen provides scant evidence to counter Appellants’ asserted utility because portions of Chen support Appellants’ assertions, and the remaining portions provide little insight into the relationship between mRNA levels and corresponding protein levels for mRNA that is differentially expressed in tumor cells relative to normal cells.

Appellants have asserted that changes in mRNA levels, particularly those which are two-fold or greater, will correspond with measurable changes in polypeptide expression. The data in Chen support Appellants’ assertion. In Figures 2A-2C, Chen plots mRNA value vs. protein value for three genes. In these figures, a wide range of mRNA expression levels were observed (approximately seven- to eight-fold), and a correlation between mRNA and protein levels was observed for all three mRNA/protein pairs. This supports Appellants’ assertion that there is a correlation between changes in mRNA levels which are two-fold or greater and changes in polypeptide expression.

The Examiner relies on the fact that Chen also reports a lack of correlation for some mRNA/protein pairs to support her assertion that polypeptide levels cannot be accurately predicted from mRNA levels. However, as is explained below, the apparent lack of a correlation cannot be used as evidence that Appellants’ assertion of a general correlation is wrong.

To determine if there is a correlation between changes in mRNA and changes in protein levels, one would have to conduct experiments where a measurable change in mRNA for a particular gene is observed, and then examine if there was a corresponding change in the level of

Appl. No. : 10/063,584
Filed : May 3, 2002

the corresponding protein. Stated differently, if there was no substantial change in mRNA levels for a particular gene, one cannot measure a correlation between changes in mRNA and changes in the encoded protein for that gene. Therefore, one must know if the individual genes studied by Chen were differentially expressed to know if the observed lack of correlation has any relevance to Appellants' assertions of a general correlation between changes in mRNA and protein.

Importantly, unlike Appellants, Chen did not examine differences in mRNA between tumor and normal tissue where one would expect to find substantial changes in the level of mRNA for certain genes. Instead, Chen merely selected proteins whose identity could be determined regardless of any changes in expression level. *Chen* at 306, right column. Therefore, it is not known if there was any substantial difference in mRNA levels for the various studied genes across samples – in short, with the exception of the genes in Figures 2A-2C, it is not known if the genes examined were differentially expressed. Also of significance for Appellants' asserted utility is the fact that Chen did not attempt to examine any differential expression between the cancerous lung samples and the non-cancerous lung samples – Chen did not distinguish between cancer and normal samples in their analysis. Since almost all samples tested by Chen were from the same type of tissue, one would expect most genes examined by Chen to have similar mRNA or protein levels across the samples. In the absence of substantial differential expression, no correlation would be observed. Because it is not known if there was a change in the level of the genes studied by Chen, *i.e.* whether they were differentially expressed, the lack of an observed correlation cannot be used to counter Appellants' assertion.

In sum, the only data reported by Chen which shows substantial changes in the expression of mRNA, Figures 2A-C, confirms Appellants' assertion that substantial changes in mRNA levels (e.g., 2-fold or greater) will correspond to substantial changes in polypeptide expression. Further, these data explain the lack of observed correlation between mRNA levels and protein levels for other genes reported by Chen – there is no indication the genes are differentially expressed. Thus, Chen's results do not refute Appellants' position. Instead, Chen supports Appellants' position that a significant correlation between mRNA and protein levels exists for changes in mRNA levels that are 2-fold or greater.

In further support of Appellants' position, Chen cites Celis *et al.* (FEBS Lett., 480:2-16 (2000)) stating that the authors "found a good correlation between transcript and protein levels

Appl. No. : 10/063,584
Filed : May 3, 2002

among 40 well resolved, abundant proteins using a proteomic and microarray study of bladder cancer.” *Chen* at 311, first column (emphasis added). As mentioned above, the lack of a correlation across genes is not relevant to Appellants’ asserted utility, as the Examiner has apparently acknowledged, and therefore Chen’s discussion of this issue and citation of Anderson and Seilhamer (Electrophoresis, 18:533-37 (1997)) and Gygi *et al.* (Mol. Cell. Bio., 19:1720-30 (1999)) offer no support for the Examiner’s position.

Given the fact that portions of Chen as well as the relevant references cited by Chen support Appellants’ position, and the remainder of Chen cannot be relied on as contrary to the Appellants’ position, the Examiner has failed to establish a *prima facie* case that one of skill in the art would doubt Appellants’ asserted utility.

d. Conclusion – Examiner has failed to establish a Prima Facie case that one of skill in the art would doubt Appellants’ asserted utility

The Examiner has relied on essentially three unsupported arguments in rejecting the pending claims for lack of utility. First, the Examiner has questioned the sufficiency, reliability and significance of the data reported in Example 18 as well as the supporting first Grimaldi declaration. Second, the Examiner has argued that absent some known translocation or mutation of PRO1335, or some role for PRO1335 in cancer formation or development, the disclosure is insufficient. Finally, in the Advisory Action, the Examiner relies on Chen *et al.* for the first time to support the assertion that it cannot be assumed that mRNA levels correlate to protein levels. Appellants have responded to each of these arguments in turn.

First, Appellants have shown that the data in Example 18 are sufficient to show that PRO1335 is useful as a cancer diagnostic tool. This assertion is supported by the first Grimaldi declaration. The Examiner has not provided any substantial reason or evidence for one of skill in the art to doubt the reliability or usefulness of Example 18, or the facts and conclusions in the first Grimaldi declaration.

Second, Appellants have shown that the lack of a known translocation or mutation of PRO1335, or the lack of a known role for PRO1335 in the formation or development of cancer is not required to use PRO1335 as a diagnostic tool. One does not need to know why PRO1335 is differentially expressed in certain tumors, or what the consequence of the differential expression is, in order to exploit the differential expression to distinguish tumor from normal tissue.

Appl. No. : 10/063,584
Filed : May 3, 2002

Finally, Appellants have shown that portions of Chen *et al.*, as well as some of the references cited by Chen, actually support Appellants assertion that changes in mRNA levels generally correlate with changes in the level of the encoded polypeptide. The remainder of Chen is not reliable enough to offer any support for the Examiner's position.

Taken together, the Examiner's arguments are not sufficient to satisfy the Examiner's burden to "provide[] evidence showing that one of ordinary skill in the art would reasonably doubt the asserted utility." *In re Brana*, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d 1436 (Fed. Cir. 1995). The Examiner's arguments are conclusory statements which are not supported by any evidence or reasoning which explains why one of ordinary skill in the art would reasonably doubt the asserted utility. Therefore, the Board should accept the Appellants' disclosure of utility. *See Ex parte Rubin*, 5 U.S.P.Q. 2d 1461 (Bd. Pat. App. & Interf. 1987) ("There is no factual support in this record for the examiner's questioning of the denaturation test reported in the specification. ... No reason to doubt 'the objective truth' of the asserted utility having been advanced by the examiner, we accept appellant's disclosure of utility corresponding in scope to the claimed subject matter.").

7. Appellants have provided Sufficient Rebuttal Evidence of Utility

"Only after the PTO provides evidence showing that one of ordinary skill in the art would reasonably doubt the asserted utility does the burden shift to the Appellant to provide rebuttal evidence." *In re Brana*, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d 1436 (Fed. Cir. 1995). The rebuttal evidence must be sufficient such that when it is considered as a whole, it is more likely than not that the asserted utility is true. *See In re Oetiker*, 977 F.2d 1443, 1445, 24 U.S.P.Q.2d 1443, 1444 (Fed. Cir. 1992) (stating that the evidentiary standard to be used throughout *ex parte* examination in setting forth a rejection is a preponderance of the evidence, or "more likely than not" standard). The M.P.E.P. summarizes the standard of proof required:

[T]he Appellant does not have to provide evidence sufficient to establish that an asserted utility is true "beyond a reasonable doubt." Nor must the Appellant provide evidence such that it establishes an asserted utility as a matter of statistical certainty. Instead, evidence will be sufficient if, considered as a whole, it leads a person of ordinary skill in the art to conclude that the asserted utility is more likely than not true. M.P.E.P. at § 2107.02, part VII (emphasis in original, citations omitted).

Appl. No. : 10/063,584
Filed : May 3, 2002

Appellants remind the Board that the Federal Circuit has stated that the standard for satisfying the utility requirement is a low one: "The threshold of utility is not high: An invention is "useful" under section 101 if it is capable of providing some identifiable benefit. *Juicy Whip, Inc. v. Orange Bang, Inc.*, 185 F.3d 1364, 1366, 51 U.S.P.Q. 2d 1700 (Fed. Cir. 1999).

Even if the Examiner has satisfied her burden of presenting a *prima facie* case of lack of utility, Appellants have supplied more than enough rebuttal evidence, such that when considered as a whole, one of skill in the art would conclude that the asserted utility is more likely than not true. Appellants have provided sufficient evidence that the gene encoding the PRO1335 polypeptide is differentially expressed in certain cancers and can therefore be used as a diagnostic tool. In addition, Appellants have shown that it is well established in the art that there is a reasonable correlation between changes in mRNA level and changes in the corresponding protein level such that one of skill in the art would believe that the PRO1335 polypeptide is also differentially expressed in certain cancers. Therefore, considering the evidence as a whole, one of skill in the art would believe that it is more likely than not that the claimed antibodies are useful as diagnostic tools for cancer, particularly stomach, lung, rectal, and melanoma tumors.

a. Appellants have established that the gene encoding the PRO1335 polypeptide is differentially expressed in certain cancers

As discussed above, the Examiner has not provided any evidence to challenge the reliability and significance of the data in Example 18 which reports that the mRNA for PRO1335 is more highly expressed in normal stomach, lung, rectal, and skin tissue compared to stomach, lung, rectal, and melanoma tumor, respectively. In contrast to this complete lack of evidence on the part of the Examiner, Appellants have submitted the first Grimaldi declaration. That declaration establishes that it is the opinion of an expert in the field who has personal knowledge of the facts surrounding Example 18 that there is at least a two-fold difference in mRNA for PRO1335 between the tumor tissue and the counterpart normal tissue, and that the PRO1335 genes, polypeptides and antibodies are useful for differentiating tumor tissue from normal tissue. The Examiner has not provided any evidence to challenge the facts and conclusions of the first Grimaldi declaration in support of Example 18.

Given the disclosure of Example 18 and the supporting first Grimaldi declaration on the one hand, and the complete lack of any evidence on the other, it is clear that considering the evidence as a whole, one of skill in the art would conclude that it is more likely than not that the

Appl. No. : 10/063,584
Filed : May 3, 2002

PRO1335 gene is differentially expressed in stomach, lung, rectal, and melanoma tumor tissue compared to their normal tissue counterparts such that is useful as a diagnostic tool to distinguish tumor tissue from normal tissue.

As Appellants explain below, it is more likely than not that the PRO1335 polypeptide is also differentially expressed in stomach, lung, rectal, and melanoma tumor tissue, and can therefore be used to distinguish tumor tissue from normal tissue. This provides utility for the claimed antibodies to the PRO1335 polypeptide.

b. Appellants have established that generally there is a correlation between changes in mRNA expression levels and changes in the expression level of the encoded protein

Appellants next turn to the second portion of their argument in support of their asserted utility – that it is well-established in the art that in most cases a change in the level of mRNA for a particular protein leads to a corresponding change in the level of the encoded protein. Given Appellants’ evidence of differential expression of the mRNA for the PRO1335 polypeptide in stomach, lung, rectal, and melanoma tumor, it is more likely than not that the PRO1335 polypeptide is likewise differentially expressed, and therefore the claimed antibodies are useful as diagnostic tools, particularly for stomach, lung, rectal, and melanoma tumor.

In support of the assertion that changes in mRNA are positively correlated to changes in protein levels, Appellants submitted a second Declaration by J. Christopher Grimaldi, an expert in the field of cancer biology. As stated in paragraph 5 of the declaration, “Those who work in this field are well aware that in the vast majority of cases, when a gene is over-expressed...the gene product or polypeptide will also be over-expressed.... This same principal applies to gene under-expression.” *Second Grimaldi Declaration* at ¶ 5. Further, “increased mRNA expression is expected to result in increased polypeptide expression, and the detection of decreased mRNA expression is expected to result in decreased polypeptide expression.” *Id.*

Appellants also submitted the declaration of Paul Polakis, Ph.D. an expert in the field of cancer biology (attached as Exhibit 3 to Appellants’ Amendment and Response to Office Action). As stated in paragraph 6 of his declaration:

Based on my own experience accumulated in more than 20 years of research, including the data discussed in paragraphs 4 and 5 above [showing a positive correlation between mRNA levels and encoded protein levels in the vast majority of cases studied in relation to the present invention] and my knowledge of the relevant scientific literature, it is my considered scientific opinion that for human

Appl. No. : 10/063,584
Filed : May 3, 2002

genes, an increased level of mRNA in a tumor cell relative to a normal cell typically correlates to a similar increase in abundance of the encoded protein in the tumor cell relative to the normal cell. In fact, *it remains a central dogma in molecular biology that increased mRNA levels are predictive of corresponding increased levels of the encoded protein.* (Emphasis added).

Dr. Polakis acknowledges that there are published cases where such a correlation does not exist, but states that it is his opinion, based on over 20 years of scientific research, that “such reports are exceptions to the commonly understood general rule that increased mRNA levels are predictive of corresponding increased levels of the encoded protein.” *Polakis Declaration* at ¶ 6.

The statements of Grimaldi and Polakis are supported by the teachings in *Molecular Biology of the Cell*, a leading textbook in the field (Bruce Alberts, *et al.*, *Molecular Biology of the Cell* (3rd ed. 1994) (submitted with Appellants’ After Final Amendment as Exhibit 2, hereinafter “Cell 3rd”) and (4th ed. 2002) (submitted with Appellants’ After Final Amendment as Exhibit 3, hereinafter “Cell 4th”). Figure 9-2 of Cell 3rd shows the steps at which eukaryotic gene expression can be controlled. The first step depicted is transcriptional control. Cell 3rd provides that “[f]or most genes transcriptional controls are paramount. This makes sense because, of all the possible control points illustrated in Figure 9-2, only transcriptional control ensures that no superfluous intermediates are synthesized.” *Cell 3rd* at 403 (emphasis added). In addition, the text states that “Although controls on the initiation of gene transcription are the predominant form of regulation for most genes, other controls can act later in the pathway from RNA to protein to modulate the amount of gene product that is made.” *Cell 3rd* at 453 (emphasis added). Thus, as established in Cell 3rd, the predominant mechanism for regulating the amount of protein produced is by regulating transcription.

In Cell 4th, Figure 6-3 on page 302 illustrates the basic principle that there is a correlation between increased gene expression and increased protein expression. The accompanying text states that “a cell can change (or regulate) the expression of each of its genes according to the needs of the moment – *most obviously by controlling the production of its mRNA.*” *Cell 4th* at 302 (emphasis added). Similarly, Figure 6-90 on page 364 of Cell 4th illustrates the path from gene to protein. The accompanying text states that while potentially each step can be regulated by the cell, “the initiation of transcription is the most common point for a cell to regulate the expression of each of its genes.” *Cell 4th* at 364 (emphasis added). This point is repeated on

Appl. No. : 10/063,584
Filed : May 3, 2002

page 379, where the authors state that of all the possible points for regulating protein expression, “[f]or most genes transcriptional controls are paramount.” *Cell* 4th at 379 (emphasis added).

Further support for Appellants’ position can be found in the textbook, *Genes VI*, (Benjamin Lewin, *Genes VI* (1997)) (submitted with Appellants’ After Final Amendment as Exhibit 4) which states “having acknowledged that control of gene expression can occur at multiple stages, and that production of RNA cannot inevitably be equated with production of protein, it is clear that the overwhelming majority of regulatory events occur at the initiation of transcription.” *Genes VI* at 847-848 (emphasis added).

Additional support is also found in Zhigang *et al.*, *World Journal of Surgical Oncology* 2:13, 2004 (submitted with Appellants’ After Final Amendment as Exhibit 5). Zhigang studied the expression of prostate stem cell antigen (PSCA) protein and mRNA to validate it as a potential molecular target for diagnosis and treatment of human prostate cancer. The data showed “a high degree of correlation between PSCA protein and mRNA expression” *Zhigang* at 4. Of the samples tested, 81 out of 87 showed a high degree of correlation between mRNA expression and protein expression. The authors conclude that “it is demonstrated that PSCA protein and mRNA overexpressed in human prostate cancer, and that the increased protein level of PSCA was resulted from the upregulated transcription of its mRNA.” *Id.* at 6. Even though the correlation between mRNA expression and protein expression occurred in 93% of the samples tested, not 100%, the authors state that “PSCA may be a promising molecular marker for the clinical prognosis of human Pca and a valuable target for diagnosis and therapy of this tumor.” *Id.* at 7.

Further, Meric *et al.*, *Molecular Cancer Therapeutics*, vol. 1, 971-979 (2002), (submitted with Appellants’ After Final Amendment as Exhibit 6), states the following:

The **fundamental principle** of molecular therapeutics in cancer is to exploit the differences in gene expression between cancer cells and normal cells...[M]ost efforts have concentrated on identifying differences in gene expression at the level of mRNA, which can be attributable to either DNA amplification or to differences in transcription. *Meric et al.* at 971 (emphasis added).

Those of skill in the art would not be focusing on differences in gene expression between cancer cells and normal cells if there were no correlation between gene expression and protein expression.

Together, the declarations of Grimaldi and Polakis, the accompanying references, and the excerpts and references discussed above all establish that the accepted understanding in the art is that there is a reasonable correlation between changes in gene expression and changes in the level of the encoded protein. In contrast to this substantial amount of evidence supporting Appellants' position, the Examiner has cited a single reference, Chen *et al.* However, as discussed above, portions of Chen and the relevant references cited by Chen actually support Appellants' position, and the remainder of Chen is inconclusive. It is clear that when considered as a whole, the preponderance of the evidence clearly weighs in favor of Appellants.

Appellants have presented sufficient evidence to establish that the mRNA for PRO1335 is differentially expressed in stomach, lung, rectal, and melanoma tumors compared to their normal tissue counterparts, and that it is more likely than not that this leads to differential expression of the PRO1335 polypeptide. This makes the claimed antibodies to PRO1335 polypeptide useful for diagnosing cancer, particularly stomach, lung, rectal, and melanoma tumors. Given the overwhelming amount of evidence in support of Appellants' position, and the near absence of any evidence in support of the Examiner's position, when considered as a whole the evidence leads a person of ordinary skill in the art to conclude that the asserted utility is more likely than not true.

8. ***The Courts have held that the Utility Requirement was Satisfied in Similar Cases***

The seminal decision interpreting the utility requirement of 35 U.S.C. § 101 is *Brenner v. Manson*, 383 U.S. 519, 148 U.S.P.Q. 689 (1966). At issue in *Brenner* was a claim to "a chemical process which yields an already known product whose utility – other than as a possible object of scientific inquiry – ha[d] not yet been evidenced." *Id.* at 529, 148 U.S.P.Q. at 693. The Patent Office rejected the claimed process for lack of utility because the product produced by the claimed process had no known use. *See id.* at 521-22, 148 U.S.P.Q. at 690. On appeal, the Court of Customs and Patent Appeals reversed, holding "where a claimed process produces a known product it is not necessary to show utility for the product." *Id.* at 522, 148 U.S.P.Q. at 691.

In reviewing the lower court's decision, the Court made its oft quoted statement that "[t]he basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility.

Appl. No. : 10/063,584
Filed : May 3, 2002

Unless and until a process is refined and developed to this point – where specific benefit exists in currently available form – there is insufficient justification for permitting an Appellant to engross what may prove to be a broad field.” *Id.* at 534-35, 148 U.S.P.Q. at 695.

The first opinion of the C.C.P.A. applying *Brenner* was *In re Kirk*, 376 F.2d 936, 153 U.S.P.Q. 48 (C.C.P.A. 1967). The invention claimed in *Kirk* was a set of steroid derivatives said to have valuable biological properties and to be of value “in the furtherance of steroidal research and in the application of steroidal materials to veterinary or medical practice.” *Id.* at 938, 153 U.S.P.Q. at 50. In affirming the claim rejection based on a lack of utility, the court held that the “nebulous expressions ‘biological activity’ or ‘biological properties’” did not adequately convey how to use the claimed compounds. *Id.* at 941, 153 U.S.P.Q. at 52. The court also rejected Appellants’ supporting affidavit, stating, “the sum and substance of the affidavit appears to be that one of ordinary skill in the art would know ‘how to use’ the compounds to find out in the first instance whether the compounds are – or are not – in fact useful or possess useful properties, and to ascertain what those properties are.” *Id.* at 942, 153 U.S.P.Q. at 53.

Since these early decisions, the courts have continued to clarify what is sufficient to satisfy the utility requirement. Three more recent decisions are of particular relevance to the instant application: *Nelson v. Bowler*, 626 F.2d 853, 206 U.S.P.Q. 881 (C.C.P.A. 1980), *Cross v. Iizuka*, 753 F.2d 1040, 224 U.S.P.Q. 739 (Fed. Cir. 1985), and *Fujikawa v. Wattanasin*, 93 F.3d 1559, 39 U.S.P.Q. 2d 1895 (Fed. Cir. 1996).

The earliest of these cases, *Nelson v. Bowler*, involved an interference between two applications related to derivatives of naturally occurring prostaglandins (PG). *Nelson*, 626 F.2d at 854-55. The issue was whether Nelson had shown at least one utility for the compounds at issue to establish an actual reduction to practice. *Id.* at 855. The Appellants relied on two tests to prove practical utility: an *in vivo* rat blood pressure (BP) test and an *in vitro* gerbil colon smooth muscle stimulation (GC-SMS) test. In the BP test, the blood pressure of anesthetized rats was recorded on a polygraph chart to determine whether an injected compound had any effect. Responses were categorized as either a depressor (lowering) effect or a pressor (elevating) effect. *Id.* In the GC-SMS test a section of colon was excised from a freshly-killed gerbil for suspension in a physiological solution, and a lever arm was connected to the colon in such a way that any contraction was recorded as a polygraph trace. *Id.* The Board held that

Appl. No. : 10/063,584
Filed : May 3, 2002

Nelson had not shown adequate proof of practical utility, characterizing the tests as “rough screens, uncorrelated with actual utility.” *Id.* at 856.

On appeal the C.C.P.A. reversed, holding that the Board “erred in not recognizing that tests evidencing pharmacological activity may manifest a practical utility even though they may not establish a specific therapeutic use.” *Id.* The Court stated that “practical utility” was characterized as a use of the claimed discovery in a manner which provides some immediate benefit to the public, establishing the following rule:

Knowledge of the pharmacological activity of any compound is obviously beneficial to the public. It is inherently faster and easier to combat illnesses and alleviate symptoms when the medical profession is armed with an arsenal of chemicals having known pharmacological activities. Since it is crucial to provide researchers with an incentive to disclose pharmacological activities in as many compounds as possible, we conclude that adequate proof of any such activity constitutes a showing of practical utility. *Id.* (emphasis added).

The Court rejected Bowler’s argument that the BP and GC-SMS tests are inconclusive showings of pharmacological activity since confirmation by statistically significant means did not occur until after the critical date. The Court stated that “a rigorous correlation is not necessary where the test for pharmacological activity is reasonably indicative of the desired response.” *Id.* (emphasis added). The Court concluded that a “reasonable correlation” between the observed properties and the suggested use was sufficient to establish practical utility. *Id.* at 857.

The sufficiency of a “reasonable correlation” in establishing utility was affirmed by the Court of Appeals for the Federal Circuit in *Cross v. Iizuka*, 753 F.2d 1040, 224 U.S.P.Q. 739 (Fed. Cir. 1985). In *Cross*, the subject of the interference before the Court was imidazole derivative compounds which inhibit the synthesis of thromboxane synthetase, an enzyme which leads to the formation of thromboxane A₂. At the time the applications were filed, thromboxane A₂ was postulated to be involved in platelet aggregation, which was associated with several deleterious conditions. *Id.* at 1042.

The question before the Board and reviewed by the Court was whether Iizuka was entitled to the benefit of his Japanese priority application. *Id.* The Japanese application disclosed that the imidazole derivatives showed strong inhibitory action for thromboxane synthetase from human or bovine platelet microsomes, an *in vitro* utility. *Id.* at 1043. Relying in part on *Nelson*, the Board held that tests evidencing pharmacological activity may manifest a

Appl. No. : 10/063,584
Filed : May 3, 2002

practical utility even though they may not establish a specific therapeutic use, and concluded that the *in vitro* tests were sufficient to establish a practical utility. *Id.*

On appeal, Cross argued that the basic *in vitro* tests conducted in cellular fractions did not establish a practical utility for the claimed compounds, and that more sophisticated *in vitro* or *in vivo* tests were necessary to establish a practical utility. *Id.* at 1050. The Court rejected this argument, noting that adequate proof of any pharmaceutical activity constitutes a showing of practical utility. *Id.* The Court accepted the argument that initial testing of compounds is widely done *in vitro*:

[I]n *vitro* results...are generally predictive of *in vivo* test results, i.e., there is a reasonable correlation therebetween. Were this not so, the testing procedures of the pharmaceutical industry would not be as they are. Iizuka has not urged, and rightly so, that there is an invariable exact correlation between *in vitro* test results and *in vivo* test results. Rather, Iizuka's position is that successful *in vitro* testing for a particular pharmacological activity establishes a significant probability that *in vivo* testing for this particular pharmacological activity will be successful. *Id.* (emphasis added).

The Court also noted that in previous decisions, its predecessor court had accepted evidence of *in vivo* utility as sufficient to establish practical utility. The Court reasoned that:

This *in vivo* testing is but an intermediate link in a screening chain which may eventually lead to the use of the drug as a therapeutic agent in humans. We perceive no insurmountable difficulty, under appropriate circumstances, in finding that the first link in the screening chain, *in vitro* testing, may establish a practical utility for the compound in question. Successful *in vitro* testing will marshal resources and direct the expenditure of effort to further *in vivo* testing of the most potent compounds, thereby providing an immediate benefit to the public, analogous to the benefit provided by the showing of an *in vivo* utility. *Id.* at 1051, citing *Nelson*, 626 F.2d at 856 (emphasis added).

Based on this reasoning, the Court affirmed the decision of the Board, stating that "based upon the relevant evidence as a whole, there is a reasonable correlation between the disclosed *in vitro* utility and an *in vivo* activity, and therefore a rigorous correlation is not necessary where the disclosure of pharmacological activity is reasonable based upon the probative evidence." *Id.* at 1050 (emphasis added). The Court therefore held that the disclosed *in vitro* utility was "sufficient to comply with the practical utility requirement of § 101." *Id.* at 1051.

The holdings of *Nelson* and *Cross* were more recently affirmed in *Fujikawa v. Wattanasin*, 93 F.3d 1559, 39 U.S.P.Q.2d 1895 (Fed. Cir. 1996). In *Fujikawa*, the Court again affirmed the notion that initial screens of compounds provide a practical utility even though they

Appl. No. : 10/063,584
Filed : May 3, 2002

may not provide a therapeutic use because “[i]t is inherently faster and easier to combat illnesses and alleviate symptoms when the medical profession is armed with an arsenal of chemicals having known pharmacological activities.” *Id.* at 1564, *quoting Nelson*, 626 F.2d at 856. The Court noted that it may be difficult to predict whether novel compounds will exhibit pharmacological activity, and consequently testing is often required to establish practical utility.

Id. However the Court went on to state:

But the test results need not absolutely prove that the compound is pharmacologically active. All that is required is that the tests be “*reasonably* indicative of the desired [pharmacological] response.” In other words, there must be a sufficient correlation between the tests and an asserted pharmacological activity so as to convince those skilled in the art, to a reasonable probability, that the novel compound will exhibit the asserted pharmacological behavior.” *Id.* (internal citations omitted, underline emphasis added, italics in original).

On appeal, Fujikawa argued that Wattanasin had failed to establish an adequate correlation between the *in vitro* and *in vivo* results to permit Wattanasin to rely on positive *in vitro* results to establish a practical utility. The Court stated that the Board relied on testimony from those skilled in the art that the *in vitro* results convinced the experts that the claimed compounds would exhibit the desired pharmacological activity when administered *in vivo*, including testimony that *in vivo* activity is typically highly correlatable to a compound’s *in vitro* activity in the field. *Id.* at 1565. To overcome this evidence and counter the Board’s decision, Fujikawa pointed to the testimony of its expert that “there is a reasonable element of doubt that some elements may be encountered which are active in the *in vitro* assay, but yet inactive in the *in vivo* assay.” *Id.*

The Court rejected this argument: “Of course, it is possible that some compounds active *in vitro* may not be active *in vivo*. But, as our predecessor court in *Nelson* explained, a ‘rigorous correlation’ need not be shown in order to establish practical utility; ‘reasonable correlation’ suffices.” *Id.* (emphasis added). The Court also rejected Fujikawa’s reliance on two articles. The Court noted that while one article taught that “*in vitro* testing is sometimes not a good indicator of how potent a compound will be *in vivo*, it does imply that compounds which are active *in vitro* will normally exhibit some *in vivo* activity.” *Id.* at 1566. Similarly, the Court noted that the second article expressly stated that “[f]or most substances, although not for all, the relative potency determined in *in vitro* ... parallels the *in vivo* activity.” *Id.*

Appl. No. : 10/063,584
Filed : May 3, 2002

The Court concluded that the facts in the case were analogous to the ones in *Cross* where the court relied on a known reasonable correlation between *in vitro* tests and *in vivo* activity, and therefore affirmed the Board's decision that Wattanasin had established a practical utility with the *in vitro* results. *Id.* at 1565-66.

The *Nelson*, *Cross*, and *Fujikawa* cases are very similar to the present case. The reasoning of the courts in all three cases that "[i]t is inherently faster and easier to combat illnesses and alleviate symptoms when the medical profession is armed with an arsenal of chemicals having known pharmacological activities" applies to the asserted utility for the claimed antibodies. *Fujikawa*, 93 F.3d at 1564, *quoting Nelson*, 626 F.2d at 856; *see also Cross*, 753 F.2d at 1051 ("Successful *in vitro* testing will marshal resources and direct the expenditure of effort to further *in vivo* testing of the most potent compounds, thereby providing an immediate benefit to the public, analogous to the benefit provided by the showing of an *in vivo* utility."). Like pharmaceutical compounds, nucleic acids, polypeptides, and antibodies which are associated with cancer will make it inherently faster and easier to combat cancer. The greater the number of biological markers of cancer medical professionals have access to, the more accurate and detailed a diagnosis they can make. The determination that a gene is differentially expressed in cancer constitutes at least as significant a development in the field of cancer diagnostics as *in vitro* screening for pharmaceutical activity. *See Cross*, 753 F.2d at 1051 ("the first link in the screening chain, *in vitro* testing, may establish a practical utility for the compound in question. Successful *in vitro* testing will marshal resources and direct the expenditure of effort to further *in vivo* testing of the most potent compounds, thereby providing an immediate benefit to the public.").

In addition, like *in vitro* tests in the pharmaceutical industry, those of skill in the field of biotechnology rely on the reasonable correlation that exists between gene expression and protein expression (see discussion *supra*). Were there no reasonable correlation between the two, the techniques that measure gene levels such as microarray analysis, differential display, and quantitative PCR would not be so widely used by those in the art. *See Second Grimaldi Declaration* at ¶ 5. As in *Cross*, Appellants here do not argue that there is "an invariable exact correlation" between gene expression and protein expression. *See Cross*, 753 F.2d at 1050. Instead, Appellants' position detailed above is that a measured change in gene expression in cancer cells establishes a "significant probability" that the expression of the encoded polypeptide

Appl. No. : 10/063,584
Filed : May 3, 2002

in cancer will also be changed based on “a reasonable correlation therebetween.” *Id.*; *see also Fujikawa*, 93 F.3d at 1565 (“a ‘rigorous correlation’ need not be shown in order to establish practical utility; ‘reasonable correlation’ suffices”); *Nelson*, 626 F.2d at 857 (holding that “a rigorous correlation is not necessary” and that a “reasonable correlation” will suffice).

Also of importance is the Court’s rejection of the notion that any *in vitro* testing must be statistically significant to support a practical utility. *Nelson*, 626 F.2d at 857. Likewise, qualitative characterizations of a test compound as either increasing or decreasing blood pressure was acceptable. *Id.* at 855 (stating that responses were categorized as either a depressor (lowering) effect or a pressor (elevating) effect). This is similar to the data in Example 18, where the change in mRNA levels is described as “more highly expressed.”

There are additional similarities. In *Fujikawa*, the Board and Court rejected the argument that there was no utility because there was no exact correlation between the *in vitro* and *in vivo* results in spite of supporting testimony and references. *Fujikawa*, 93 F.3d at 1565-66. Like the two references rejected by the Board and Court in *Fujikawa*, the *Chen et al.* reference cited by the Examiner may suggest that the correlation between changes in mRNA levels and protein levels is not exact. But like *Fujikawa*, portions of *Chen et al.* also support Appellants’ assertion, and Appellants have submitted the declaration of two experts in the field which state that those in the field rely on the correlation between changes in mRNA and protein. *See Second Grimaldi Declaration* at ¶ 5; *Polakis Declaration* at ¶ 6. Thus, as was the case in *Fujikawa*, although there may be some evidence that the correlation relied on is not exact, the declarations and numerous references submitted by Appellants is more than enough evidence to establish that there is a “reasonable correlation” between changes in mRNA levels and changes in the level of the encoded protein.

In conclusion, Appellants have asserted that the claimed antibodies are useful for the diagnosis of cancer, particularly stomach, lung, rectal, and skin cancer based on the data in Example 18. This utility is far beyond the nebulous expressions “biological activity” or “biological properties” rejected in *In re Kirk*, 376 F.2d 936, 153 U.S.P.Q. 48 (C.C.P.A. 1967). Like *Nelson*, *Cross*, and *Fujikawa*, Appellants have asserted a utility which relies on a reasonable correlation between the data disclosed in the application and the asserted utility. The fact that there may be limited evidence that the correlation is not exact does not invalidate Appellants’ showing of utility since the correlation need not be a rigorous or exact one.

Appl. No. : 10/063,584
Filed : May 3, 2002

Considering the relevant evidence as a whole, Appellants have provided sufficient evidence to establish a reasonable correlation between changes in the level of mRNA and corresponding changes in the level of the encoded polypeptide. Therefore the claimed antibodies have a practical utility as diagnostic tools for stomach, lung, rectal, and skin cancer.

9. Utility – Conclusion

Appellants' asserted utility for the claimed antibodies as diagnostic tools for cancer corresponds in scope to the subject matter sought to be patented and therefore "must be taken as sufficient to satisfy the utility requirement of § 101 for the entire claimed subject." *In re Langer*, 503 F.2d 1380, 1391, 183 U.S.P.Q. 288, 297 (C.C.P.A. 1974). The Examiner's unsupported arguments and single inconclusive reference are not sufficient evidence to make a *prima facie* showing that "one of ordinary skill in the art would reasonably doubt the asserted utility." *In re Brana*, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d 1436 (Fed. Cir. 1995). And even if the Examiner has established a *prima facie* case, Appellants have offered sufficient rebuttal evidence in the form of expert declarations and references, which, when considered as a whole, establish that it is more likely than not that the asserted utility is true. *See In re Oetiker*, 977 F.2d 1443, 1445, 24 U.S.P.Q.2d 1443, 1444 (Fed. Cir. 1992) (stating that the evidentiary standard to be used throughout *ex parte* examination in setting forth a rejection is a preponderance of the evidence, or "more likely than not" standard); *M.P.E.P.* at § 2107.02, part VII ("evidence will be sufficient if, considered as a whole, it leads a person of ordinary skill in the art to conclude that the asserted utility is more likely than not true." (emphasis in original)). Finally, the courts' decisions in similar cases make clear that the evidence provided by Appellants is sufficient to establish the asserted utility. The evidence does not need to be direct evidence, nor does it need to provide an exact correlation between the submitted evidence and the asserted utility. Instead, evidence which is "reasonably" correlated with the asserted utility is sufficient. *See Fujikawa*, 93 F.3d at 1565 ("a 'rigorous correlation' need not be shown in order to establish practical utility; 'reasonable correlation' suffices"); *Cross*, 753 F.2d at 1050 (same); *Nelson*, 626 F.2d at 857 (same). Considering the evidence as a whole in light of the relevant cases, the Board should find that Appellants have established at least one specific, substantial, and credible utility, and the Examiner's rejection of the pending claims as lacking utility should be reversed.

Appl. No. : 10/063,584
Filed : May 3, 2002

B. Enablement Rejection

The second issue before the Board is whether Appellants have enabled the pending claims such that one of skill in the art would be able to make and use the claimed invention. The Examiner has rejected Claims 1-5 under 35 U.S.C. §112, first paragraph, arguing that because the claimed invention is not supported by either a specific or substantial asserted utility or a well-established utility, one skilled in the art clearly would not know how to use the claimed invention. *See First Office Action at 5; Final Office Action at 5; Advisory Action at 2.*

1. Because the Claimed Invention is Supported by a Specific, Substantial and Credible Utility, the Enablement Rejection should be Reversed

For the reasons stated above, the claimed invention is supported by a specific, substantial and credible utility. Because the lack of a supporting utility is the only basis for the Examiner's rejection under 35 U.S.C. § 112, first paragraph, the Board should reverse the rejection of Claims 1-5 as lacking enablement.

C. Conclusion

In view of the arguments presented above, Appellants submit that the specification as filed provides a specific, substantial and credible utility for the claimed antibodies and request withdrawal of the rejection under 35 U.S.C. §101, and the related rejection under 35 U.S.C. §112.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 27, 2005

By: AnneMarie Kaiser

AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550

Appl. No. : **10/063,584**
Filed : **May 3, 2002**

VIII. APPENDIX A – CLAIMS ON APPEAL

1. An isolated antibody that specifically binds to the polypeptide of SEQ ID NO: 74.
2. The antibody of claim 1 which is a monoclonal antibody.
3. The antibody of claim 1 which is a humanized antibody.
4. The antibody of claim 1 which is an antibody fragment.
5. The antibody of claim 1 which is labeled.

Appl. No. : 10/063,584
Filed : May 3, 2002

IX. APPENDIX B – EVIDENCE

Attached hereto is a copy of the evidence cited in Appellants' Brief. The list of evidence below is accompanied by a statement setting forth where in the record that evidence was entered into the record by the Examiner.

Tab	Reference	Submitted	Entered
1	Second Declaration of J. Christopher Grimaldi	Originally submitted with Appellants' 1 st Amendment and Response to Office Action as Exhibit 2	Entered by Examiner in Final Office Action
2	Chen <i>et al.</i> (<i>Molecular and Cellular Proteomics</i> , 1:304-313 (2002))		Cited by Examiner in Advisory Action
3	First Declaration of J. Christopher Grimaldi	Originally submitted with Appellants' 1 st Amendment and Response to Office Action as Exhibit 1	Entered by Examiner in Final Office Action
4	U.S. Patent No. 6,414,117	Originally submitted with Appellants' After Final Amendment as Exhibit 7	Entered by Examiner in Advisory Action
5	U.S. Patent No. 6,124,433	Originally submitted with Appellants' After Final Amendment as Exhibit 8	Entered by Examiner in Advisory Action
6	U.S. Patent No. 6,156,500	Originally submitted with Appellants' After Final Amendment as Exhibit 9	Entered by Examiner in Advisory Action
7	U.S. Patent No. 6,562,343	Originally submitted with Appellants' After Final Amendment as Exhibit 10	Entered by Examiner in Advisory Action
8	Declaration of Paul Polakis, Ph.D.	Originally submitted with Appellants' 1 st Amendment and Response to Office Action as Exhibit 3	Entered by Examiner in Final Office Action

Appl. No. : **10/063,584**
Filed : **May 3, 2002**

9	Bruce Alberts, <i>et al.</i> , Molecular Biology of the Cell (3 rd ed. 1994)	Originally submitted with Appellants' After Final Amendment as Exhibit 2	Entered by Examiner in Advisory Action
10	Bruce Alberts, <i>et al.</i> , Molecular Biology of the Cell (4 th ed. 2002)	Originally submitted with Appellants' After Final Amendment as Exhibit 3	Entered by Examiner in Advisory Action
11	Benjamin Lewin, Genes VI (1997)	Originally submitted with Appellants' After Final Amendment as Exhibit 4	Entered by Examiner in Advisory Action
12	Zhigang <i>et al.</i> , World Journal of Surgical Oncology 2:13, 2004	Originally submitted with Appellants' After Final Amendment as Exhibit 5	Entered by Examiner in Advisory Action
13	Meric <i>et al.</i> , Molecular Cancer Therapeutics, vol. 1, 971-979 (2002)	Originally submitted with Appellants' After Final Amendment as Exhibit 6	Entered by Examiner in Advisory Action

Appl. No. : **10/063,584**
Filed : **May 3, 2002**

X. APPENDIX C – RELATED PROCEEDINGS

There are no decisions rendered by a court or the Board in any related proceedings identified above.



GNE.3230R1C39

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Eaton, et al.
Appl. No.	: 10/063,557
Filed	: May 2, 2002
For	: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
Examiner	: David J. Blanchard
Group Art Unit	: 1642

DECLARATION OF J. CHRISTOPHER GRIMALDI, UNDER 37 C.F.R. § 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, J. Christopher Grimaldi, declare and say as follows:

1. I am a Senior Research Associate in the Molecular Biology Department of Genentech, Inc., South San Francisco, CA 94080.
2. I joined Genentech in January of 1999. From 1999 to 2003, I directed the Cloning Laboratory in the Molecular Biology Department. During this time I directed or performed numerous molecular biology techniques including qualitative Polymerase Chain Reaction (PCR) analyses. I am currently involved in, among other projects, the isolation of genes coding for membrane associated proteins which can be used as targets for antibody therapeutics against cancer. In connection with the above-identified patent application, I personally performed or directed the semi-quantitative PCR analyses in the assay entitled "Tumor Versus Normal Differential Tissue Expression Distribution" which is described in EXAMPLE 18 in the specification that were used to identify differences in gene expression between tumor tissue and their normal counterparts.
3. My scientific Curriculum Vitae, including my list of publications, is attached to and forms part of this Declaration (Exhibit A).
4. In differential gene expression studies, one looks for genes whose expression levels differ significantly under different conditions, for example, in normal versus diseased tissue.

Appl. No. : 10/063,557
Filed : May 2, 2002

Chromosomal aberrations, such as gene amplification, and chromosomal translocations are important markers of specific types of cancer and lead to the aberrant expression of specific genes and their encoded polypeptides, including over-expression and under-expression. For example, gene amplification is a process in which specific regions of a chromosome are duplicated, thus creating multiple copies of certain genes that normally exist as a single copy. Gene under-expression can occur when a gene is not transcribed into mRNA. In addition, chromosomal translocations occur when two different chromosomes break and are rejoined to each other chromosome resulting in a chimeric chromosome which displays a different expression pattern relative to the parent chromosomes. Amplification of certain genes such as Her2/Neu [Singleton *et al.*, Pathol. Annu., 27Pt1:165-190], or chromosomal translocations such as t(5;14), [Grimaldi *et al.*, Blood, 73(8):2081-2085(1989); Meeker *et al.*, Blood, 76(2):285-289(1990)] give cancer cells a growth or survival advantage relative to normal cells, and might also provide a mechanism of tumor cell resistance to chemotherapy or radiotherapy. When the chromosomal aberration results in the aberrant expression of a mRNA and the corresponding gene product (the polypeptide), as it does in the aforementioned cases, the gene product is a promising target for cancer therapy, for example, by the therapeutic antibody approach.

5. Comparison of gene expression levels in normal versus diseased tissue has important implications both diagnostically and therapeutically. For example, those who work in this field are well aware that in the vast majority of cases, when a gene is over-expressed, as evidenced by an increased production of mRNA, the gene product or polypeptide will also be over-expressed. It is unlikely that one identifies increased mRNA expression without associated increased protein expression. This same principle applies to gene under-expression. When a gene is under-expressed, the gene product is also likely to be under-expressed. Stated in another way, two cell samples which have differing mRNA concentrations for a specific gene are expected to have correspondingly different concentration of protein for that gene. Techniques used to detect mRNA, such as Northern Blotting, Differential Display, *in situ* hybridization, quantitative PCR, Taqman, and more recently Microarray technology all rely on the dogma that a change in mRNA will represent a similar change in protein. If this dogma did not hold true then these techniques would have little value and not be so widely used. The use of mRNA quantitation techniques have identified a seemingly endless number of genes which are differentially expressed in various tissues and these genes have subsequently been shown to have correspondingly similar changes in their protein levels. Thus, the detection of increased mRNA expression is expected to result in increased polypeptide expression, and the detection of decreased mRNA expression is expected to result in decreased polypeptide expression. The detection of increased or decreased polypeptide expression can be used for cancer diagnosis and treatment.

6. However, even in the rare case where the protein expression does not correlate with the mRNA expression, this still provides significant information useful for cancer diagnosis and treatment. For example, if over- or under-expression of a gene product does not correlate with over- or under-expression of mRNA in certain tumor types but does so in others, then identification of both gene expression and protein expression enables more accurate tumor classification and hence better determination of suitable therapy. In addition, absence of over- or

Appl. No. : 10/063,557
Filed : May 2, 2002

under-expression of the gene product in the presence of a particular over- or under-expression of mRNA is crucial information for the practicing clinician. For example, if a gene is over-expressed but the corresponding gene product is not significantly over-expressed, the clinician accordingly will decide not to treat a patient with agents that target that gene product.

7. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____

J. Christopher Grimaldi

Date: _____

8/10/2001

S:\DOCS\AOK\ADK-5479.DOC
071904

EXHIBIT A

J. Christopher Grimaldi

1434-36th Ave.
San Francisco, CA 94122
(415) 681-1639 (Home)

EDUCATION

University of California, Berkeley
Bachelor of Arts in Molecular Biology, 1984

EMPLOYMENT EXPERIENCE

SRA

Genentech Inc., South San Francisco; 1/99 to present

Previously, was responsible to direct and manage the Cloning Lab. Currently focused on isolating cancer specific genes for the Tumor Antigen (TAP), and Secreted Tumor Protein (STOP) projects for the Oncology Department as well as Immunologically relevant genes for the Immunology Department. Directed a lab of 6 scientists focused on a company-wide team effort to identify and isolate secreted proteins for potential therapeutic use (SPDI). For the SPDI project my duties were, among other things, the critically important coordination of the cloning of thousands of putative genes, by developing a smooth process of communication between the Bioinformatics, Cloning, Sequencing, and Legal teams. Collaborated with several groups to discover novel genes through the Curagen project, a unique differential display methodology. Interacted extensively with the Legal team providing essential data needed for filing patents on novel genes discovered through the SPDI, TAP and Curagen projects. My group has developed, implemented and patented high throughput cloning methodologies that have proven to be essential for the isolation of hundreds of novel genes for the SPDI, TAP and Curagen projects as well as dozens of other smaller projects.

Scientist

DNAX Research Institute, Palo Alto; 9/91 to 1/99

Involved in multiple projects aimed at understanding novel genes discovered through bioinformatics studies and functional assays. Developed and patented a method for the specific depletion of eosinophils in vivo using monoclonal antibodies. Developed and implemented essential technical methodologies and provided strategic direction in the areas of expression, cloning, protein purification, general molecular biology, and monoclonal antibody production. Trained and supervised numerous technical staff.

Facilities

Manager

Corixa, Redwood City; 5/89 - 7/91.

Directed plant-related activities, which included expansion planning, maintenance, safety, purchasing, inventory control, shipping and receiving, and laboratory management. Designed and implemented the safety program. Also served as liaison to regulatory agencies at the local, state and federal level. Was in charge of property leases, leasehold improvements, etc. Negotiated vendor contracts and directed the purchasing department. Trained and supervised personnel to carry out the above-mentioned duties.

SRA University of California, San Francisco
Cancer Research Institute; 2/87-4/89.

Was responsible for numerous cloning projects including: studies of somatic hypermutation, studies of AIDS-associated lymphomas, and cloning of t(5;14), t(11;14), and t(8;14) translocations. Focused on the activation of hemopoietic growth factors involved in the t(5;14) translocation in leukemia patients..

Research Berlex Biosciences, South San Francisco; 7/85-2/87.
Technician

Worked on a subunit porcine vaccine directed against *Mycoplasma hyopneumoniae*. Was responsible for generating genomic libraries, screening with degenerate oligonucleotides, and characterizing and expressing clones in *E. coli*. Also constructed a general purpose expression vector for use by other scientific teams.

PUBLICATIONS

1. Hilary F. Clark, et al. "The Secreted Protein Discovery Initiative (SPDI), a Large-scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: a bioinformatics assessment." *Genome Res.* Vol 13(10), 2265-2270, 2003
2. Sean H. Adams, Clarissa Chui, Sarah L. Schilbach, Xing Xian Yu, Audrey D. Goddard, J. Christopher Grimaldi, James Lee, Patrick Dowd, David A. Lewin, & Steven Colman. "BFTT, a Unique Acyl-CoA Thioesterase Induced in Thermogenic Brown Adipose Tissue: Cloning, organization of the human gene and assessment of a potential link to obesity" *Biochemical Journal*, Vol 360, 135-142, 2001
3. Szeto W, Jiang W, Tice DA, Rubinfeld B, Hollingshead PG, Fong SE, Dugger DL, Pham T, Yansura D, Wong TA, Grimaldi JC, Corpuz RT, Singh JS, Frantz GD, Devaux B, Crowley CW, Schwall RH, Eberhard DA, Rastelli L, Polakis P, and Pennica D. "Overexpression of the Retinoic Acid-Responsive Gene *Stra6* in Human Cancers and its Synergistic Activation by Wnt-1 and Retinoic Acid." *Cancer Research* Vol. 61(10), 4197-4205, 2001
4. Jeanne Kahn, Fuad Mehraban, Gladdys Ingle, Xiaohua Xin, Juliet E. Bryant, Gordon Vehar, Jill Schoenfeld, J. Christopher Grimaldi (incorrectly named as "Grimaldi, CJ"), Franklin Peale, Aparna Draksharapu, David A. Lewin, and Mary E. Gerritsen. "Gene Expression Profiling in an in Vitro Model of Angiogenesis." *American Journal of Pathology* Vol 156(6), 1887-1900, 2000.
5. Grimaldi JC, Yu NX, Grunig G, Seymour BW, Cottrez F, Robinson DS, Hosken N, Ferlin WG, Wu X, Soto H, O'Garra A, Howard MC, Coffman RL. "Depletion of eosinophils in mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3). *Journal of Leukocyte Biology*; Vol. 65(6), 846-53, 1999
6. Oliver AM, Grimaldi JC, Howard MC, Kearney JF. "Independently ligating CD38 and Fc gammaRIIB relays a dominant negative signal to B cells." *Hybridoma* Vol. 18(2), 113-9, 1999

7. Cockayne DA, Muchamuel T, Grimaldi JC, Muller-Steffner H, Randall TD, Lund FE, Murray R, Schuber F, Howard MC. "Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses." *Blood* Vol. 92(4), 1324-33, 1998
8. Frances E. Lund, Nanette W. Solvason, Michael P. Cooke, Andrew W. Heath, J. Christopher Grimaldi, Troy D. Randall, R. M. E. Parkhouse, Christopher C Goodnow and Maureen C. Howard. "Signaling through murine CD38 is impaired in antigen receptor unresponsive B cells." *European Journal of Immunology*, Vol. 25(5), 1338-1345, 1995
9. M. J. Guimaraes, J. F. Bazan, A. Zolotnik, M. V. Wiles, J. C. Grimaldi, F. Lee, T. McClanahan. "A new approach to the study of haematopoietic development in the yolk sac and embryoid body." *Development*, Vol. 121(10), 3335-3346, 1995
10. J. Christopher Grimaldi, Sriram Balasubramanian, J. Fernando Bazan, Armen Shanafelt, Gerard Zurawski and Maureen Howard. "CD38-mediated protein ribosylation." *Journal of Immunology*, Vol. 155(2), 811-817, 1995
11. Leopoldo Santos-Argumedo, Frances F. Lund, Andrew W. Heath, Nanette Solvason, Wei Wei Wu, J. Christopher Grimaldi, R. M. E. Parkhouse and Maureen Howard. "CD38 unresponsiveness of xid B cells implicates Bruton's tyrosine kinase (btk) as a regulator of CD38 induced signal transduction." *International Immunology*, Vol 7(2), 163-170, 1995
12. Frances Lund, Nanette Solvason, J. Christopher Grimaldi, R. M. E. Parkhouse and Maureen Howard. "Murine CD38: An immunoregulatory ectoenzyme." *Immunology Today*, Vol. 16(10), 469-473, 1995
13. Maureen Howard, J. Christopher Grimaldi, J. Fernando Bazan, Frances E. Lund, Leopoldo Santos-Argumedo, R. M. E. Parkhouse, Timothy F. Walseth, and Hon Cheung Lee. "Formation and Hydrolysis of Cyclic ADP-Ribose Catalyzed by Lymphocyte Antigen CD38." *Science*, Vol. 262, 1056-1059, 1993
14. Nobuyuki Harada, Leopoldo Santos-Argumedo, Ray Chang, J. Christopher Grimaldi, Frances Lund, Camilynn I. Brannan, Neal G. Copeland, Nancy A. Jenkins, Andrew Heath, R. M. E. Parkhouse and Maureen Howard. "Expression Cloning of a cDNA Encoding a Novel Murine B Cell Activation Marker: Homology to Human CD38." *The Journal of Immunology*, Vol. 151, 3111-3118, 1993
15. David J. Rawlings, Douglas C. Saffran, Satoshi Tsukada, David A. Largaespada, J. Christopher Grimaldi, Lucie Cohen Randolph N. Mohr, J. Fernando Bazan, Maureen Howard, Neal G. Copeland, Nancy A. Jenkins, Owen Witte. "Mutation of Unique Region of Bruton's Tyrosine Kinase in Immunodeficient XID Mice." *Science*, Vol. 261, 358-360, 1993
16. J. Christopher Grimaldi, Raul Torres, Christine A. Kozak, Ray Chang, Edward Clark, Maureen Howard, and Debra A. Cockayne. "Genomic Structure and Chromosomal Mapping of the Murine CD40 Gene." *The Journal of Immunology*, Vol 149, 3921-3926, 1992
17. Timothy C. Meeker, Bruce Shiramizu, Lawrence Kaplan, Brian Herndier, Henry Sanchez, J. Christopher Grimaldi, James Baumgartner, Jacob Rachlin, Ellen Feigal, Mark Rosenblum and Michael S. McGrath. "Evidence for Molecular Subtypes of HIV-Associated Lymphoma:

Division into Peripheral Monoclonal, Polyclonal and Central Nervous System Lymphoma." AIDS, Vol. 5, 669-674, 1991

18. Ann Grimaldi and Chris Grimaldi. "Small-Scale Lambda DNA Prep." Contribution to Current Protocols in Molecular Biology, Supplement 5, Winter 1989
19. J. Christopher Grimaldi, Timothy C. Meeker. "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene." Blood, Vol. 73, 2081-2085, 1989
20. Timothy C. Meeker, J. Christopher Grimaldi, et al. "An Additional Breakpoint Region in the BCL-1 Locus Associated with the t(11;14) (q13;q32) Translocation of B-Lymphocytic Malignancy." Blood, Vol. 74, 1801-1806, 1989
21. Timothy C. Meeker, J. Christopher Grimaldi, Robert O'Rourke, et al. "Lack of Detectable Somatic Hypermutation in the V Region of the Ig H Chain Gene of a Human Chronic B Lymphocytic Leukemia." The Journal of Immunology, Vol. 141, 3994-3998, 1988

MANUSCRIPTS IN PREPARATION

1. Sriram Balasubramanian, J. Christopher Grimaldi, J. Fernando Bazan, Gerard Zurawski and Maureen Howard. "Structural and functional characterization of CD38: Identification of active site residues"

PATENTS

1. "Methods for Eosinophil Depletion with Antibody to CCR3 Receptor" (US 6,207,155 B1).
2. "Amplification Based Cloning Method." (US 6,607,899)
3. Ashkenazi et al., "Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same." (this patent covers several hundred genes)
4. "IL-17 Homologous Polypeptides and Therapeutic Uses Thereof"
5. "Method of Diagnosing and Treating Cartilaginous Disorders."

MEMBERSHIPS AND ACTIVITIES

Editor	Frontiers in Bioscience
Member	DNAX Safety Committee 1991-1999
	Biological Safety Affairs Forum (BSAF) 1990-1991
	Environmental Law Foundation (ELF) 1990-1991

The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene

By J. Christopher Grimaldi and Timothy C. Meeker

Chromosomal translocations have proven to be important markers of the genetic abnormalities central to the pathogenesis of cancer. By cloning chromosomal breakpoints one can identify activated proto-oncogenes. We have studied a case of B-lineage acute lymphocytic leukemia (ALL) that was associated with peripheral blood eosinophilia. The chromosomal translocation t(5;14) (q31;q32) from this sample was cloned and studied at the molecular level. This

translocation joined the immunoglobulin heavy chain joining (Jh) region to the promotor region of the interleukin-3 (IL-3) gene in opposite transcriptional orientations. The data suggest that activation of the IL-3 gene by the enhancer of the immunoglobulin heavy chain gene may play a central role in the pathogenesis of this leukemia and the associated eosinophilia.

© 1989 by Grune & Stratton, Inc.

KARYOTYPIC STUDIES of leukemia and lymphoma have identified frequent nonrandom chromosomal translocations. Some of these translocations juxtapose the immunoglobulin heavy chain (IgH) gene with important

protooncogenes, such as *c-myc* and *bcl-2*.^{1,2} In this way, the IgH gene can activate proto-oncogenes, resulting in disordered gene expression and a step in the development of cancer. The investigation of additional nonrandom translocations into the IgH locus allows us to identify new genes promoting the generation of leukemia and lymphoma.

A distinct subtype of acute lymphocytic leukemia (ALL) has been characterized by B-lineage phenotype, associated eosinophilia in the peripheral blood, and a t(5;14)(q31;q32) chromosomal translocation.^{3,4} This syndrome probably occurs in <1% of all patients with ALL. We hypothesized that the cloning of the translocation characteristic of this leukemia might allow the identification of an important gene on chromosome 5 that plays a role in the evolution of this disease. In this report we demonstrate that the interleukin-3 gene (IL-3) and the IgH gene are joined by this translocation.

MATERIALS AND METHODS

Sample and DNA blots. A bone marrow aspirate from a representative patient with ALL (L1 morphology by French-American-British [FAB] criteria), peripheral eosinophilia (up to 20,000 per microliter with a normal value of <350 per microliter) and a t(5;14)(q31;q32) translocation was studied. Using published methods, genomic DNA was isolated and DNA blots were made.⁵ Briefly, 10 µg of high molecular weight (mol wt) DNA were digested using an appropriate restriction enzyme and electrophoresed on a 0.8% agarose gel. The gel was stained with ethidium bromide, photographed, denatured, neutralized, and transferred to Hybond (Amersham, Arlington Heights, IL). After treatment of the filter with ultraviolet light, hybridization was performed. The filter was washed to a final stringency of 0.2% saturated sodium citrate (SSC) and 0.1% sodium lauryl sulfate (SDS) and exposed to film. The human Jh probe has been previously reported.⁶

Genomic library. The genomic library was made using pub-




Fig 1. DNA blots of the leukemia sample. The restriction fragment pattern of normal human DNA (N) and the leukemia sample (L) were compared using a human Jh probe. Rearranged bands are indicated by arrows. Sample L exhibits a single rearranged band with both *Hind* III/*Eco*RI and *Sau*3A restriction digests. The rearranged bands are less intense than the other bands because the majority of cells in the sample represent normal bone marrow elements.

From the Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco.

Submitted February 22, 1989; accepted March 8, 1989.

Supported by NIH Grant No. CA01102.

Address reprint requests to Timothy C. Meeker, MD, UCSF/VAMC 111H, 4150 Clement St, San Francisco, CA 94121.

Dr Grimaldi's current address is Biostan Inc, 440 Chesapeake Dr, Seaport Centre, Redwood City, CA 94063.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1989 by Grune & Stratton, Inc.

0006-4971/89/7308-0031\$3.00/0

lished methods.⁵ Approximately 100 μ g of high mol wt genomic DNA were partially digested with the *Sau*3A restriction enzyme. Fragments from 9 to 23 kilobases (kb) in size were isolated on a sucrose gradient and ligated into phage EMBL3A (Stratagene, San Diego). Recombinant phage were packaged, plated, and screened as previously reported.⁵

DNA sequencing. Fragments for sequencing were cloned into M13 vectors and sequenced by the chain termination method using Sequenase (United States Biochemical, Cleveland).⁷ All sequence data were derived from both strands.

RESULTS

We studied a bone marrow sample from a patient with ALL and associated peripheral eosinophilia. Karyotypic analysis showed the characteristic t(5;14)(q31;q32) translocation. These features define a distinctive subtype of ALL.^{3,4} The leukemic cells were analyzed for cell surface phenotype by immunofluorescence. They were positive for B1 (CD20), B4 (CD19), cALLA (CD10), HLA-DR, and terminal deoxynucleotidyl transferase (Tdt), but negative for surface immunoglobulin. This phenotypic profile describes an immature cell from the B-lymphocytic lineage.⁸

The leukemia DNA was analyzed by Southern blotting for rearrangements of the IgH gene. Using a human immunoglobulin Jh probe, a single rearranged band was detected by *Eco*RI, *Hind*III, *Sst*I, *Sau*3A, and *Eco*RI plus *Hind*III restriction digests, suggesting rearrangement of one allele (Fig 1). The immunoglobulin Jh region from the other allele was presumably either deleted or in the germline configuration.

We hypothesized that the t(5;14)(q31;q32) juxtaposed a

growth-promoting gene on chromosome 5 with the immunoglobulin Jh region on chromosome 14. Therefore, a genomic library was made from the leukemic sample and screened with a Jh probe. Fifteen distinct positive clones were isolated and screened for the presence of the rearranged *Sau*3A fragment that was detected by DNA blotting. By this analysis, five clones appeared to represent the rearranged allele identified by DNA blots. One of these clones (clone no. 4) was chosen for further study and a detailed restriction map was generated. The *Eco*RI, *Hind*III/*Eco*RI, and *Sst*I fragments from clone no. 4 that hybridized to the human Jh probe were also identical in size to the rearranged fragments from the leukemia sample, confirming that clone no. 4 represented the rearranged leukemic allele.

Phage clone no. 4 contained 3.7 kb of unknown origin joined to the IgH gene in the region of Jh4 (Fig 2). The IgH gene from Jh4 to the Cmu region appeared to be in germline configuration. Previously, the gene encoding hematopoietic growth factor IL-3 had been mapped to chromosome 5q31 so it was suspected that clone no. 4 might contain part of this gene.⁹⁻¹² When the restriction map of human IL-3 and clone no. 4 were compared, they were identical for more than 3 kb (Fig 2).

We confirmed the juxtaposition of the IL-3 gene and the IgH gene by nucleic acid sequencing of the subcloned *Bst*EII/*Hpa*I fragment (Fig 2). The sequence of this fragment showed no disruption of the protein coding region or the messenger RNA of the IL-3 gene. The break in the IL-3 gene occurred in the promoter region, 452 base pairs (bp) upstream of the transcriptional start site (position 64, Fig




Fig 2. Breakpoint region: t(5;14)(q31;q32). Comparative mapping of phage clone no. 4, the germline IgH region, and the germline IL-3 gene.^{20,28} The map of clone no. 4 is identical to that of IgH until it diverges in the region of Jh4 (at the dashed line), after which it is identical to the map of IL-3. The two genes are positioned in a head-to-head orientation. The Ig μ chain constant region (C μ), switch region (S μ), enhancer (E), and Jh segments are indicated (open symbols). The five exons (dark boxes) and four introns of the IL-3 gene are shown. The hatched box indicates the sequenced region.

3A). The break in the IgH gene occurred 2 bp upstream of the Jh4 region. Between the two breaks, 25 bp of uncertain origin (putative N sequence) were inserted.^{13,14} No sequences homologous to the immunoglobulin heptamer and nonamer could be identified in the IL-3 sequence (Fig 3B). Therefore, nucleic acid sequencing confirmed the juxtaposition of the IL-3 gene and the IgH gene. The sequence data clearly showed that the genes were positioned in opposite transcriptional orientations (head-to-head).

Available data also allowed us to determine the normal positions of the IL-3 gene and the GM-CSF gene in relation to the centromere of chromosome 5 (Fig 4). The IgH gene is known to be positioned with the variable regions toward the telomere on chromosome 14q.^{2,15} It has also been shown that

GM-CSF maps within 9 kb of IL-3 in the same transcriptional orientation.¹⁶ Using this information and assuming a simple translocation event in our sample, we can conclude that the IL-3 gene is normally more centromeric, and the GM-CSF gene more telomeric on chromosome 5q (Fig 4). Furthermore, both are transcribed with their 5' ends toward the centromere.

DISCUSSION

In this report we have cloned a unique chromosomal translocation that appears to be a consistent feature of a rare, yet distinct, clinical form of acute leukemia. This translocation joined the promotor of the IL-3 gene to the IgH gene. Except for the altered promotor, the IL-3 gene appeared




Fig 3. Sequence of t(5;14)(q31;q32) breakpoint region. (A) Nucleotide sequence of the *Bst*II/*Hpa*I fragment indicated on Fig 2. Nucleotides 1 to 36 represent the Jh4 coding region underlined on the coding strand. Nucleotides 39 to 63 are a putative N region. The sequence from position 64 to 668 is that of the germline IL-3 gene.²⁰ The IL-3 TATA box (485), transcription start (515), and initiation methionine (567) are underlined. Two proposed regulatory sequences in the promotor are marked by asterisks (positions 182 and 389). (B) Comparative sequence of the t(5;14)(q31;q32) breakpoint region. The IgJh4 region is shown with its coding region, heptamer, and nonamer underlined. Clone no. 4 is shown with putative N region sequences underlined. The IL-3 sequence is also shown. A plus sign (+) denotes the identical nucleotide between sequences. No heptamer or nonamer is identified in the IL-3 sequence.




Fig 4. Diagram of the translocation. The normal chromosome 5q31 is shown with the GM-CSF gene telomeric to the IL-3 gene in the transcriptional orientation shown. On normal chromosome 14q32 the V_H regions are telomeric. The t(5;14)(q31;q32) translocation results in the head-to-head orientation of these genes. Symbols are defined in Fig 2. BP, breakpoint position.

intact as no deletions, insertions, or point mutations were detected by restriction mapping of the entire gene and sequencing of part of the gene. The IgH gene has been truncated at the J_H4 region, which places the immunoglobulin enhancer within 2.5 kb of the IL-3 gene.^{17,18} This leads to the hypothesis that the enhancer is increasing transcription of a structurally normal IL-3 gene. The same mechanism is important for activation of the *c-myc* gene in some cases of Burkitt's lymphoma.¹⁹ An alternate hypothesis is that the elimination of an upstream IL-3 promoter element is crucial to the activation of the IL-3 gene.

The proposed activation of the IL-3 gene suggests that an autocrine loop is important for the pathogenesis of this leukemia.²⁰ Over-expression of the IL-3 gene coupled with

the presence of the IL-3 receptor in these cells could account for a strong stimulus for proliferation. In this regard, there are data indicating that immature B-lineage lymphocytes and B-lineage leukemias may express the IL-3 receptor.^{21,22}

An additional feature of this type of leukemia is the dramatic eosinophilia, consisting of mature forms. It has been hypothesized that the eosinophils do not arise from the malignant clone, but are stimulated by the tumor.^{23,24} Because of the known effect of IL-3 on eosinophil differentiation, secretion of high levels of IL-3 by leukemic cells might have a role in the eosinophilia in this type of leukemia.¹²

The data suggest that the recombination mechanism that is active in the IgH gene during normal differentiation has a role in this translocation.^{13,14} This is supported by the breakpoint location at the 5' end of J_H4 and the presence of putative N-region sequences. On the other hand, no recombination signal sequence (heptamer and nonamer) was found in this region on chromosome 5, suggesting that additional factors also played a role. Further studies will elucidate the mechanism of this and other translocations.

In the leukemia we studied, it is possible that the immunoglobulin enhancer also activates the GM-CSF gene, since this gene is probably positioned only 14 kb away (Fig 4). This is known to be within the range of enhancer activation.²⁵ The interleukin-5 (IL-5) gene maps to chromosome 5q31.²⁶ Deregulation of the IL-5 gene by this translocation would act synergistically with IL-3 in the stimulation of eosinophil proliferation and differentiation.²⁷ These and other questions will be answered by the study of more patient samples. We plan to determine whether the t(5;14)(q31;q32) translocation is capable of activating multiple lymphokines simultaneously and whether they cooperate in the generation of this leukemia.

REFERENCES

1. Klein G, Klein E: Evolution of tumours and the impact of molecular oncology. *Nature* 315:190, 1985
2. Showe L, Croce C: The role of chromosomal translocations in B- and T-cell neoplasia. *Annu Rev Immunol* 5:253, 1987
3. Hogan T, Koss W, Murgo A, Amato R, Fontana J, VanScoy F: Acute lymphoblastic leukemia with chromosomal 5;14 translocation and hyper eosinophilia: Case report and literature review. *J Clin Oncol* 5:382, 1987
4. Tono-oka T, Sato Y, Matsumoto T, Ueno N, Ohkawa M, Shikano T, Takeda T: Hyper eosinophilic syndrome in acute lymphoblastic leukemia with a chromosome translocation t(5q;14q). *Med Pediatr Oncol* 12:33, 1984
5. Meeker T, Grimaldi JC, O'Rourke R, Loeb J, Juliusson G, Einhorn S: Lack of detectable somatic hypermutation in the V region of the IgH gene of a human chronic B-lymphocytic leukemia. *J Immunol* 141:3394, 1988
6. Ravetch J, Siebenlist U, Korsmeyer S, Waldmann T, Leder P: Structure of the human immunoglobulin μ locus: Characterization of embryonic and rearranged J and D genes. *Cell* 27:583, 1981
7. Norrander U, Kempe T, Messing J: Construction of improved M13 vectors using oligodeoxynucleotide-directed mutagenesis. *Gene* 26:101, 1983
8. Foon K, Todd R: Immunologic classification of leukemia and lymphoma. *Blood* 68:1, 1986
9. LeBeau M, Epstein N, O'Brien SJ, Nienhuis AW, Yang Y-C, Clark S, Rowley J: The interleukin-3 gene is located on human

chromosome 5 and is deleted in myeloid leukemias with a deletion of 5q. *Proc Natl Acad Sci USA* 84:5913, 1987

10. LeBeau M, Chandrasekharappi S, Lemons R, Schwartz J, Larson R, Arai N, Westbrook C: Molecular and cytogenetic analysis of chromosome 5 abnormalities in myeloid disorders, in cancer cells, in *Proceedings of Molecular Diagnostics of Human Cancer*. Cold Spring Harbor Laboratory, NY, 1989 (in press)

11. Ihle J, Weinstein Y: Immunological regulation of hematopoietic/lymphoid stem cell differentiation by interleukin-3. *Adv Immunol* 39:1, 1986

12. Clark S, Kamen R: The human hematopoietic colony-stimulating factors. *Science* 236:1229, 1987

13. Bakhshi A, Wright J, Graninger W, Seto M, Owens J, Cossman J, Jensen J, Goldman P, Korsmeyer S: Mechanism of the t(14;18) chromosomal translocation: Structural analysis of both derivative 14 and 18 reciprocal partners. *Proc Natl Acad Sci USA* 84:2396, 1987

14. Tsujimoto Y, Louie E, Bashir M, Croce C: The reciprocal partners of both the t(14;18) and the t(11;14) translocations involved in B-cell neoplasms are rearranged by the same mechanism. *Oncogene* 2:347, 1988

15. Erikson J, Finan J, Nowell P, Croce C: Translocation of immunoglobulin VH genes in Burkitt lymphoma. *Proc Natl Acad Sci USA* 80:810, 1982

16. Yang Y-C, Kovacic S, Kriz R, Wolf S, Clark S, Wellems T, Nienhuis A, Epstein N: The human genes for GM-CSF and IL-3 are closely linked in tandem on chromosome 5. *Blood* 71:958, 1988

17. Gillies S, Morrison S, Oi V, Tonegawa S: A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene. *Cell* 33:717, 1983

18. Banerji J, Olson L, Schaffner W: A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes. *Cell* 33:729, 1983

19. Hayday A, Gillies S, Saito H, Wood C, Wiman K, Hayward

W, Tonegawa S: Activation of a translocated human *c-myc* gene by an enhancer in the immunoglobulin heavy-chain locus. *Nature* 307:334, 1984

20. Sporn M, Roberts A: Autocrine growth factors and cancer. *Nature* 313:745, 1985

21. Palacios R, Steinmetz M: IL-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ line configuration, and generate B lymphocytes in vivo. *Cell* 41:727, 1985

22. Uckun F, Gesner T, Song C, Myers D, Mufson A: Leukemic B-cell precursors express functional receptors for human interleukin-3. *Blood* 73:533, 1989

23. Spitzer G, Garson O: Lymphoblastic leukemia with marked eosinophilia: A report of two cases. *Blood* 42:377, 1973

24. Catovsky D, Bernasconi C, Verkonck P, Postma A, Howss J, Berg A, Rees J, Castelli G, Morra E, Galton D: The association of eosinophilia with lymphoblastic leukemia or lymphoma: A study of seven patients. *Br J Haematol* 45:523, 1980

25. Wang X-F, Calame K: The endogenous immunoglobulin heavy chain enhancer can activate tandem Vh promoters separated by a large distance. *Cell* 43:659, 1985

26. Sutherland G, Baker E, Callen D, Campbell H, Young I, Sanderson C, Garson O, Lopez A, Vadas M: Interleukin-5 is at 5q31 and is deleted in the 5q-syndrome. *Blood* 71:1150, 1988

27. Warren D, Moore M: Synergism among interleukin-1, interleukin-3, and interleukin-5 in the production of eosinophils from primitive hemopoietic stem cells. *J Immunol* 140:94, 1988

28. Yang Y-C, Clark S: Molecular cloning of a primate cDNA and the human gene for interleukin-3. *Lymphokines* 15:375, 1988

29. Yang Y-C, Ciarletta A, Temple P, Chung M, Kovacic S, Witek-Giannotti J, Leary A, Kriz R, Donahue R, Wong G, Clark S: Human IL-3 (multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. *Cell* 47:3, 1986

RAPID COMMUNICATION

Activation of the Interleukin-3 Gene by Chromosome Translocation in Acute Lymphocytic Leukemia With Eosinophilia

By Timothy C. Meeker, Dan Hardy, Cheryl Willman, Thomas Hogan, and John Abrams

The t(5;14)(q31;q32) translocation from B-lineage acute lymphocytic leukemia with eosinophilia has been cloned from two leukemia samples. In both cases, this translocation joined the IgH gene and the interleukin-3 (IL-3) gene. In one patient, excess IL-3 mRNA was produced by the leukemic cells. In the second patient, serum IL-3 levels were measured and shown to correlate with disease

activity. There was no evidence of excess granulocyte/macrophage colony stimulating factor (GM-CSF) or IL-5 expression. Our data support the formulation that this subtype of leukemia may arise in part because of a chromosome translocation that activates the IL-3 gene, resulting in autocrine and paracrine growth effects.

© 1990 by The American Society of Hematology.

A NUMBER OF chromosome translocations have been associated with human leukemia and lymphoma. In many cases the study of these translocations has led to the discovery or characterization of proto-oncogenes, such as *bcl-2*, *c-abl*, and *c-myc*, that are located adjacent to the translocation.^{1,2} It is now widely understood that cancer-associated translocations disrupt nearby proto-oncogenes.

A distinct subtype of acute leukemia is characterized by the triad of B-lineage immunophenotype, eosinophilia, and the t(5;14)(q31;q32) translocation.^{3,4} Leukemic cells from such patients have been positive for terminal deoxynucleotidyl transferase (Tdt), common acute lymphoblastic leukemia antigen (CALLA), and CD19, but negative for surface or cytoplasmic immunoglobulin. In previous work, we cloned the t(5;14) breakpoint from one leukemic sample (Case 1) and determined that the IgH and interleukin-3 (IL-3) genes were joined by this abnormality.⁵ In this report, we extend those findings by showing that the t(5;14)(q31;q32) translocation from a second leukemia sample (Case 2) has a similar structure, and we report our study of growth factor expression in these patients.

MATERIALS AND METHODS

Samples and Southern blots. Case 1 has been described.^{5,6} Clinical features of Case 2 have been described in detail.⁷ DNA isolation and Southern blotting was done using previously described methods.⁸ Filters were hybridized with an immunoglobulin Jh probe, a 280 bp *Bam*HI/*Eco*RI genomic IL-3 fragment, and an IL-3 cDNA probe.^{7,8}

Northern blots. RNA isolation and Northern blotting have been described.⁹ Briefly, Northern blots were done by separating 9 µg total RNA on 1% agarose-formaldehyde gels. Equal RNA loading in each lane was confirmed by ethidium bromide staining. Blots were hybridized with an IL-3 cDNA probe extending to the *Xho* I site in exon 5, a 720 bp *Sst* I/*Kpn* I probe derived from intron 2 of the IL-3 gene, a 600 bp *Nhe* I/*Hpa* I IL-5 cDNA probe, and a 500 bp *Pst* I/*Nco* I granulocyte-macrophage colony stimulating factor (GM-CSF) cDNA probe.¹⁰⁻¹²

Polymerase chain reaction. Primers were designed with *Bam*HI sites for cloning. One primer hybridized to the Jh sequences from the IgH gene (Primer 144: 5'-TAGGATCCGACGGTGACCAGGGT), and the other hybridized to the region of the TATA box in the IL-3 gene (Primer 161: 5'-AACAGGATCCCGCCTTATATGTGCAG). Polymerase chain reaction (PCR) (95°C for 1 minute, 61°C for 30 seconds, and 72°C for 3 minutes) was done using 500 ng genomic DNA and 50 pmol of each primer in 100 µL containing 67 mmol/L Tris-HCl pH 8.8, 6.7 mmol/L MgCl₂, 10% dimethyl sulfoxide (DMSO), 170 µg/mL bovine serum albumin (BSA) (fraction V),

16.6 mmol/L ammonium sulfate, 1.5 mmol/L each dNTP and Taq polymerase (Perkin-Elmer, Norwalk, CT).¹³

Sequencing. Sequencing was done by chain termination in M13 vectors.¹⁴ As part of this study, we sequenced a subclone of a normal IL-3 promoter, covering 598 base pairs from a *Sma* I site at position -1240 (with respect to the proposed site of transcription initiation) to an *Nhe* I site at position -642. The plasmid containing this region was a gift from Naoko Arai of the DNAX Research Institute.

Expression in Cos7 cells. A genomic IL-3 fragment from Case 1 was cloned into the pXM expression vector.¹⁵ Briefly, the *Hind*III/*Sal* I fragment containing the IL-3 gene was subcloned from the previously described phage clone 4 into pUC18.⁵ The 2.6 kb fragment extending from the *Sma* I site 61 bp upstream of the IL-3 transcription start to the *Sma* I site in the polylinker was cloned into the blunt *Xho* I site of pXM. The negative control construct was the pXM vector without insert. Plasmids were introduced into Cos7 cells by electroporation, and supernatant was collected after 48 hours in culture.

TF1 bioassay. TF-1 cells were passaged in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 2 mmol L-glutamine, and 1 ng/mL human GM-CSF.¹⁶ Samples and antibodies were diluted in this same medium lacking GM-CSF but containing penicillin and streptomycin. A 25 µL volume of serial dilutions of patient serum was added to wells in a flat bottom 96-well microtiter plate. Rat anti-cytokine monoclonal antibody in a volume of 25 µL was added to appropriate wells and preincubated for 1 hour at 37°C. Fifty microliters of twice washed TF-1 cells were added to each well, giving a final cell concentration of 1 × 10⁴ cells per well (final volume, 100 µL). The plate was incubated for 48 hours. The remaining cell viability was determined metabolically by the colori-

From the Division of Hematology/Oncology 111H, Department of Medicine, University of California and the Veterans Administration Medical Center, San Francisco, CA; the Center for Molecular and Cellular Diagnostics, Department of Pathology and Cell Biology, University of New Mexico, Albuquerque, NM; the Division of Hematology/Oncology, Department of Medicine, West Virginia University, Morgantown, WV; and DNAX Research Institute, Palo Alto, CA.

Submitted March 27, 1990; accepted April 19, 1990.

Supported in part by the University of California Cancer Research Coordinating Committee and University of New Mexico Cancer Center funding from the state of New Mexico. The DNAX Research Institute is supported by Schering-Plough.

Address reprint requests to Timothy C. Meeker, MD, Division of Hematology/Oncology 111H, Department of Medicine, University of California and the Veterans Administration Medical Center, 4150 Clement St, San Francisco, CA 94121.

© 1990 by The American Society of Hematology.

0006-4971/90/7602-0022\$3.00/0


Fig 1. Breakpoint sequences for Case 2. The germline IgJh5 region sequence (protein coding region and recombination signal sequences are underlined) is on top, the translocation sequence from Case 2 (PCR primer sequences and putative N region are underlined) is in the middle, and the germline IL-3 sequence, which we derived from a normal IL-3 clone, is on the bottom.⁷ + indicates that each sequence has the same nucleotide. The sequence documents the head-to-head joining of the IL-3 and IgH genes. The breakpoint in the IL-3 gene occurred at position -934 (*).

fragment, comigrating with the rearranged Jh fragment, was identified. When leukemic DNA was digested with *HindIII* plus *EcoRI*, a rearranged Jh fragment was detected at 6 kb. The IL-3 probes also identified a comigrating fragment of this size. These experiments indicated that the leukemic sample studied was clonal and that a single fragment contained both Jh and IL-3 sequences, suggesting a translocation had occurred.

To characterize better the joining of the IL-3 gene and the immunoglobulin heavy chain (IgH) gene, the polymerase chain reaction (PCR) was used to clone the translocation.¹³ A Jh primer and an IL-3 primer were designed to produce an amplified product in the event of a head-to-head translocation. While control DNA gave no PCR product, Case 2 DNA yielded a PCR-derived fragment of approximately 980 bp, which was cloned and sequenced.

The DNA sequence of the translocation clone from Case 2 confirmed the joining of the Jh region with the promoter of the IL-3 gene in a head-to-head configuration (Fig 1). Sequence analysis indicated that the breakpoint on chromosome 14 was just upstream of the Jh5 coding region. The breakpoint on chromosome 5 occurred 934 bp upstream of the putative site of transcription initiation of the IL-3 gene. We also determined that a putative N sequence of 17 bp was inserted between the chromosome 5 and chromosome 14 sequences during the translocation event.^{17,18} Figure 2 shows

Leukemic DNA from Case 2 was studied by Southern blotting. When digested with the *Hind*III restriction enzyme and hybridized with a human immunoglobulin heavy chain joining region (Jh) probe, a rearranged fragment at approximately 14 kb was detected (data not shown). When reprobed with either of two different IL-3 probes, a rearranged 14 kb






Fig 3. Documentation of IL-3 mRNA over-expression. A Northern blot was prepared and hybridized with a probe for IL-3. Lane 1 contained RNA from unstimulated peripheral blood lymphocytes (PBL) as a negative control. Lane 2 contained RNA from PBL stimulated for 4 hours with concanavalin A (ConA), and lane 3 contained RNA from PBL stimulated with ConA for 48 hours. As in the positive control lanes (2 and 3), a 1 kb band was identified in the leukemic sample from Case 1 (lane 4, lower arrow), suggesting aberrant expression of the IL-3 gene. In addition, the leukemic sample showed over-expression of an unspliced 2.9 kb IL-3 transcript (lane 4, upper arrow). We documented that this represented an unspliced precursor of the mature 1 kb transcript by showing that this band hybridized to a probe from intron 2 of the IL-3 gene. A similar 2.9 kb band was detected in lane 2, suggesting that an IL-3 mRNA of this size is sometimes detectable in normal mitogen-stimulated cells. Lane 5 through 10 represent RNA from six samples of B-lineage acute lymphocytic leukemia without the t(5;14) translocation, indicating that only the sample with the translocation exhibited IL-3 over-expression. Case 2 could not be analyzed by Northern blot because too few cells were available for study.

the locations of the two cloned breakpoints in relation to the IL-3 gene. The two chromosome 5 breakpoints were separated by less than 500 bp.

The genomic structure in Cases 1 and 2 suggested that a normal IL-3 gene product was over-expressed as a result of the altered promoter structure. This would predict that the IL-3 gene on the translocated chromosome was capable of making IL-3 protein. This prediction was tested by expressing a genomic fragment from the translocated allele of Case 1 containing all five IL-3 exons under the control of the SV40 promoter/enhancer in the Cos7 cell line. Cell supernatants were studied in a proliferation assay using the factor dependent erythroleukemic cell line, TF-1. The supernatants derived from transfections using the vector plus insert supported TF-1 proliferation, while supernatants from transfections using the vector alone were negative in this assay (data not shown). Furthermore, the biologic activity could be blocked by an antibody to human IL-3 (BVD3-6G8). This result showed that the translocated allele retained the ability to make IL-3 mRNA and protein.

The level of expression of IL-3 mRNA in leukemic cells from Case 1 was assessed. Northern blotting showed that the mature IL-3 mRNA (approximately 1 kb) and a 2.9 kb unspliced IL-3 mRNA were excessively produced by the leukemia (Fig 3). The 2.9 kb form of the mRNA is also present at low levels in normal peripheral blood T lymphocytes after mitogen activation (Fig 3). Several B-lineage acute leukemia samples without the t(5;14) translocation had undetectable levels of IL-3 mRNA in these experiments. In addition, although genes for GM-CSF and IL-5 map close to the IL-3 gene and might have been deregulated by the translocation, no IL-5 or GM-CSF mRNA could be detected in the leukemic sample (data not shown).^{19,20}

Three serum samples from Case 2 were assayed by immunoassay for levels of IL-3, GM-CSF, and IL-5 (Table 1). Serum IL-3 could be detected and correlated with the clinical course. When the patient's leukemic cell burden was

highest, the IL-3 level was highest. No serum GM-CSF or IL-5 could be detected.

Since the IL-3 immunoassay measured only immunoreactive factor, we confirmed that biologically active IL-3 was present by using the TF-1 bioassay. This bioassay can be rendered monospecific using appropriate neutralizing monoclonal antibodies specific for IL-3, IL-5, or GM-CSF. We observed that sera from 1-16-84 and 3-14-84 contained TF-1 stimulating activity that could be blocked with anti-IL-3 MoAb (BVD3-6G8), but not with MoAbs to IL-5 (JES1-39D10) or GM-CSF (BVD2-23B6) (Fig 4; GM-CSF data not shown). The amount of neutralizable bioactivity in these two samples correlated very well with the difference in IL-3 levels obtained by immunoassay for these samples. Furthermore, the failure to block TF-1 proliferating activity with either anti-IL-5 or anti-GM-CSF was consistent with the inability to measure these factors by immunoassay and

Table 1. Peripheral Blood Counts and Growth Factor Levels at Different Times in Case 2

	Sample Date		
	11/15/83	1/16/84	3/14/84
Peripheral blood counts (cells/ μ L)			
WBC	81,800	116,500	12,300
Lymphoblasts	0	33,785	0
Eosinophils	46,626	73,080	615
Serum growth factor levels (pg/mL)			
IL-3	<444	7,995	1,051
GM-CSF	<15	<15	<15
IL-5	<50	<50	<50

Peripheral blood counts from Case 2 at three different time points with the corresponding growth factor levels quantified by immunoassay. The patient received chemotherapy between 1/16/84 and 3/14/84 to lower his leukemic burden.³ No serum samples were available for a similar analysis of Case 1.

Abbreviation: WBC, white blood cells.




Fig 4. Bioassay of serum IL-3. Leukemic patient sera were tested for bioactive IL-3 and IL-5 in the TF-1 proliferation assay. The reciprocal of the dilution is indicated on the horizontal axis and the optical density indicating the amount of proliferation is indicated on the vertical axis. Serum from all three time points was assayed simultaneously. The assay was rendered monospecific by using a $1 \mu\text{g/mL}$ final concentration of monoclonal rat anti-IL-3, BVD3-6G8 (■), or anti-IL-5, JES1-39D10 (△); □ indicates no MoAb. On 1/16/84 and 3/14/84, inhibition of proliferation was evident in the presence of anti-IL-3 antibody, documenting serum levels of IL-3 on those days. Serum IL-5 was not detected in this assay, as anti-IL-5 did not alter TF-1 proliferation.

indicated that these other myeloid growth factors were not detectably circulating in the serum of this patient.

DISCUSSION

In this report, we have extended our analysis of acute lymphocytic leukemia and eosinophilia associated with the t(5;14) translocation. In both cases we have studied, we have documented the joining of the IL-3 gene from chromosome 5 to the IgH gene from chromosome 14. The breakpoints on chromosome 5 are within 500 bp of each other, suggesting that additional breakpoints will be clustered in a small region of the IL-3 promoter. The PCR assay we have developed will be useful in the screening of additional clinical samples for this abnormality.

The finding of a disrupted IL-3 promoter associated with an otherwise normal IL-3 gene implied that this translocation might lead to the over-expression of a normal IL-3 gene product. In this work, we have documented that this is true. In addition, neither GM-CSF nor IL-5 are over-expressed by the leukemic cells. Furthermore, in one patient, serum IL-3 could be measured and correlated with disease activity. To our knowledge, this is the first measurement of human IL-3 in serum and its association with a disease process. The measurement of serum IL-3 in this and other clinical settings may now be indicated.

The finding of the IL-3 gene adjacent to a cancer-associated translocation breakpoint suggests that its activation is important for oncogenesis. It is our thesis that an autocrine loop for IL-3 is important for the evolution of this leukemia.²¹ The excessive IL-3 production that we have documented would be one feature of such an autocrine loop. The final proof of our thesis must await additional data. In particular, from the study of additional clinical samples, it will be necessary to document that the IL-3 receptor is present on the leukemic cells and that anti-IL-3 antibody decreases proliferation of the leukemia in vitro.

An important aspect of this work is the suggestion of a therapeutic approach for this disease. If an autocrine loop for IL-3 can be documented in this disease, attempts to lower circulating IL-3 levels or block the interaction of IL-3 with its receptor may prove useful. Because it is also possible that the eosinophilia in these patients is mediated by the paracrine effects of leukemia-derived IL-3, similar interventions may improve this aspect of the disease. Antibodies or engineered ligands to accomplish these goals may soon be available.

ACKNOWLEDGMENT

We thank Naoko Arai, Ken-ichi Arai, R. O'Rourke, J. Grimaldi, and T. O'Connell for technical assistance and/or helpful discussions.

REFERENCES

1. Klein G, Klein E: Evolution of tumours and the impact of molecular oncology. *Nature* 315:190, 1985
2. Showe L, Croce C: The role of chromosomal translocations in B- and T-cell neoplasia. *Ann Rev Immunol* 5:253, 1987
3. Hogan T, Koss W, Murgo A, Amato R, Fontana J, VanScoy F: Acute lymphoblastic leukemia with chromosomal 5;14 translocation and hypereosinophilia: Case report and literature review. *J Clin Oncol* 5:382, 1987
4. Tono-oka T, Sato Y, Matsumoto T, Ueno N, Ohkawa M, Shikano T, Takeda T: Hypereosinophilic syndrome in acute lymphoblastic leukemia with a chromosome translocation t(5q;14q). *Med Ped Oncol* 12:33, 1984
5. Grimaldi J, Meeker T: The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. *Blood* 73:2081, 1989
6. McConnell T, Foucar K, Hardy W, Saiki J: Three-way reciprocal chromosomal translocation in an acute lymphoblastic leukemia patient with hypereosinophilia syndrome. *J Clin Oncol* 5:2042, 1987
7. Ravetch J, Siebenlist U, Korsmeyer S, Waldmann T, Leder P: Structure of the human immunoglobulin m locus: Characterization of embryonic and rearranged J and D genes. *Cell* 27:583, 1981
8. Otsuka T, Miyajima A, Brown N, Otsu K, Abrams J, Saeland S, Caux C, Malefijt R, Vries J, Meyerson P, Yokota K, Gemmel L,

- Rennick D, Lee F, Arai N, Arai K, Yokota T: Isolation and characterization of an expressible cDNA encoding human IL-3. *J Immunol* 140:2288, 1988
9. Sambrook J, Fritsch E, Maniatis T: *Molecular Cloning*. Cold Spring Harbor, NY, Cold Spring Harbor Press, 1989
10. Yang Y-C, Ciarletta A, Temple P, Chung M, Kovacic S, Wittek-Giannotti J, Leary A, Kriz R, Donahue R, Wong G, Clark S: Human IL-3 (multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. *Cell* 47:3, 1986
11. Yokota T, Coffman R, Hagiwara H, Rennick D, Takebe Y, Yokota K, Gemmell L, Shrader B, Yang G, Meyerson P, Luh J, Hoy P, Pene J, Briere F, Spits H, Banchereau J, Vries J, Lee F, Arai N, Arai K: Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor and eosinophil colony-stimulating factor activities: Relationship to interleukin 5. *Proc Natl Acad Sci USA* 84:7388, 1987
12. Wong G, Wittek J, Temple P, Wilkens K, Leary A, Luxenberg D, Jones S, Brown E, Kay R, Orr E, Shoemaker C, Golde D, Kaufman R, Hewick R, Wang E, Clark S: Human GM-CSF: Molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. *Science* 228:810, 1985
13. Saiki R, Scharf S, Faloona F, Mullis K, Horn G, Erlich H, Arnheim N: Enzymatic amplification of B-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. *Science* 230:1350, 1985
14. Norrander U, Kempe T, Messing J: Construction of improved M13 vectors using oligodeoxynucleotide-directed mutagenesis. *Gene* 26:101, 1983
15. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, Piao Y, Miyazono K, Urabe A, Takaku F: Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. *J Cell Physiol* 140:323, 1989
16. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J Immunol Methods* 65:55, 1983
17. Bakhshi A, Wright J, Graninger W, Seto M, Owens J, Cossman J, Jensen J, Goldman P, Korsmeyer S: Mechanism of the t(14;18) chromosomal translocation: Structural analysis of both derivative 14 and 18 reciprocal partners. *Proc Natl Acad Sci USA* 84:2396, 1987
18. Tsujimoto Y, Louie E, Bashir M, Croce C: The reciprocal partners of both the t(14;18) and the t(11;14) translocations involved in B-cell neoplasms are rearranged by the same mechanism. *Oncogene* 2:347, 1988
19. Yang Y-C, Kovacic S, Kriz R, Wolf S, Clark S, Wellems T, Nienhuis A, Epstein N: The human genes for GM-CSF and IL-3 are closely linked in tandem on chromosome 5. *Blood* 71:958, 1988
20. Sutherland G, Baker E, Callen D, Campbell H, Young I, Sanderson C, Garson O, Lopez A, Vadas M: Interleukin-5 is at 5q31 and is deleted in the 5q- syndrome. *Blood* 71:1150, 1988
21. Sporn M, Roberts A: Autocrine growth factors and cancer. *Nature* 313:745, 1985

Clinical and Pathologic Significance of the *c-erbB-2* (*HER-2/neu*) Oncogene

Timothy P. Singleton and John G. Strickler

The *c-erbB-2* oncogene was first shown to have clinical significance in 1987 by Slamon et al,⁷⁰ who reported that *c-erbB-2* DNA amplification in breast carcinomas correlated with decreased survival in patients with metastasis to axillary lymph nodes. Subsequent studies, however, of *c-erbB-2* activation in breast carcinoma reached conflicting conclusions about its clinical significance. This oncogene also has been reported to have clinical and pathologic implications in other neoplasms. Our review summarizes these various studies and examines the clinical relevance of *c-erbB-2* activation, which has not been emphasized in recent reviews.^{37,38,55} The molecular biology of the *c-erbB-2* oncogene has been extensively reviewed^{37,38,55} and will be discussed only briefly here.

BACKGROUND

The *c-erbB-2* oncogene was discovered in the 1980s by three lines of investigation. The *neu* oncogene was detected as a mutated transforming gene in neuroblastomas induced by ethylnitrosurea treatment of fetal rats.^{6,73,74,76} The *c-erbB-2* was a human gene discovered by its homology to the retroviral gene *v-erbB*.^{33,49,76} *HER-2* was isolated by screening a human genomic DNA library for homology with *v-erbB*.²⁴ When the DNA sequences were determined subsequently, *c-erbB-2*, *HER-2*, and *neu* were found to represent the same gene. Recently, the *c-erbB-2* oncogene also has been referred to as *NGL*.

The *c-erbB-2* DNA is located on human chromosome 17q21^{24,33,66} and codes for *c-erbB-2* mRNA (4.6 kb), which translates *c-erbB-2* protein (p185). This

protein is a normal component of cytoplasmic membranes. The *c-erbB-2* oncogene is homologous with, but not identical to, *c-erbB-1*, which is located on chromosome 7 and codes for the epidermal growth factor receptor.^{8,100} The *c-erbB-2* protein is a receptor on cell membranes and has intracellular tyrosine kinase activity and an extracellular binding domain.^{2,106} Electron microscopy with a polyclonal antibody detects *c-erbB-2* immunoreactivity on cytoplasmic membranes of neoplasms, especially on microvilli and the non-villous outer cell membrane.⁶¹ In normal cells, immunohistochemical reactivity for *c-erbB-2* is frequently present at the basolateral membrane or the cytoplasmic membrane's brush border.^{22,62}

There is experimental evidence that *c-erbB-2* protein may be involved in the pathogenesis of breast neoplasia. Overproduction of otherwise normal *c-erbB-2* protein can transform a cell line into a malignant phenotype.²⁵ Also, when the *neu* oncogene containing an activating point mutation is placed in transgenic mice with a strong promoter for increased expression, the mice develop multiple independent mammary adenocarcinomas.^{18,63} In other experiments, monoclonal antibodies against the *neu* protein inhibit the growth (in nude mice) of a *neu*-transformed cell line,²⁶⁻²⁸ and immunization of mice with *neu* protein protects them from subsequent tumor challenge with the *neu*-transformed cell line.¹⁴ Some authors have speculated that the use of antagonists for the unknown ligand could be useful in future chemotherapy.⁶⁵ Further review of this experimental evidence is beyond the scope of this article.

The *c-erbB-2* activation most likely occurs at an early stage of neoplastic development. This hypothesis is supported by the presence of *c-erbB-2* activation in both in situ and invasive breast carcinomas. In addition, studies of metastatic breast carcinomas usually demonstrate uniform *c-erbB-2* activation at multiple sites in the same patient,^{11,12,39,41,52} although *c-erbB-2* activation has rarely been detected in metastatic lesions but not in the primary tumor.^{57,66,107} Even more rarely, *c-erbB-2* DNA amplification has been detected in a primary breast carcinoma but not in its lymph node metastasis.⁵ In patients who have bilateral breast neoplasms, both lesions have similar patterns of *c-erbB-2* activation, but only a few such cases have been studied.¹¹

MECHANISMS OF *c-erbB-2* ACTIVATION

The most common mechanism of *c-erbB-2* activation is genomic DNA amplification, which almost always results in overproduction of *c-erbB-2* mRNA and protein.^{17,34,65,81} The *c-erbB-2* amplification may stabilize the overproduction of mRNA or protein through unknown mechanisms. Human breast carcinomas with *c-erbB-2* amplification contain 2 to 40 times more *c-erbB-2* DNA⁴³ and 4 to 128 times more *c-erbB-2* mRNA^{34,90} than found in normal tissue. Most human breast carcinomas with *c-erbB-2* amplification have 2 to 15 times more *c-erbB-2* DNA. Tumors with greater amplification tend to have greater overproduction.^{17,52,65} The non-mammary neoplasms that have been studied tend to have

similar levels of c-erbB-2 amplification or overproduction relative to the corresponding normal tissue.

The second most common mechanism of c-erbB-2 activation is overproduction of c-erbB-2 mRNA and protein without amplification of c-erbB-2 DNA.⁸¹ The quantities of mRNA and protein usually are less than those in amplified cases and may approach the small quantities present in normal breast or other tissues.^{17,60,82} The c-erbB-2 protein overproduction without mRNA overproduction or DNA amplification has been described in a few human breast carcinoma cell lines.⁴⁷

Other rare mechanisms of c-erbB-2 activation have been reported. Translocations involving the c-erbB-2 gene have been described in a few mammary and gastric carcinomas, although some reported cases may represent restriction fragment length polymorphisms or incomplete restriction enzyme digestions that mimic translocations.^{31,63,75,84,90,108} A single point mutation in the transmembrane portion of *neu* has been described in rat neuroblastomas induced by ethylnitrosurea.^{9,65} The mutated *neu* protein has increased tyrosine kinase activity and aggregates at the cell membrane.^{10,83,98} Although there has been speculation that some of the amplified c-erbB-2 genes may contain point mutations,⁴⁶ none has been detected in primary human neoplasms.^{41,53,81}

TECHNIQUES FOR DETECTING c-erbB-2 ACTIVATION

Detection of c-erbB-2 DNA Amplification

Amplification of c-erbB-2 DNA is usually detected by DNA dot blot or Southern blot hybridization. In the dot blot method, the extracted DNA is placed directly on a nylon membrane and hybridized with a c-erbB-2 DNA probe. In the Southern blot method, the extracted DNA is treated with a restriction enzyme, and the fragments are separated by electrophoresis, transferred to a nylon membrane, and hybridized with a c-erbB-2 DNA probe. In both techniques, c-erbB-2 amplification is quantified by comparing the intensity (measured by densitometry) of the hybridization bands from the sample with those from control tissue.

Several technical problems may complicate the measurement of c-erbB-2 DNA amplification. First, the extracted tumor DNA may be excessively degraded or diluted by DNA from stromal cells.⁸¹ Second, the c-erbB-2 DNA probe must be carefully chosen and labeled. For example, oligonucleotide c-erbB-2 probes may not be sensitive enough for measuring a low level of c-erbB-2 amplification, because diploid copy numbers can be difficult to detect (unpublished data). Third, the total amounts of DNA in the sample and control tissue must be compensated for, often with a probe to an unamplified gene. Many studies have used control probes to genes on chromosome 17, the location of c-erbB-2, to correct for possible alterations in chromosome number. Identical results, however, are obtained by using control probes to genes on other chromosomes,^{5,63,80} with rare exception.¹⁷ Studies using control probes to the beta-

globin gene must be interpreted with caution, because one allele of this gene is deleted occasionally in breast carcinomas.³

Amplification of *c-erbB-2* DNA was assessed by using the polymerase chain reaction (PCR) in one recent study.³² Oligoprimers for the *c-erbB-2* gene and a control gene are added to the sample's DNA, and PCR is performed. If the sample contains more copies of *c-erbB-2* DNA than of the control gene, the *c-erbB-2* DNA is replicated preferentially.

Detection of *c-erbB-2* mRNA Overproduction

Overproduction of *c-erbB-2* mRNA usually is measured by RNA dot blot or Northern blot hybridization. Both techniques require extraction of RNA but otherwise are analogous to DNA dot blot and Southern blot hybridization. Use of PCR for detection of *c-erbB-2* mRNA has been described in two recent abstracts.^{89,102}

Overproduction of *c-erbB-2* mRNA can be measured by in situ hybridization. Sections are mounted on glass slides, treated with protease, hybridized with a radiolabeled probe, washed, treated with nuclease to remove unbound probe, and developed for autoradiography. Silver grains are seen only over tumor cells that overproduce *c-erbB-2* mRNA. Negative control probes are used.^{65,96,106} Our experience indicates that these techniques are relatively insensitive for detecting *c-erbB-2* mRNA overproduction in routinely processed tissue. Although the sensitivity may be increased by modifications that allow simultaneous detection of *c-erbB-2* DNA and mRNA, in situ hybridization still is cumbersome and expensive (unpublished data).

All of the above *c-erbB-2* mRNA detection techniques have several problems that make them more difficult to perform than techniques for detecting DNA amplification. One major problem is the rapid degradation of RNA in tissue that is not immediately frozen or fixed. In addition, during the detection procedure, RNA can be degraded by RNase, a ubiquitous enzyme, which must be eliminated meticulously from laboratory solutions. Third, control probes to genes that are uniformly expressed in the tissue of interest need to be carefully selected.

Detection of *c-erbB-2* Protein Overproduction

The most accurate methods for detecting *c-erbB-2* protein overproduction are the Western blot method and immunoprecipitation. Both techniques can document the binding specificity of various antibodies against *c-erbB-2* protein. In Western blot studies, protein is extracted from the tissue, separated by electrophoresis (according to size), transferred to a membrane, and detected by using antibodies to *c-erbB-2*. In immunoprecipitation studies, antibodies against *c-erbB-2* are added to a tumor lysate, and the resulting protein-antibody precipitate is separated by gel electrophoresis and stained for protein. Both Western blot and immunoprecipitation are useful research tools but currently are not practical for diagnostic pathology. Two recent abstracts have described an enzyme-linked immunosorbent assay (ELISA) for detection of *c-erbB-2* protein.^{18,45}

Overproduction of *c-erbB-2* protein is most commonly assessed by various immunohistochemical techniques. These procedures often generate conflicting results, which are explained at least partially by three factors. First, various studies have used different polyclonal and monoclonal antibodies. Because some polyclonal antibodies recognize weak bands in addition to the *c-erbB-2* protein band on Western blot or immunoprecipitation, the results of these studies should be interpreted with caution.^{22,36,47,61} Even some monoclonal antibodies immunoprecipitate protein bands in addition to *c-erbB-2* (p185).^{30,59,86} Second, tissue fixation contributes to variability between studies. For example, some antibodies detect *c-erbB-2* protein only in frozen tissue and do not react in fixed tissue. In general, formalin fixation diminishes the sensitivity of immunohistochemical methods and decreases the number of reactive cells.^{61,86} When Bouin's fixative is used, there may be a higher percentage of positive cases.⁴² Third, minimal criteria for interpreting immunohistochemical staining are generally lacking. Although there is general agreement that distinct crisp cytoplasmic membrane staining is diagnostic for *c-erbB-2* activation in breast carcinoma, the number of positive cells and the staining intensity required to diagnose *c-erbB-2* protein overproduction varies from study to study and from antibody to antibody. Degradation of *c-erbB-2* protein is not a problem because it can be detected in intact form more than 24 hours after tumor resection without fixation or freezing.⁶⁴

ACTIVATION OF *c-erbB-2* IN BREAST LESIONS

Incidence of *c-erbB-2* Activation

Most studies of *c-erbB-2* oncogene activation do not specify histological subtypes of infiltrating breast carcinoma. Amplification of *c-erbB-2* DNA was found in 19.1 percent (519 of 2715) of invasive carcinomas in 25 studies (Table 1), and *c-erbB-2* mRNA or protein overproduction was detected in 20.9 percent (566 of 2714) of invasive carcinomas in 20 studies. Twelve studies have documented *c-erbB-2* mRNA or protein overproduction in 15 percent (88 of 604) of carcinomas that lacked *c-erbB-2* DNA amplification.

The incidence of *c-erbB-2* activation in infiltrating breast carcinoma varies with the histological subtype. Approximately 22 percent (142 of 650) of infiltrating ductal carcinomas have *c-erbB-2* activation, as expected from the above data. Other variants of breast carcinoma with frequent *c-erbB-2* activation are inflammatory carcinoma (62 percent, 54 of 87), Paget's disease (82 percent, 9 of 11), and medullary carcinoma (22 percent, 5 of 23). In contrast, *c-erbB-2* activation is infrequent in infiltrating lobular carcinoma (7 percent, 5 of 73) and tubular carcinoma (7 percent, 1 of 15).

The *c-erbB-2* protein overproduction is present in 44 percent (44 of 100) of ductal carcinomas in situ and especially comedocarcinoma in situ (68 percent, 49 of 72). The micropapillary type of ductal carcinoma in situ also tends to have *c-erbB-2* activation,^{40,54,68} especially if larger cells are present. The greater fre-

TABLE 1. c-erbB-2 ACTIVATION IN MALIGNANT HUMAN BREAST NEOPLASMS

Histological Diagnosis	c-erbB-2 DNA Amplification ^a	c-erbB-2 mRNA Overproduction	c-erbB-2 Protein Overproduction ^b
Carcinoma, not otherwise specified	146/528, ⁸¹ 52/310, ¹⁷	42/180, ⁸³ 48/126, ³⁴	118/728, ^{85b}
	52/291, ¹⁰⁶ 28/176, ¹⁷	19/62, ⁸⁶ 19/57, ⁸⁰	58/330, ¹⁷⁶ 47/313, ⁸⁶
	17/157, ¹¹³ 22/141, ⁸⁵	3/11, ⁸⁸ 6/10, ⁸⁸ 3/3 ⁸¹	17/195, ¹¹ 32/191, ⁸⁸
	14/136, ⁹⁷ 12/122, ¹		31/185, ¹⁰¹ 34/102, ⁴²
	19/103, ⁷⁰ 15/95, ⁹⁰		24/53, ^{82b} 23/47, ¹³
	15/86, ¹¹¹ 17/73, ¹⁷		22/45, ⁸ 11/36, ⁸⁴
	16/66, ⁴⁹ 6/51, ⁸⁰		7/24, ⁸¹ 1/10 ⁸¹
	11/57, ⁸² 10/57, ⁸⁵		
	13/51, ¹³ 8/49, ⁸¹		
	10/38, ⁸² 12/36, ⁸⁴		
	1/25, ¹⁵ 7/24, ⁸¹		
	7/15, ³¹ 7/10, ⁸⁶		
	2/10 ¹⁰⁷		
	—	18/136, ⁸¹ 14/73, ³⁴	16/231, ¹⁷⁰ 18/136, ⁸¹
Carcinoma, type not specified but lacking c-erbB-2 DNA amplification		8/16, ⁸⁵ 0/8, ⁸⁰ 1/4, ³¹	13/35, ¹³ 14/29, ^{82b}
		0/3 ⁸⁶	1/28, ⁸² 3/24, ⁸⁴
Infiltrating ductal carcinoma			0/17 ⁸¹
	21/118, ⁸² 23/107, ³⁴	35/85 ³⁴	22/137, ⁴⁰ 14/93, ⁸⁰
	17/50, ⁴⁴ 7/37 ⁸⁰		9/34 ⁸⁶
	14/53 (comedo-carcinoma) ¹¹⁸		
	3/33 (tubuloductal carcinoma) ¹¹⁸		

Inflammatory carcinoma	33/60, ^a 3/6 ³²	46/75 ³⁵	5/6 ^{32b}
Paget's disease	—	—	5/6, ^a 2/3, ³⁴ 2/2 ³²
Tubular carcinoma	0/5, ¹⁶ 0/1 ³³	—	1/8 ⁴⁰
Medullary carcinoma	2/4, ¹⁶ 0/1 ³⁴	0/1 ³⁴	1/12, ⁴⁰ 1/3, ³³ 1/2, ³²
Mucinous carcinoma	0/1, ¹⁶ 0/1 ³³	—	0/1 ³³
Invasive papillary carcinoma	0/2 ³³	—	1/2 ³³
Infiltrating lobular carcinoma	1/15, ¹⁶ 0/6 ³⁴	1/5 ³⁴	2/27, ³² 0/12, ⁴⁰ 0/9, ³³
Mammary fibrosarcoma	0/1 ³³	—	1/5 ³³
"Benign cystosarcoma"	—	—	0/1 ³³
Ductal CIS ^c with minimal invasion	3/5 ³²	—	—
Ductal CIS	0/2 ³⁴	1/2 ³⁴	33/74, ⁴⁰ 10/24 ³³
Ductal CIS, solid or comedo type	—	—	20/33, ³⁴ 19/29, ³²
Ductal CIS, micropapillary type	—	—	10/10 ³⁴
Ductal CIS, micropapillary or cribriform type	—	—	10/10 ³³
Ductal CIS, papillary or cribriform type	—	—	1(focal)/14 ³⁴
Lobular CIS	—	—	0/16, ³² 1/9, ³³ 0/3 ⁴⁰
	—	—	0/16 ⁴⁰

^aShown as number of cases with activation/number of cases studied; reference is given as a superscript.

^bThese protein studies used Western blots; the rest used immunohistochemical methods.

^cCIS = carcinoma in situ.

quency of *c-erbB-2* protein overproduction in comedocarcinoma in situ, compared with infiltrating ductal carcinoma, could be explained by the fact that many infiltrating ductal carcinomas arise from other types of intraductal carcinoma, which show *c-erbB-2* activation infrequently. Others have speculated that carcinoma in situ with *c-erbB-2* activation tends to regress or to lose *c-erbB-2* activation during progression to invasion.^{40,63,62} Infiltrating and in situ components of ductal carcinoma, however, usually are similar with respect to *c-erbB-2* activation,^{11,39} although some authors have noted more heterogeneity of the immunohistochemical staining pattern in invasive than in in situ carcinoma.^{43,42,68} Activation of *c-erbB-2* is infrequent in lobular carcinoma in situ. If lesions contain more than one histological pattern of carcinoma in situ, the *c-erbB-2* protein overproduction tends to occur in the comedocarcinoma in situ but may include other areas of carcinoma in situ.^{42,54,68} Overproduction of *c-erbB-2* protein in ductal carcinoma in situ correlates with larger cell size and a periductal lymphoid infiltrate.⁶⁸

Activation of *c-erbB-2* has not been identified in benign breast lesions, including fibrocystic disease, fibroadenomas, and radial scars (Table 2). Strong membrane immunohistochemical reactivity for *c-erbB-2* has not been described in atypical ductal hyperplasia, although weak accentuation of membrane staining has been noted infrequently.^{39,42,54} In normal breast tissue, *c-erbB-2* DNA is diploid, and *c-erbB-2* is expressed at lower levels than in activated tumors.^{34,33,65,68}

These preliminary data suggest that *c-erbB-2* activation may not be useful for resolving many of the common problems in diagnostic surgical pathology. For example, *c-erbB-2* activation is infrequent in tubular carcinoma and radial scars. In addition, because *c-erbB-2* activation is unusual in atypical ductal hyperplasia, cribriform carcinoma in situ, and papillary carcinoma in situ, detection of *c-erbB-2* activation in these lesions may not be helpful in their differential diagnosis. The histological features of comedocarcinoma in situ, which commonly overproduces *c-erbB-2*, are unlikely to be mistaken for those of benign lesions. Activation of

TABLE 2. *c-erbB-2* ACTIVATION IN BENIGN HUMAN BREAST LESIONS

Histological Diagnosis	<i>c-erbB-2</i> DNA Amplification ^a	<i>c-erbB-2</i> mRNA Overproduction	<i>c-erbB-2</i> Protein Overproduction
Fibrocystic disease	0/10 ³³	—	0/32, ³⁹ 0/9, ⁶⁸ 0/8 ⁶⁵
Atypical ductal hyperplasia	—	—	2(weak)/21, ⁵⁴ 1(cytoplasmic)/13 ³⁹
Benign ductal hyperplasia	—	—	0/12 ³⁹
Sclerosing adenosis	—	—	0/4 ³⁹
Fibroadenomas	0/16, ³⁴ 0/6, ⁶⁵ 0/2, ²¹ 0/1 ⁶¹	0/6, ³⁵ 0/3 ³⁴	0/21, ³⁹ 0/10, ⁶⁸ 0/8, ⁶⁵ 0/3 ⁴²
Radial scars	—	—	0/22 ³⁹
Blunt duct adenosis	—	—	0/14 ³⁹
"Breast mastosis"	—	0/3 ³⁵	—

^aShown as number of cases with activation/number of cases studied; reference is given as a superscript.

c-erbB-2, however, does favor infiltrating ductal carcinoma over infiltrating lobular carcinoma. Further studies of these issues would be useful.

Correlation of c-erbB-2 Activation With Pathologic Prognostic Factors

Multiple studies have attempted to correlate c-erbB-2 activation with various pathologic prognostic factors (Table 3). Activation of c-erbB-2 was correlated with lymph node metastasis in 8 of 28 series, with higher histological grade in 6 of 17 series, and with higher stage in 4 of 14 series. Large tumor size was not associated with c-erbB-2 activation in most studies (11 of 14). Tetraploid DNA content and low proliferation, measured by Ki-67, have been suggested as prognostic factors and may correlate with c-erbB-2 activation.^{6,7}

Correlation of c-erbB-2 Activation With Clinical Prognostic Factors

Various studies have attempted also to correlate c-erbB-2 activation with clinical features that may predict a poor outcome (Table 4). Activation of c-erbB-2 correlated with absence of estrogen receptors in 10 of 28 series and with absence of progesterone receptors in 6 of 18 series. In most studies, patient age did not correlate with c-erbB-2 activation, and, in the rest of the reports, c-erbB-2 activation was associated with either younger or older ages.

Correlation of c-erbB-2 Activation With Patient Outcome

Slamon et al^{7a,81} first showed that amplification of the c-erbB-2 oncogene independently predicts decreased survival of patients with breast carcinoma. The correlation of c-erbB-2 amplification with poor outcome was nearly as strong as the correlation of number of involved lymph nodes with poor outcome. Slamon et al also reported that c-erbB-2 amplification is an important prognostic indicator only in patients with lymph node metastasis.^{7a,81}

A large number of subsequent studies also attempted to correlate c-erbB-2 activation with prognosis (Table 5). In 12 series, there was a correlation between c-erbB-2 activation and tumor recurrence or decreased survival. In five of these series, the predictive value of c-erbB-2 activation was reported to be independent of other prognostic factors. In contrast, 18 series did not confirm the correlation of c-erbB-2 activation with recurrence or survival. Four possible explanations for this controversy are discussed below.

One problem is that c-erbB-2 amplification correlates with prognosis mainly in patients with lymph node metastasis. As summarized in Table 5, most studies of patients with axillary lymph node metastasis showed a correlation of c-erbB-2 activation with poor outcome. In contrast, most studies of patients without axillary metastasis have not demonstrated a correlation with patient outcome. Table 6 summarizes the studies in which all patients (with and without axillary metastasis) were considered as one group. There is a trend for studies with a higher percentage of metastatic cases to show an association between c-erbB-2 activation and poor outcome. Thus, most of the current evidence suggests that c-erbB-2 activation has prognostic value only in patients with metastasis to lymph nodes.

TABLE 3. CORRELATION OF c-erbB-2 ACTIVATION WITH PATHOLOGIC PROGNOSTIC FACTORS IN BREAST CARCINOMA

Prognostic Factor	P ^a	c-erbB-2 DNA Amplification ^b	c-erbB-2 mRNA Overproduction ^c	c-erbB-2 Protein Overproduction ^c
Metastasis to axillary lymph nodes	<0.05 0.05-0.15 >0.15	(118) ³² (105) ³⁴ (49) ²¹ (103) ³² (86) ³² (58) ¹¹¹ (279) ¹⁷ (176) ²⁷ (157) ¹¹³ (122) ⁴ (85) ³² (50) ³² (50) ⁴⁴ (47) ¹³ (41) ³²	(104) ³² (82) ³⁴ (9) ²¹ (50) ³²	(350) ¹²⁰ (38) ¹³ (183) ³² (329) ¹⁷² (261) ³² (195) ¹¹ (185) ¹⁰¹ (102) ³² (50) ³²
Larger size	<0.05 0.05-0.15 >0.15	(280) ¹⁷ (86) ³² (178) ²⁷ (157) ¹¹³ (103) ³² (64) ⁷⁷ (58) ¹¹¹ (45) ²¹	— (51) ³²	(330) ¹⁷² (189) ³² (350) ¹²⁰ (185) ¹⁰¹ (34) ³²
Higher stage	<0.05 0.05-0.15 >0.15	(300) ¹⁷ (64) ⁷⁷ (58) ¹¹¹ (56) ³² (176) ²⁷ (157) ¹¹³ (84) ³² (61) ³⁰ (53) ³² (52) ²⁷ (41) ³²	— (53) ³²	(349) ¹⁷² (102) ³² (56) ³²
Higher histological grade	<0.05 0.05-0.15 >0.15	(47) ¹³ (16) ³¹ (122) ⁴ (113) ³⁴ (95) ³² (58) ¹¹¹ (50) ⁴⁴ (41) ³²	(53) ³² (86) ³² (65) ³²	(178) ¹⁰¹ (168) ¹¹ (38) ¹³ (280) ³² (189) ³² (102) ³²

^aA correlation is statistically significant at <0.05, equivocal at best between 0.05 and 0.15, and not statistically significant at >0.15.^bNumbers inside parentheses are the number of patients in an individual study; superscript is the reference. Some studies analyzed more than one group of patients.^cBy Western blot method; all other protein studies used immunohistochemical methods.

TABLE 4. CORRELATION OF c-erbB-2 ACTIVATION WITH CLINICAL PROGNOSTIC FACTORS IN BREAST CARCINOMA

Prognostic Factor	P ^a	c-erbB-2 DNA Amplification ^b	c-erbB-2 mRNA Overproduction ^c	c-erbB-2 Protein Overproduction ^c
Absence of estrogen receptors	<0.05	(253) ¹⁰³ (141) ³⁵ (109) ³⁴ (86) ⁷⁸ (50) ⁴⁴ (47) ¹³	(104) ³⁵	(350) ³⁵² (330) ¹⁷⁶ (185) ¹⁰¹
	0.05-0.15	—	—	—
	>0.15	(157) ¹¹³ (122) ⁴ (103) ⁷⁹ (95) ³⁰ (64) ⁷⁷ (61) ³⁰ (58) ¹¹¹ (53) ²¹ (51) ³² (41) ³⁰	(180) ³⁰ (62) ³⁵ (62) ³⁵ (57) ⁵⁰	(290) ³⁵² (172) ¹¹ (51) ³²⁰ (38) ³⁰
Absence of progesterone receptors	<0.05	(253) ¹⁰³ (141) ³⁵ (109) ³⁴ (80) ⁴⁴	—	(350) ³⁵² (306) ¹⁷⁶
	0.05-0.15	(86) ⁷⁸ (49) ³²	—	—
	>0.15	(157) ¹¹³ (122) ⁴ (103) ⁷⁹ (64) ⁷⁷	(180) ³⁰ (103) ³⁵ (62) ³⁵ (56) ³⁵	(90) ¹¹ (49) ³²⁰
Age (menopausal status)	<0.05	—	—	(younger: 330) ¹⁷⁶ (older: 56) ³⁵²
	0.05-0.15	(younger: 86) ⁷⁸ (230) ¹¹⁷ (176) ³⁷ (157) ¹¹³	—	—
	>0.15	(122) ⁴ (116) ³⁴ (103) ⁷⁹ (95) ³⁰ (64) ⁷⁷ (58) ¹¹¹ (56) ³² (53) ²¹ (49) ¹³ (41) ³⁰ (15) ³⁷	(62) ³⁵	(350) ³⁵² (250) ³⁵² (189) ³² (162) ¹¹ (45) ³²

^aA correlation is statistically significant at <0.05, equivocal at best between 0.05 and 0.15, and not statistically significant at >0.15^bNumbers inside parentheses are the number of patients in an individual study; superscript is the reference. Some studies analyzed more than one group of patients.^cBy Western blot method; all other protein studies used immunohistochemical methods.

TABLE 5. CORRELATION OF c-erbB-2 ACTIVATION WITH OUTCOME IN PATIENTS WITH BREAST CARCINOMA


Number of Patients							
P ^a	Type of c-erbB-2 Activation ^b	Total	With Metastasis to Axillary Lymph Nodes		No Metastasis	Statistical Analysis ^c	Reference
<0.05	DNA	176				M	87
<0.05	DNA	61				U	60
<0.05	DNA	57				U	65
<0.05	DNA	41				U	93
<0.05	mRNA	62				U	65
<0.05	Protein	102				M	101
<0.05	DNA		345			M	81
<0.05	DNA		120			U	17
<0.05	DNA		91			U	87
<0.05	DNA		86			M	79
<0.05	Protein-WB		350			M	85
<0.05	Protein		62		44	U	101
0.05-0.15	DNA	57				U	111
0.05-0.15	Protein	189				M	92
0.05-0.15	Protein		120			U	86
>0.15	DNA	130				U	113
>0.15	DNA	122				M	4
>0.15	DNA	50				U	44
>0.15	mRNA	57				U	50
>0.15	Protein	290				M	88
>0.15	Protein	195				U	11
>0.15	Protein	102				U	39
>0.15	Protein		137			U	17
>0.15	DNA				181	M	81
>0.15	DNA				159	U	17
>0.15	DNA				73	U	87
>0.15	Protein-WB				378	U	85
>0.15	Protein-WB				182	U	17
>0.15	Protein				141	U	86
>0.15	Protein				41	U	40

^aThe endpoints of these studies were tumor recurrence or decreased survival or both. Correlation between c-erbB-2 activation and a poorer patient outcome is statistically significant at <0.05, is of equivocal significance at 0.05 to 0.15, and is not significant at >0.15.

^bShown as variable measured. Letters "WB" indicate assay by Western blot; the other protein studies used immunohistochemical methods.

^cM = multivariate statistical analysis; U = univariate statistical analysis.

TABLE 6. PERCENTAGE OF BREAST CARCINOMAS WITH METASTASIS COMPARED WITH PROGNOSTIC SIGNIFICANCE OF c-erbB-2 ACTIVATION



P for correlation of c-erbB-2 activation with patient outcome.

Each study's percentage of breast carcinomas with metastasis is compared with the correlation between c-erbB-2 activation and outcome. These data include only those studies that considered, as one group, all breast cancer patients, whether or not they had axillary metastasis. Superscripts are the references. In parentheses are the types of c-erbB-2 activation. *P* values are interpreted as in Table 3.

A second problem is that various types of breast carcinoma are grouped together in many survival studies. Because the current literature suggests that c-erbB-2 activation is infrequent in lobular carcinoma, studies that combine infiltrating ductal and lobular carcinomas may dilute the prognostic effect of c-erbB-2 activation in ductal tumors. In addition, most studies do not analyze inflammatory breast carcinoma separately. This condition frequently shows c-erbB-2 activation and has a worse prognosis than the usual mammary carcinoma, but it is an uncommon lesion.

A third potential problem is the paucity of studies that attempt to correlate c-erbB-2 activation with clinical outcome in subsets of breast carcinoma without metastasis. Two recent abstracts reported that in patients without lymph node metastasis who had various risk factors for recurrence (such as large tumor size and absence of estrogen receptors), c-erbB-2 overexpression predicted early recurrence.^{23,67} In patients with ductal carcinoma in situ, one small study found no association between tumor recurrence and c-erbB-2 activation.⁴⁰

A fourth problem is the lack of data regarding whether the prognosis correlates better with c-erbB-2 DNA amplification or with mRNA or protein overproduction. Most studies that find a correlation between c-erbB-2 activa-

tion and poor patient outcome measure *c-erbB-2* DNA amplification (Table 5), and breast carcinoma patients with greater amplification of *c-erbB-2* may have poorer survival.^{79,81} Recent studies suggest that amplification has more prognostic power than overproduction,^{17,34,35} but the clinical significance of *c-erbB-2* overproduction without DNA amplification deserves further research.^{17,53} Few studies have attempted to correlate patient outcome with *c-erbB-2* mRNA overproduction, and many studies of *c-erbB-2* protein overproduction use relatively less reliable methods such as immunohistochemical studies with polyclonal antibodies.

Comparison of *c-erbB-2* Activation With Other Oncogenes in Breast Carcinoma

Other oncogenes that may have prognostic implications in human breast cancer are reviewed elsewhere.^{71,106} This section will be restricted to a comparison between the clinical relevance of *c-erbB-2* and these other oncogenes.

The *c-myc* gene is often activated in breast carcinomas, but *c-myc* activation generally has less prognostic importance than *c-erbB-2* activation.^{21,34,77,87,93} One study found a correlation between increased mRNAs of *c-erbB-2* and *c-myc*, although other reports have not confirmed this.^{34,106} Subsequent research, however, could demonstrate a subset of breast carcinomas in which *c-myc* has more prognostic importance than *c-erbB-2*.

The gene *c-erbB-1* for the epidermal growth factor receptor (EGFR) is homologous with *c-erbB-2* but is infrequently amplified in breast carcinomas.⁷⁹ Overproduction of EGFR, however, occurs more frequently than amplification and may correlate with a poor prognosis. In studies that have examined both *c-erbB-2* and EGFR in the same tumor, *c-erbB-2* has a stronger correlation with poor prognostic factors.^{35,52} Studies have tended to show no correlation between amplification of *c-erbB-2* and *c-erbB-1* or overproduction of *c-erbB-2* and EGFR, although at the molecular level EGFR mediates phosphorylation of *c-erbB-2* protein.^{51,52,61,68,109} Recent reviews describe EGFR in breast carcinoma.^{43,100}

The genes *c-erbA* and *ear-1* are homologous to the thyroid hormone receptor, and they are located adjacent to *c-erbB-2* on chromosome 17. These genes are frequently coamplified with *c-erbB-2* in breast carcinomas. The absence of *c-erbA* expression in breast carcinomas, however, is evidence against an important role for this gene in breast neoplasia.⁹⁰ Amplification of *c-erbB-2* can occur without *ear-1* amplification, and these tumors have a decreased survival that is similar to tumors with both *c-erbB-2* and *ear-1* amplification.⁸⁷ Consequently, *c-erbB-2* amplification seems to be more important than amplification of *c-erbA* or *ear-1*.

Other genes also have been compared with *c-erbB-2* activation in breast carcinomas. One study found a significant correlation between increased *c-erbB-2* mRNA and increased mRNAs of *fos*, platelet-derived growth factor chain A, and *Ki-ras*.¹⁰⁶ Allelic deletion of *c-Ha-ras* may indicate a poorer prognosis in breast carcinoma,²¹ but it has not been compared with *c-erbB-2* activation. Some studies have suggested a correlation between advanced stage or recurrence of breast carcinoma and activation of any one of several oncogenes.^{21,113}

ACTIVATION OF c-erbB-2 IN NON-MAMMARY TISSUES

Incidence of c-erbB-2 Activation in Non-Mammary Tissues

Table 7 summarizes the normal tissues in which c-erbB-2 expression has been detected, usually with immunohistochemical methods using polyclonal anti-

TABLE 7. PRESENCE OR ABSENCE OF c-erbB-2 mRNA OR c-erbB-2 PROTEIN IN NORMAL HUMAN TISSUES

Tissues With c-erbB-2 mRNA	Tissues Producing c-erbB-2 Protein ^a	Tissues Lacking c-erbB-2 mRNA	Tissues Lacking c-erbB-2 Protein
Skin ²⁴	Epidermis ⁶² External root sheath ⁶² Eccrine sweat gland ⁶² Fetal oral mucosa ⁶² Fetal esophagus ⁶²		Postnatal oral mucosa ⁶² Postnatal esophagus ⁶²
Stomach ²⁴	Stomach ^{22,62} Fetal intestine ^{62a}		
Jejunum ²⁴	Small intestine ^{22,62}		
Colon ²⁴	Colon ^{22,62}		
Kidney ²⁴	Fetal kidney ^{62a}	Kidneys ¹⁰⁴	Glomerulus ⁶² Postnatal Bowman's capsule ⁶² Postnatal proximal tubule ⁶²
	Fetal proximal tubule ⁶² Distal tubule ⁶² Fetal collecting duct ⁶² Fetal renal pelvis ⁶² Fetal ureter ⁶²		Postnatal collecting duct ⁶² Postnatal renal pelvis ⁶² Postnatal fetal ureter ⁶²
Liver ²⁴	Hepatocytes ⁶² Pancreatic acini ⁶² Pancreatic ducts ^{22,62} Endocrine cells of islets of Langerhans ⁶²		Liver ^{62,65} Pancreatic islets ⁶²
Lung ²⁴	Fetal trachea ⁶² Fetal bronchioles ⁶² Bronchioles ⁶²		Postnatal trachea ⁶² Postnatal bronchioles ⁶² Postnatal alveoli ^{62,66}
Fetal brain ²⁴	Fetal ganglion cells ⁶²		Postnatal brain ⁶² Postnatal ganglion cells ⁶²
Thyroid ¹			
Uterus ²⁴	Ovary ¹² Blood vessels ⁴²		Endothelium ⁶²
Placenta ²⁴			Adrenocortical cells ⁶² Postnatal thymus ⁶² Fibroblasts ⁶² Smooth muscle cells ⁶² Cardiac muscle cells ⁶²

^aThis protein study used Western blots; the rest used immunohistochemical methods.

bodies. Only a few studies have been performed, and some of these do not demonstrate convincing cell membrane reactivity in the published photographs. The interpretations in these studies, however, are listed, with the caveat that these findings should be confirmed by immunoprecipitation or Western or RNA blots. Production of *c-erbB-2* has been identified in normal epithelium of the gastrointestinal tract and skin. Discrepancies regarding *c-erbB-2* protein in other tissues could be due, at least in part, to differences in techniques.

The data on *c-erbB-2* activation in various non-mammary neoplasms should be interpreted with caution, because only small numbers of tumors have been studied, usually by immunohistochemical methods using polyclonal antibodies. Studies using cell lines have been excluded, because cell culture can induce amplification and overexpression of other genes, although this has not been documented for *c-erbB-2*.

Activation of *c-erbB-2* has been identified in 32 percent (64 of 203) of ovarian carcinomas in eight studies (Table 8). One abstract⁴⁵ stated that ovarian carcinomas contained significantly more *c-erbB-2* protein than ovarian non-epithelial malignancies. Another report⁶¹ showed that 12 percent of ovarian carcinomas had *c-erbB-2* overproduction without amplification.

Activation of *c-erbB-2* has been identified in 20 percent (40 of 198) of gastric adenocarcinomas in seven studies, including 33 percent (21 of 64) of

TABLE 8. *c-erbB-2* ACTIVATION IN HUMAN GYNECOLOGIC TUMORS^a

Tumor Type	<i>c-erbB-2</i> DNA Amplification	<i>c-erbB-2</i> mRNA Over-production	<i>c-erbB-2</i> Protein Over-production
Ovary—carcinoma, not otherwise specified	31/120, ⁶¹ 1/11, ⁵⁷ 0/6, ¹⁰⁷ 0/5, ⁶⁴ 0/3, ¹¹² 0/2, ⁷² 0/1 ¹¹⁰	23/67 ⁶¹	23/73, ¹² 36/72 ⁶¹
Ovary—serous (papillary) carcinoma	2/7, ¹¹⁰ 1/7, ¹¹² 0/6 ⁷²	—	—
Ovary—endometrioid carcinoma	0/3 ¹¹⁰	—	—
Ovary—mucinous carcinoma	1/2, ¹¹⁰ 0/1 ⁷²	—	—
Ovary—clear cell carcinoma	0/2, ¹¹² 0/1 ⁷²	—	—
Ovary—mixed epithelial carcinoma	0/2 ⁷²	—	—
Ovary—endometrioid borderline tumor	0/1 ⁷²	—	—
Ovary—mucinous borderline tumor	0/3 ⁷²	—	—
Ovary—serous cystadenoma	0/4 ⁷²	—	—
Ovary—mucinous cystadenoma	0/2 ⁷²	—	—
Ovary—sclerosing stromal tumor	0/1 ⁷²	—	—
Ovary—fibrothecoma	0/1 ⁷²	—	—
Uterus—endometrial adenocarcinoma	0/4, ⁶⁴ 0/1 ¹¹⁰	—	—

^aShown as number of cases with amplification (or overproduction)/total number of cases studied; reference is given as superscript. All protein studies used immunohistochemical methods.

intestinal or tubular subtypes and 9 percent (4 of 47) of diffuse or signet ring cell subtypes (Table 9). Activation of c-erbB-2 has been detected in 2 percent (6 of 281) of colorectal carcinomas, although an additional immunohistochemical study detected c-erbB-2 protein in seven of eight tissues fixed in Bouin's solution. One study found greater immunohistochemical reactivity for c-erbB-2 protein in colonic adenomatous polyps than in the adjacent normal epithelium, using Bouin's fixative. Lesions with anaplastic features and progression to invasive carcinoma tended to show decreased immunohistochemical reactivity for c-erbB-2 protein.²² Hepatocellular carcinomas (12 of 14 cases) and cholangiocarcinomas (46 of 63 cases) reacted with antibodies against c-erbB-2 in one study, but some of these "positive" cases showed only diffuse cytoplasmic staining, which

TABLE 9. c-erbB-2 ACTIVATION IN HUMAN GASTROINTESTINAL TUMORS*

Tumor Type	c-erbB-2 DNA Amplification	c-erbB-2 Protein Overproduction
Esophagus—squamous cell carcinoma	0/1 ¹⁰⁷	0/1 ⁸¹
Stomach—carcinoma, poorly differentiated	0/22 ¹⁰⁸	—
Stomach—adenocarcinoma	2/24, ⁸⁴ 2/8, ¹⁰⁷ 2/8, ¹¹¹ 2/8, ⁸⁷ 0/1 ¹⁰⁸	4/27, ²⁹ 3/10 ⁸¹
Stomach—carcinoma, intestinal or tubular type	5/10 ¹⁰⁸	16/54 ²⁹
Stomach—carcinoma, diffuse or signet ring cell type	0/2 ¹⁰⁸	4/45 ²⁹
Colorectum—carcinoma	2/49, ⁸⁴ 1/45, ¹¹¹ 1/45, ⁸⁷ 1/45, ⁸⁰ 0/40, ⁸¹ 0/32, ¹⁰⁷ 0/3 ⁸²	1/22, ⁵⁸ 7/8 ^{22b}
Colon—villous adenoma	0/1 ⁸⁰	—
Colon—tubulovillous adenoma	0/5 ⁸⁰	—
Colon—tubular adenoma	0/7 ⁸⁰	19/19 ^{22b}
Colon—hyperplastic polyp	0/1 ⁸⁰	—
Intestine—leiomyosarcoma	—	0/1 ⁸¹
Hepatocellular carcinoma	0/12 ¹¹¹	12/14, ⁸⁵ 0/2 ⁸¹
Hepatoblastoma	0/1 ⁸⁷	—
Cholangiocarcinoma	—	46/63 ⁸⁵
Pancreas—adenocarcinoma	—	2/80, ^{41c} 0/2 ⁸¹
Pancreas—acinar carcinoma	—	0/1 ⁴¹
Pancreas—clear cell carcinoma	—	0/2 ⁴¹
Pancreas—large cell carcinoma	—	0/3 ⁴¹
Pancreas—signet ring carcinoma	—	0/1 ⁴¹
Pancreas—chronic inflammation	—	0/14 ^{41c}

*Shown as number of cases with amplification (or overproduction)/total number of cases studied; reference is given as superscript. All protein studies used immunohistochemical methods. No studies analyzed for c-erbB-2 mRNA.

^bTissues fixed in Bouin's solution.

^cOnly cases with distinct membrane staining are interpreted as showing c-erbB-2 overproduction.

TABLE 10. *c-erbB-2* ACTIVATION IN HUMAN PULMONARY TUMORS^a

Tumor Type	<i>c-erbB-2</i> DNA Amplification	<i>c-erbB-2</i> Protein Overproduction
Non-small cell carcinoma	2/60, ⁷⁵ 0/60 ⁸¹	1/84 ⁸³
Epidermoid carcinoma	0/13, ⁸² 0/10, ⁸⁷ 0/6 ⁹⁰	3/5 ⁸⁸
Adenocarcinoma	0/21, ⁸² 1/13, ⁸⁰ 0/7, ¹¹¹ 0/7, ⁸⁷ 0/3 ¹⁰⁷	4/12 ⁸⁸
Large cell carcinoma	0/9, ⁸² 0/6 ⁹⁰	—
Small cell carcinoma	—	0/26, ⁸⁸ 0/3 ⁸⁹
Carcinoid tumor	0/1 ⁸²	0/3 ⁸⁹

^aShown as number of cases with amplification (or overproduction)/total number of cases studied; reference is given as superscript. All protein studies used immunohistochemical methods. No studies analyzed for *c-erbB-2* mRNA.

does not indicate *c-erbB-2* activation in breast neoplasms.⁸⁵ Also, some pancreatic carcinomas and chronic pancreatitis tissue had cytoplasmic immunohistochemical reactivity for *c-erbB-2* protein, in addition to the rare case of pancreatic adenocarcinoma with distinct cell membrane staining.⁴¹

Tables 10 through 14 summarize the studies of *c-erbB-2* activation in other neoplasms. The *c-erbB-2* oncogene is not activated in most of these tumors. Activation of *c-erbB-2* has been detected in 1 percent (4 of 299) of pulmonary non-small cell carcinomas in nine studies, although one additional report⁸⁹ found *c-erbB-2* protein overproduction in 41 percent (7 of 17). Renal cell carcinoma had *c-erbB-2* activation in 7 percent (2 of 30) in four studies. Overproduction of *c-erbB-2* protein was described in one transitional cell carcinoma of the urinary bladder, a grade 2 papillary lesion.⁸⁸ Squamous cell carcinoma and basal cell carcinoma of the skin may contain *c-erbB-2* protein, but it is not clear

TABLE 11. *c-erbB-2* ACTIVATION IN HUMAN HEMATOLOGIC PROLIFERATIONS^a

Tumor Type	<i>c-erbB-2</i> DNA Amplification	<i>c-erbB-2</i> mRNA Overproduction	<i>c-erbB-2</i> Protein Overproduction
Hematologic malignancies	0/23 ¹¹¹	—	—
Malignant lymphoma	0/9, ⁸⁷ 0/3 ¹⁰⁷	0/1 ¹	0/15 ⁸¹
Acute leukemia	0/14 ⁸⁷	—	—
Acute lymphoblastic leukemia	0/1 ¹⁰⁷	—	—
Acute myeloblastic leukemia	0/3 ¹⁰⁷	—	—
Chronic leukemia	0/19 ⁸⁷	—	—
Chronic lymphocytic leukemia	0/6 ¹⁰⁷	—	—
Chronic myelogenous leukemia	0/8 ¹⁰⁷	—	—
Myeloproliferative disorder	0/1 ⁸⁷	—	—

^aShown as number of cases with amplification (or overproduction)/total number of cases studied; reference is given as superscript. All protein studies used immunohistochemical methods.

TABLE 12. c-erbB-2 ACTIVATION IN HUMAN TUMORS OF SOFT TISSUE AND BONE*

Tumor Type	c-erbB-2 DNA Amplification
Sarcoma	0/10, ¹¹¹ 0/8 ⁹⁷
Malignant fibrous histiocytoma	0/1 ¹⁰⁷
Liposarcoma	0/3 ¹⁰⁷
Pleomorphic sarcoma	0/1 ¹⁰⁷
Rhabdomyosarcoma	0/1 ¹⁰⁷
Osteogenic sarcoma	0/2, ¹⁰⁷ 0/2 ⁹⁷
Chondrosarcoma	0/1 ¹⁰⁷
Ewing's sarcoma	0/1 ⁹⁷
Schwannoma	0/1 ⁹⁷

*Shown as number of cases with amplification (or overproduction)/total number of cases studied; reference is given as superscript. No studies analyzed for c-erbB-2 mRNA or c-erbB-2 protein.

whether the protein level is increased over that of normal skin.⁵⁶ Thyroid carcinomas and adenomas can have low levels of increased c-erbB-2 mRNA. One abstract described low-level c-erbB-2 DNA amplification in one of ten salivary gland pleomorphic adenomas.⁴⁸

Correlation of c-erbB-2 Activation With Patient Outcome

Very few studies have attempted to correlate c-erbB-2 activation in non-mammary tumors with outcome. Slamon et al⁸¹ showed that c-erbB-2 amplification or overexpression in ovarian carcinomas correlates with decreased survival, especially when marked activation is present. However, they did not report the stage, histological grade, or histological subtype of these neoplasms. Another study of stages III and IV ovarian carcinomas found a correlation between decreased survival and c-erbB-2 protein overproduction, but not between survival and histological grade.¹⁸ One abstract stated that c-erbB-2 protein overproduction in 10 of 16 pulmonary adenocarcinomas correlated with decreased disease-free interval.⁷⁰ Another abstract described a tendency for immunohisto-

TABLE 13. c-erbB-2 ACTIVATION IN HUMAN TUMORS OF THE URINARY TRACT*

Tumor Type	c-erbB-2 DNA Amplification	c-erbB-2 mRNA Overproduction	c-erbB-2 Protein Overproduction
Kidney—renal cell carcinoma	1/5, ⁹⁷ 1/4, ¹⁰⁷ 0/5 ⁸⁴	0/16 ¹⁰⁹	—
Wilms' tumor	0/4 ⁹⁷	—	—
Prostate—adenocarcinoma	—	—	0/23 ⁵⁹
Urinary bladder—carcinoma	—	—	1/48 ⁵⁸

*Shown as number of cases with amplification (or overproduction)/total number of cases studied; reference is given as superscript. All protein studies used immunohistochemical methods.

TABLE 14. *c-erbB-2* ACTIVATION IN MISCELLANEOUS HUMAN TUMORS*

Tumor Type	<i>c-erbB-2</i> DNA Amplification	<i>c-erbB-2</i> mRNA Overproduction	<i>c-erbB-2</i> Protein Over- production
Skin—malignant melanoma	—	—	0/10 ⁸⁸
Skin, head and neck—squamous cell carcinoma	0/7 ⁹⁷	—	—
Site not stated—squamous cell carcinoma	0/8, ⁹⁷ 0/2 ⁷⁶	—	—
Salivary gland—adenocarcinoma	1/1 ⁷⁶	—	—
Parotid gland—adenoid cystic carcinoma	—	—	0/1 ⁸¹
Thyroid—anaplastic carcinoma	0/1 ¹	0/1 ¹	—
Thyroid—papillary carcinoma	0/5 ¹	3(low levels)/5 ¹	—
Thyroid—adenocarcinoma	0/1 ⁸⁴	—	—
Thyroid—adenoma	0/2 ¹	1(low levels)/2 ¹	—
Neuroblastoma	0/35, ⁹¹ 0/9, ⁹⁷ 0/1 ⁷⁶	—	—
Meningioma	0/2 ⁵⁷	—	—

*Shown as number of cases with amplification (or overproduction)/total number of cases studied; reference is given as superscript. All protein studies used immunohistochemical methods.

chemical reactivity for *c-erbB-2* protein to correlate with higher grades of prostatic adenocarcinoma.⁹⁷ Additional prognostic studies of ovarian carcinomas and other neoplasms are needed.

SUMMARY

Activation of the *c-erbB-2* oncogene can occur by amplification of *c-erbB-2* DNA and by overproduction of *c-erbB-2* mRNA and *c-erbB-2* protein. Approximately 20 percent of breast carcinomas show evidence of *c-erbB-2* activation, which correlates with a poor prognosis primarily in patients with metastasis to axillary lymph nodes. Studies that have attempted to correlate *c-erbB-2* activation with other prognostic factors in breast carcinoma have reported conflicting conclusions. The pathologic and clinical significance of *c-erbB-2* activation in other neoplasms is unclear and should be assessed by additional studies.

REFERENCES

1. Aasland R, Lillehaug JR, Male R, et al. Expression of oncogenes in thyroid tumors: Coexpression of *c-erbB2/neu* and *c-erbB*. *Br J Cancer*. 57:358, 1988
2. Akiyama T, Sudo C, Ogawara H, et al. The product of the human *c-erbB-2* gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. *Science*. 232:1644, 1986

3. Ali IU, Lidereau R, Theillet C, Callahan R. Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. *Science*. 238:185, 1987
4. Ali IU, Campbell G, Lidereau R, Callahan R. Amplification of c-erbB-2 and aggressive human breast tumors. *Science*. 240:1795, 1988
5. Ali IU, Campbell G, Lidereau R, Callahan R. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. *Oncogene Res*. 3:139, 1988
6. Bacus SS, Bacus JW, Slamon DJ, Press MF. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. *Arch Pathol Lab Med*. 114:164, 1990
7. Bacus SS, Ruby SG, Weinberg DS, et al. HER-2/neu oncogene expression and proliferation in breast cancers. *Am J Pathol*. 137:103, 1990
8. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. *Nature*. 319:226, 1986
9. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. *Cell*. 45:649, 1986
10. Bargmann CI, Weinberg RA. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. *EMBO J*. 7:2043, 1988
11. Barnes DM, Lammie GA, Millis RR, et al. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. *Br J Cancer*. 58:448, 1988
12. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. *Cancer Res*. 50:4087, 1990
13. Berger MS, Locher GW, Saurer S, et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. *Cancer Res*. 48:1238, 1988
14. Bernards R, Destree A, McKenzie S, et al. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. *Proc Natl Acad Sci USA*. 84:6854, 1987
15. Blunno I, Pozzi MR, Pierotti MA, et al. Structure and expression of oncogenes in surgical specimens of human breast carcinomas. *Br J Cancer*. 57:464, 1988
16. Borg A, Linell F, Idvall I, et al. Her2/neu amplification and comedo type breast carcinoma. *Lancet*. 1:1268, 1989
17. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. *Cancer Res*. 50:4332, 1990
18. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. *Cell*. 57:931, 1989
19. Carney WP, Retos C, Petit D, et al. Quantitation of the neu oncogene protein using a monoclonal antibody based immunoassay (abstract). *Mod Pathol*. 3:15A, 1990
20. Cline MJ, Battifora H. Abnormalities of protooncogenes in non-small cell lung cancer: Correlations with tumor type and clinical characteristics. *Cancer*. 60:2669, 1987
21. Cline MJ, Battifora H, Yokota J. Proto-oncogene abnormalities in human breast cancer: Correlations with anatomic features and clinical course of disease. *J Clin Oncol*. 5:999, 1987
22. Cohen JA, Weiner DB, More KF, et al. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185^{neu}) in normal and transformed epithelial tissues of the digestive tract. *Oncogene*. 4:81, 1989
23. Colnaghi MI, Miotti S, Andreola S, et al. New prognostic factors in breast cancer (abstract). *Am Assoc Cancer Res Ann Meeting*. 30:230A, 1989

24. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with *neu* oncogene. *Science*. 230:1132, 1985
25. Di Fiore PP, Pierce JH, Kraus MH, et al. *erbB-2* is a potent oncogene when overexpressed in NIH/3T3 cells. *Science*. 237:178, 1987
26. Drebin JA, Link VC, Weinberg RA, Greene MI. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. *Proc Natl Acad Sci USA*. 83:9129, 1986
27. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of the *neu* oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. *Oncogene*. 2:273, 1988
28. Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the *neu* oncogene product directly mediate anti-tumor effects in vivo. *Oncogene*. 2:387, 1988
29. Falok VG, Gullick WJ. *c-erbB-2* oncogene product staining in gastric adenocarcinoma. An immunohistochemical study. *J Pathol*. 159:107, 1989
30. Fendly BM, Winget M, Hudziak RM, et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or *HER2/neu* gene product. *Cancer Res*. 50:1550, 1990
31. Fontaine J, Tesseraux M, Klein V, et al. Gene amplification and expression of the *neu* (*c-erbB-2*) sequence in human mammary carcinoma. *Oncology*. 45:360, 1988
32. Frye RA, Benz CC, Liu E. Detection of amplified oncogenes by differential polymerase chain reaction. *Oncogene*. 4:1153, 1989
33. Fukushima SI, Matsubara KI, Yoshida M, et al. Localization of a novel *v-erbB*-related gene, *c-erbB-2*, on human chromosome 17 and its amplification in a gastric cancer cell line. *Mol Cell Biol*. 6:955, 1986
34. Guerin M, Barrois M, Terrier MJ, et al. Overexpression of either *c-myc* or *c-erbB-2/neu* proto-oncogenes in human breast carcinomas: Correlation with poor prognosis. *Oncogene Res*. 3:21, 1988
35. Guerin M, Gabillot M, Mathieu MC, et al. Structure and expression of *c-erbB-2* and EGF receptor genes in inflammatory and non-inflammatory breast cancer: Prognostic significance. *Int J Cancer*. 43:201, 1989
36. Gullick WJ, Berger MS, Bennett PLP, et al. Expression of the *c-erbB-2* protein in normal and transformed cells. *Int J Cancer*. 40:246, 1987
37. Gullick WJ, Venter DJ. The *c-erbB2* gene and its expression in human cancers. In: Waxman J, Sikora K, eds. *The Molecular Biology of Cancer*. Boston, Blackwell Sci Publ; 1989: 38-53
38. Gullick WJ. Expression of the *c-erbB-2* proto-oncogene protein in human breast cancer. *Recent Results Cancer Res*. 113:51, 1989
39. Gusterson BA, Machin LG, Gullick WJ, et al. *c-erbB-2* expression in benign and malignant breast disease. *Br J Cancer*. 58:453, 1988
40. Gusterson BA, Machin LG, Gullick WJ, et al. Immunohistochemical distribution of *c-erbB-2* in infiltrating and in situ breast cancer. *Int J Cancer*. 42:842, 1988
41. Hall PA, Hughes CM, Staddon SL, et al. The *c-erbB-2* proto-oncogene in human pancreatic cancer. *J Pathol*. 161:195, 1990
42. Hanna W, Kahn HJ, Andrulis I, Pawson T. Distribution and patterns of staining of *neu* oncogene product in benign and malignant breast diseases. *Mod Pathol*. 3:455, 1990
43. Harris AL, Nicholson S. Epidermal growth factor receptors in human breast cancer.

- In: Lippman ME, Dickson RB, eds. *Breast Cancer: Cellular and Molecular Biology*. Boston, Kluwer Academic Publ; 1988: 93-118
44. Heintz NH, Leslie KO, Rogers LA, Howard PL. Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. *Arch Pathol Lab Med*. 114:160, 1990
 45. Huettner P, Carney W, Delellis R, et al. Quantification of the neu oncogene product in ovarian neoplasms (abstract). *Mod Pathol*. 3:46A, 1990
 46. Hung MC, Yan DH, Zhao X. Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation. *Proc Natl Acad Sci USA*. 86:2545, 1989
 47. Hynes NE, Gerber HA, Saurer S, Groner B. Overexpression of the c-erbB-2 protein in human breast tumor cell lines. *J Cell Biochem*. 39:167, 1989
 48. Kahn HJ, Hanna W, Auger M, Andreulis I. Expression and amplification of neu oncogene in pleomorphic adenoma of salivary glands (abstract). *Mod Pathol*. 3:50A, 1990
 49. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. *Science*. 229:974, 1985
 50. King CR, Swain SM, Porter L, et al. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. *Cancer Res*. 49:4185, 1989
 51. Kokai Y, Dobashi K, Weiner DB, et al. Phosphorylation process induced by epidermal growth factor receptor alters the oncogenic and cellular neu (NGL) gene products. *Proc Natl Acad Sci USA*. 85:5389, 1988
 52. Lacroix H, Iglehart JD, Skinner MA, Kraus MH. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. *Oncogene*. 4:145, 1989
 53. Lemoine NR, Staddon S, Dickson C, et al. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. *Oncogene*. 5:237, 1990
 54. Lodato RF, Maguire HC, Greene MJ, et al. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. *Mod Pathol*. 3:449, 1990
 55. Maguire HC, Greene ML. The neu (c-erbB-2) oncogene. *Semin Oncol*. 16:148, 1989
 56. Maguire HC, Jaworsky C, Cohen JA, et al. Distribution of neu (c-erbB-2) protein in human skin. *J Invest Dermatol*. 89:786, 1989
 57. Masuda H, Battifora H, Yokota J, et al. Specificity of proto-oncogene amplification in human malignant diseases. *Mol Biol Med*. 4:213, 1987
 58. McCann A, Dervan PA, Johnston PA, et al. c-erbB-2 oncoprotein expression in primary human tumors. *Cancer*. 65:88, 1990
 59. McKenzie SJ, Marks PJ, Lam T, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. *Oncogene*. 4:543, 1989
 60. Meltzer SJ, Ahnen DJ, Battifora H, et al. Protooncogene abnormalities in colon cancers and adenomatous polyps. *Gastroenterology*. 92:1174, 1987
 61. Mori S, Akiyama T, Morishita Y, et al. Light and electron microscopical demonstration of c-erbB-2 gene product-like immunoreactivity in human malignant tumors. *Virchows Arch [B]*. 54:8, 1987
 62. Mori S, Akiyama T, Yamada Y, et al. C-erbB-2 gene product, a membrane protein commonly expressed in human fetal epithelial cells. *Lab Invest*. 61:93, 1989
 63. Muller WJ, Sinn E, Pattengale PK, et al. Single-step induction of mammary

- adenocarcinoma in transgenic mice bearing the activated *c-neu* oncogene. *Cell*. 54:105, 1988
64. Ong C, Gullick W, Sikora K. Oncoprotein stability after tumor resection. *Br J Cancer*. 61:538, 1990
65. Parks HC, Lillycrop K, Howell A, Craig RK. *C-erbB2* mRNA expression in human breast tumors: Comparison with *c-erbB2* DNA amplification and correlation with prognosis. *Br J Cancer*. 61:39, 1990
66. Popescu NC, King CR, Kraus MH. Localization of the *erbB-2* gene on normal and rearranged chromosomes 17 to bands q12-q21.32. *Genomics*. 4:362, 1989
67. Press MF, Pike MC, Paterson MC, et al. Overexpression of *HER-2/neu* proto-oncogene in node negative breast cancer: Correlation with increased risk of early recurrent disease (abstract). *Mod Pathol*. 3:80A, 1990
68. Ramachandra S, Machin L, Ashley S, et al. Immunohistochemical distribution of *c-erbB-2* in in situ breast carcinoma: A detailed morphological analysis. *J Pathol*. 161:7, 1990
69. Rio MC, Bellocq JP, Gairard B, et al. Specific expression of the *pS2* gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene *ERBB2*. *Proc Natl Acad Sci USA*. 84:9243, 1987
70. Robinson R, Kern J, Weiner D, et al. *p185^{neu}* expression in human lung non-small cell carcinomas: An immunohistochemical study with clinicopathologic correlation (abstract). *Mod Pathol*. 3:85A, 1990
71. Rochlitz CF, Benz CC. Oncogenes in human solid tumors. In: Benz C, Liu E, eds. *Oncogenes*. Boston, Kluwer Academic Publ; 1989: 199-240
72. Sasano H, Garret CT, Wilkinson DS, et al. Protooncogene amplification and tumor ploidy in human ovarian neoplasms. *Hum Pathol*. 21:382, 1990
73. Schechter AL, Stern DF, Vaidyanathan L, et al. The *neu* oncogene: An *erbB*-related gene encoding a 185,000-M_r tumor antigen. *Nature*. 312:513, 1984
74. Schechter AL, Hung MC, Vaidyanathan L, et al. The *neu* gene: An *erbB*-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. *Science*. 229:976, 1985
75. Schneider PM, Hung MC, Chiocca SM, et al. Differential expression of the *c-erbB-2* gene in human small cell and non-small cell lung cancer. *Cancer Res*. 49:4969, 1989
76. Semba K, Kamata N, Toyoshima K, Yamamoto T. A *v-erbB*-related protooncogene, *c-erbB-2*, is distinct from the *c-erbB-1*/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. *Proc Natl Acad Sci USA*. 82:6497, 1985
77. Seshadri R, Matthews C, Dobrovic A, Horsfall DJ. The significance of oncogene amplification in primary breast cancer. *Int J Cancer*. 43:270, 1989
78. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. *Nature*. 290:261, 1981
79. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the *HER-2/neu* oncogene. *Science*. 235:177, 1987
80. Slamon DJ, Clark GM. Amplification of *c-erbB-2* and aggressive human breast tumors. *Science*. 240:1795, 1988
81. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the *HER-2/neu* proto-oncogene in human breast and ovarian cancer. *Science*. 244:707, 1989

82. Slebos RJC, Evers SG, Wagenaar SS, Rodenhuis S. Cellular protooncogenes are infrequently amplified in untreated non-small cell lung cancer. *Br J Cancer*. 59:76, 1989
83. Stern DF, Kamps MP, Cao H. Oncogenic activation of p185^{neu} stimulates tyrosine phosphorylation in vivo. *Mol Cell Biol*. 8:3969, 1988
84. Tal M, Wetzler M, Josephberg Z, et al. Sporadic amplification of the *HER2/neu* protooncogene in adenocarcinomas of various tissues. *Cancer Res*. 48:1517, 1988
85. Tandon AK, Clark GM, Chamness GC, et al. *HER-2/neu* oncogene protein and prognosis in breast cancer. *J Clin Oncol*. 7:1120, 1989
86. Thor AD, Schwartz LH, Koerner FC, et al. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. *Cancer Res*. 49:7147, 1989
87. Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: *hst-1/int-2* and c-erbB-2/*leu-1*. *Cancer Res*. 49:3104, 1989
88. Tsutsumi Y, Naber SP, DeLellis RA, et al. *Neu* oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues. *Hum Pathol*. 21:750, 1990
89. Tsutsumi Y, Stork PJ, Wolfe HJ. Detection of DNA amplification and mRNA overexpression of the *neu* oncogene in breast carcinomas by polymerase chain reaction (abstract). *Mod Pathol*. 3:101A, 1990
90. Van de Vijver M, van de Bersselaar R, Devilee P, et al. Amplification of the *neu* (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. *Mol Cell Biol*. 7:2019, 1987
91. Van de Vijver MJ, Mooi WJ, Wisman P, et al. Immunohistochemical detection of the *neu* protein in tissue sections of human breast tumors with amplified *neu* DNA. *Oncogene*. 2:175, 1988
92. Van de Vijver MJ, Peterse JL, Mooi WJ, et al. *Neu*-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. *N Engl J Med*. 319:1239, 1988
93. Varley JM, Swallow JE, Brammar WJ, et al. Alterations to either c-erbB-2 (*neu*) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. *Oncogene*. 1:423, 1987
94. Venter DJ, Tuzi NL, Kumar S, Gullick WJ. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification. *Lancet*. 2:69, 1987
95. Voravud N, Foster CS, Gilbertson JA, et al. Oncogene expression in cholangiocarcinoma and in normal hepatic development. *Hum Pathol*. 20:1163, 1989
96. Walker RA, Senior PV, Jones JL, et al. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. *J Pathol*. 158:97, 1989
97. Ware JL, Maygarden SJ, Koontz WW, Strom SC. Differential reactivity with anti-c-erbB-2 antiserum among human malignant and benign prostatic tissue (abstract). *Am Assoc Cancer Res Ann Meeting*. 30:437A, 1989
98. Weiner DB, Liu J, Cohen JA, et al. A point mutation in the *neu* oncogene mimics ligand induction of receptor aggregation. *Nature*. 339:230, 1989
99. Weiner DB, Nordberg J, Robinson R, et al. Expression of the *neu* gene-encoded protein (p185^{neu}) in human non-small cell carcinomas of the lung. *Cancer Res*. 50:421, 1990

190 T.P. SINGLETON AND J.G. STRICKLER

100. Wells A. The epidermal growth factor receptor and its ligand. In: Benz C, Liu E, eds. *Oncogenes*. Boston, Kluwer Academic Pub; 1989: 143-168
101. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. *Cancer Res.* 49:2087, 1989
102. Wu A, Colombero A, Low J, et al. Analysis of expression and mutation of the erbB-2 gene in breast carcinoma by the polymerase chain reaction (abstract). *Mod Pathol.* 3:108A, 1990
103. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. *Nature.* 319:230, 1986
104. Yao M, Shuin T, Misaki H, Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. *Cancer Res.* 48:6753, 1988
105. Yarden Y, Weinberg RA. Experimental approaches to hypothetical hormones: Detection of a candidate ligand of the neu protooncogene. *Proc Natl Acad Sci USA.* 86:3179, 1989
106. Yee LD, Kacinski BM, Carter D. Oncogene structure, function and expression in breast cancer. *Semin Diagn Pathol.* 6:110, 1989
107. Yokota J, Yamamoto T, Toyoshima K, et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. *Lancet.* 1:765, 1986
108. Yokota J, Yamamoto T, Miyajima N, et al. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. *Oncogene.* 2:283, 1988
109. Zeillinger R, Kury F, Czerwenka K, et al. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. *Oncogene.* 4:109, 1989
110. Zhang X, Silva E, Gershenson D, Hung MC. Amplification and rearrangement of c-erbB proto-oncogenes in cancer of human female genital tract. *Oncogene.* 4:985, 1989
111. Zhou D, Battifora H, Yokota J, et al. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. *Cancer Res.* 47:6123, 1987
112. Zhou D, Gonzalez-Cadavid N, Ahuja H, et al. A unique pattern of proto-oncogene abnormalities in ovarian adenocarcinomas. *Cancer.* 62:1573, 1988
113. Zhou D, Ahuja H, Cline MJ. Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. *Oncogene.* 4:105, 1989

Discordant Protein and mRNA Expression in Lung Adenocarcinomas*

Guoan Chen†, Tarek G. Gharib‡, Chiang-Ching Huang§, Jeremy M. G. Taylor§, David E. Misek¶, Sharon L. R. Kardia||, Thomas J. Giordano**, Mark D. Iannettoni‡, Mark B. Orringer‡, Samir M. Hanash¶, and David G. Beer‡ ‡

The relationship between gene expression measured at the mRNA level and the corresponding protein level is not well characterized in human cancer. In this study, we compared mRNA and protein expression for a cohort of genes in the same lung adenocarcinomas. The abundance of 165 protein spots representing 98 individual genes was analyzed in 76 lung adenocarcinomas and nine non-neoplastic lung tissues using two-dimensional polyacrylamide gel electrophoresis. Specific polypeptides were identified using matrix-assisted laser desorption/ionization mass spectrometry. For the same 85 samples, mRNA levels were determined using oligonucleotide microarrays, allowing a comparative analysis of mRNA and protein expression among the 165 protein spots. Twenty-eight of the 165 protein spots (17%) or 21 of 98 genes (21.4%) had a statistically significant correlation between protein and mRNA expression ($r > 0.2445$; $p < 0.05$); however, among all 165 proteins the correlation coefficient values (r) ranged from -0.467 to 0.442 . Correlation coefficient values were not related to protein abundance. Further, no significant correlation between mRNA and protein expression was found ($r = -0.025$) if the average levels of mRNA or protein among all samples were applied across the 165 protein spots (98 genes). The mRNA/protein correlation coefficient also varied among proteins with multiple isoforms, indicating potentially separate isoform-specific mechanisms for the regulation of protein abundance. Among the 21 genes with a significant correlation between mRNA and protein, five genes differed significantly between stage I and stage III lung adenocarcinomas. Using a quantitative analysis of mRNA and protein expression within the same lung adenocarcinomas, we showed that only a subset of the proteins exhibited a significant correlation with mRNA abundance. *Molecular & Cellular Proteomics* 1:304–313, 2002.

Lung cancer is the leading cause of cancer death for both men and women in the United States. Adenocarcinomas of the lung comprise ~40% of all new cases of non-small cell

lung cancer and are now the most common histologic type. Functional genomics, broadly defined as the comprehensive analysis of genes and their products, have become a recent focus of the life sciences (1). Application of these approaches to lung adenocarcinomas has the potential to aid in the identification of high risk patients with resectable early stage lung cancer that may benefit from adjuvant therapy, as well as to identify new therapeutic targets. In human lung cancer, however, little is currently understood regarding the relationship between gene expression as determined by measuring mRNA levels and the corresponding abundance of the protein products.

A number of powerful techniques for analysis of gene expression have been used including differential display (2), serial analysis of gene expression (3), DNA microarrays (4), and proteomics via two-dimensional polyacrylamide gel electrophoresis and mass spectrometry (5). Bioinformatics tools have also been developed to help determine quantitative mRNA/protein expression profiles of all types of cells and tissues (6) and now can be applied to benign and malignant tumors. DNA microarrays (cDNA and oligonucleotide) permit the parallel assessment of thousands of genes and have been utilized in gene expression monitoring (7), polymorphism analysis (8), and DNA sequencing (9). Recent studies have focused on classification or identification of subgroups of lung tumors using DNA microarrays (10, 11). The use of mRNA expression patterns by themselves, however, is insufficient for understanding the expression of protein products, as additional post-transcriptional mechanisms, including protein translation, post-translational modification, and degradation, may influence the level of a protein present in a given cell or tissue. Proteomic analyses, a complementary technology to DNA microarrays for monitoring gene expression, involves protein separation and quantitative assessment of protein spots using 2D¹-PAGE and protein identification using mass spectrometry. By combining proteomic and transcriptional analyses of the same samples, however, it may be possible to understand the complex mechanisms influencing protein expression in human cancer.

In this study, we determined mRNA and protein levels for 165 proteins (98 genes) in 76 lung adenocarcinomas and nine

From the Departments of †Surgery, §Biostatistics, ||Epidemiology, **Pathology, and ¶Pediatrics, University of Michigan, Ann Arbor, Michigan 48109

Received, January 21, 2002, and in revised form, March 4, 2002

Published, MCP Papers in Press, March 12, 2001, DOI 10.1074/mcp.M200008-MCP200

¹ The abbreviations used are: 2D, two-dimensional; MALDI-MS, matrix-assisted laser desorption/ionization mass spectrometry.

Protein and mRNA Correlation in Lung Adenocarcinomas

TABLE I

Correlation coefficients of protein and mRNA where only one spot was present on 2D gels

 r , correlation coefficient value > 0.2445; p < 0.05. Values in boldface are significant at p < 0.05.

Spot	Untigene	Gene name	r	Protein name
1104	Hs.184510	SFN	0.4337	14-3-3 σ
0994	Hs.77840	ANXA4	0.4219	Annexin IV
1314	Hs.10958	DJ-1	0.3982	DJ-1 protein/MER5
1454	Hs.75428	SOD1	0.3863	Superoxide dismutase (Cu-Zn)
1638	Hs.227751	LGALS1	0.3318	Galectin 1
0264	Hs.129548	HNRPK	0.3034	Transformation up-regulated nuclear protein
1405	Hs.111334	FTL	0.2849	Ferritin light chain
0963	Hs.300711	ANXA5	0.2468	Annexin V
1252	Hs.4745	PSMC	0.2445	26 S proteasome p28
0906	Hs.234489	LDHB	0.4420	L-lactate dehydrogenase H chain (LDH-B)
1171	Hs.241515	COX11	0.2310	COX 11
1160	Hs.181013	PGAM1	0.2023	Phosphoglycerate mutase
0759	Hs.74635	DLD	0.1965	Dihydrolipoamide dehydrogenase precursor
1193	Hs.83383	AOE372	0.1932	Antioxidant enzyme AOE372
0172	Hs.3069	HSPA9B	0.1872	GRP75
0777	Hs.979	PDHB	0.1855	Pyruvate dehydrogenase E1- β subunit precursor
1249	Hs.226795	GSTP1	0.1773	Glutathione S-transferase pi (GST-pi)
1685	Hs.76136	TXN	0.1732	Thioredoxin
1205	Hs.82314	HPRT1	0.1588	HG phosphoribosyltransferase
1230	Hs.279860	TPT1	0.1466	Translationally controlled tumor protein (TCTP)
0603	Hs.181357	LAMR1	0.1463	LAMR
1358	Hs.28914	APRT	0.1399	Adenine phosphoribosyl transferase
1410	Hs.82113	DUT	0.1213	dUTP pyrophosphatase (dUTPase)
1825	Hs.112378	LIMS1	0.1213	Pinch-2 protein
0871	Hs.250502	CA8	0.1122	Carbonic anhydrase-related protein; Syntaxin
0289	Hs.82916	CCT6A	0.1106	Chaperonin-like protein
1143	Hs.11465	GSTTLp28	0.0997	Glutathione S-transferase homolog (GST homolog)
1456	Hs.118638	NME1	0.0932	Nm23 (NDPKA)
1598	Hs.278503	RIG	0.0905	RIG (U32331)
1354	Hs.89761	ATP5D	0.0904	F1FO-type ATP synthase subunit d
1445	Hs.155485	HIP2	0.0843	Huntingtin interacting protein 2 (HIP2)
1479	Hs.177486	APP	0.0746	Amyloid B4A
0608	Hs.182265	KRT19	0.0439	Cytokeratin 19
1071	Hs.10842	RAN	0.0277	GTP-binding nuclear protein RAN(TC4)
0991	Hs.297939	CTSB	0.0254	Cathepsin B
0842	Hs.77274	PLAU	0.0248	Urokinase plasminogen activator
0823	Hs.198248	B4GALT1	0.0183	β 1,4-galactosyl transferase
0613	Hs.1247	APOA4	0.0176	Apolipoprotein A4 (ApoA4)
1338	Hs.104143	CLTA	0.0123	Clathrin light chain A
0902	Hs.5123	SID6-306	0.0117	Cytosolic inorganic pyrophosphatase
1688	Hs.1473	GRP	-0.0040	Preprogastrin-releasing peptide
0265	Hs.274402	HSPA1B	-0.0071	Heat shock-induced protein
1414	Hs.77541	ARF5	-0.0096	ADP-ribosylation factor 1
0710	Hs.97206	HIP1	-0.0114	Huntingtin interacting protein 1 (HIP1)
0532	Hs.170328	MSN	-0.0132	Moesin/E
0525	Hs.284255	ALPP	-0.0148	Alkaline phosphatase, placental
0513	Hs.76901	PDIR	-0.0289	Protein disulfide isomerase-related protein 5
1659	Hs.256697	HINT	-0.0312	Protein kinase C inhibitor
1262	Hs.7016	RAB7	-0.0362	Rab 7 protein
0190	Hs.184411	ALB	-0.0470	Albumin
0948	Hs.2795	LDHA	-0.0549	Lactate dehydrogenase-A (LDHA)
0502	Hs.180532	GPI	-0.0575	Hsp89
0152	Hs.75410	HSPA5	-0.0640	GRP78
1054	Hs.74276	CLIC1	-0.0686	Nuclear chloride channel (RNCC protein)
0709	Hs.253485	SFTPD	-0.0936	Pulmonary surfactant protein D
0867	Hs.78996	PCNA	-0.0982	PCNA
0165	Hs.180414	HSPA8	-0.1014	Heat shock cognate protein, 71 kDa
1109	Hs.75103	YWHAZ	-0.1018	14-3-3 ζ/Δ
0137	Hs.554	SSA2	-0.1032	Ro/ss-A antigen

Protein and mRNA Correlation in Lung Adenocarcinomas

TABLE I—continued

Spot	Unigene	Gene name	r ²	Protein name
0278	Hs.4112	TCP1	-0.1237	T-complex protein I, α subunit
1769	Hs.9614	NPM1	-0.1738	B23/numatrin
0089	Hs.74335	HSPCB	-0.2049	Hsp90
2511	Hs.153179	FABP5	-0.2109	E-FABP/FABP5
1739	Hs.16488	CALR	-0.2344	Calreticulin 32
1138	Hs.301961	GSTM4	-0.2438	Glutathione S-transferase M4 (GST m4)
2533	Hs.77060	PSMB6	-0.2512	Macropain subunit Δ

non-neoplastic lung tissues. Protein levels were determined using quantitative 2D-PAGE analysis, and the separated protein polypeptides were identified using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The corresponding mRNA levels for the identified proteins within the same samples were determined using oligonucleotide microarrays. Correlation analyses showed that protein abundance is likely a reflection of the transcription for a subset of proteins, but translation and post-translational modifications also appear to influence the expression levels of many individual proteins in lung adenocarcinomas.

EXPERIMENTAL PROCEDURES

Tissues—Fifty-seven stage I and 19 stage III lung adenocarcinomas, as well as nine non-neoplastic lung tissue samples, were used for protein and mRNA analyses. Patient consent was obtained, and the project was approved by the Institutional Review Board. All tissues were obtained after resection at the University of Michigan Health System between May 1991 and July 1998. Tissues were all snap-frozen in liquid nitrogen and then stored at -80°C . The patients included 46 females and 30 males ranging in age from 40.9 to 84.6 (average 63.8) years. Most patients (66/76) demonstrated a positive smoking history. Sixty-one tumor samples were classified as bronchial-derived, 14 were classified as bronchoalveolar, and one had both features. Eighteen tumor samples were classified as well differentiated, 38 were classified as moderate, and 19 were classified as poorly differentiated adenocarcinomas. Hematoxylin-stained cryostat sections (5 μm), prepared from the same tumor pieces to be utilized for protein and mRNA isolation, were evaluated by a pathologist and compared with hematoxylin- and eosin-stained sections made from paraffin blocks of the same tumors. Specimens were excluded from analysis if they showed unclear or mixed histology (e.g. adenocarcinoma), tumor cellularity less than 70%, potential metastatic origin as indicated by previous tumor history, extensive lymphocytic infiltration, or fibrosis or if the patient had received prior chemotherapy or radiotherapy.

Oligonucleotide Array Hybridization—The HuGeneFL oligonucleotide arrays (Affymetrix, Santa Clara, CA) containing 6800 genes were used in this study. Total RNA was isolated from all samples using Trizol reagent (Invitrogen). The resulting RNA was then subjected to further purification using RNeasy spin columns (Qiagen). Preparation of cRNA, hybridization, and scanning of the HuGeneFL arrays were performed according to the manufacturer's protocol (Affymetrix, Santa Clara, CA). Data analysis was performed using GeneChip 4.0 software. The gene expression profile of each tumor was normalized to the median gene expression profile for the entire sample. Details of data trimming and normalization are described elsewhere (11).

2D-PAGE and Quantitative Protein Analysis—Tissue for both protein and mRNA isolation came from contiguous areas of each sample. Protein separation using 2D-PAGE, silver staining, and digitization

were performed as described previously (12, 13). Our 2D-PAGE system allows us to run 20 gels at one time (one batch). Spot detection and quantification were accomplished utilizing Bio Image Visage System software (Bioimage Corp., Ann Arbor, MI). The integrated intensity of each spot was calculated as the measured optical density units $\times \text{mm}^2$. Of the total possible 2000 spots detectable on each gel, 820 spots on the gel of each sample were matched using a Gel-ed match program with the same spots on a chosen "master" gel. In each sample, 250 ubiquitously expressed reference spots were used to adjust for variations between gels, such as that created by subtle differences in protein loading or gel staining. Slight differences because of batch were corrected after spot-size quantification.

Mass Spectrometry and 2D Western Blotting—Preparative 2D gels were run using extracts from A549 lung adenocarcinoma cells (obtained from ATCC) and using the identical experimental conditions as the analytical 2D gels, except 30% more protein was loaded. The resolved protein gels were silver-stained using successive incubations in 0.02% sodium thiosulfate for 2 min, 0.1% silver nitrate for 40 min, and 0.014% formaldehyde plus 2% sodium carbonate for 10 min. For protein identification, protein polypeptides underwent trypsin digestion followed by MALDI-MS using a MALDI-TOF Voyager-DE mass spectrometer (Perseptive Biosystems, Framingham, MA). The masses were compared with known trypsin digest databases using the MS-FIT database (University of California, San Francisco; prospector.ucsf.edu/ucsfhtml/3.2/msfit.htm). Some of the polypeptides included in the analysis had been identified prior to this study on the basis of sequencing (14). The identified protein spots used in this paper are shown in Fig. 1A. The method for 2D-PAGE Western blot verification was as described previously (15). The 2D Western blots of GRP58 and Op18 are shown in Fig. 1, C and E; the others, such as GRP78, GRP75, HSP70, HSC70, KRT8, KRT18, KRT19, Vimentin, ApoJ, 14-3-3, Annexin I, Annexin II, PGP9.5, DJ-1, GST-pi, and PGAM, are described elsewhere.²

Statistical Analysis—Missing values were replaced with the mean value of the protein spot. The transform $x \rightarrow \log(1 + x)$ was applied to normalize all protein expression values. The relationship between protein and mRNA expression levels within the same samples was examined using the Spearman correlation coefficient analysis (16). To identify potentially significant correlations between gene and protein expression, we used an analytical strategy similar to SAM (significance analysis of microarrays) (17), which uses a permutation technique to determine the significance of changes in gene expression between different biological states. To obtain permuted correlation coefficients between gene and protein expression, genes were exchanged first in such a way that permuted correlation coefficient were calculated based on pseudo pairs of genes and proteins. The distribution of permuted correlation coefficients became stable after 60 permutations. This procedure was then repeated 60 times to obtain 60 sets of permuted correlation coefficients. For each of the 60 permutations, the correlations of genes and proteins were ranked

² Chen et al., submitted for publication.

Protein and mRNA Correlation in Lung Adenocarcinomas

TABLE II

Correlation coefficients of protein and mRNA where multiple isoforms were present on 2D gels

 r^2 , correlation coefficient value > 0.2445; $p < 0.05$. Values in boldface are significant at $p < 0.05$.

Spot	Unigene	Gene name	r^2	Protein name
1494	Hs.81915	LAP18	0.4003	OP18 (Stathmin)
0957	Hs.77899	TPM1	0.3930	Tropomyosins 1-5
0353	Hs.289101	GRP58	0.3802	Protease disulfide isomerase (GRP58)
0855	Hs.169476	GAPD	0.3683	Glyceraldehyde-3-phosphate dehydrogenase
1198	Hs.41707	HSPB3	0.3668	Hsp27
1203	Hs.83848	TP11	0.3395	Triose phosphate isomerase (TPI)
0523	Hs.65114	KRT18	0.3335	Cytokeratin 18
1492	Hs.81915	LAP18	0.3234	OP18 (Stathmin)
1493	Hs.81915	LAP18	0.3154	OP18 (Stathmin)
1181	Hs.78225	ANXA1	0.3102	Annexin variant I
0439	Hs.242463	KRT8	0.3049	Cytokeratin 8
0505	Hs.297753	VIM	0.2939	Vimentin
0593	Hs.297753	VIM	0.2809	Vimentin
1874	Hs.75313	AKR1B1	0.2790	Aldose reductase
0935	Hs.75544	YWHAH	0.2775	14-3-3 η
2524	Hs.78225	ANXA1	0.2612	Annexin I
2324	Hs.65114	KRT18	0.2601	Cytokeratin 18
1192	Hs.41707	HSPB3	0.2558	Hsp27
0350	Hs.289101	GRP58	0.2516	Phospholipase C (GRP58)
0992	Hs.75313	AKR1B1	-0.2460	Aldose reductase
0861	Hs.75313	AKR1B1	0.0761	Aldose reductase
0853	Hs.75313	AKR1B1	-0.0675	Aldose reductase
2503	Hs.76392	ALDH1	-0.0565	Aldehyde dehydrogenase
0381	Hs.76392	ALDH1	-0.0371	Aldehyde dehydrogenase
0371	Hs.76392	ALDH1	-0.0680	Aldehyde dehydrogenase
1179	Hs.78225	ANXA1	0.2052	Annexin variant I
0762	Hs.78225	ANXA1	-0.0739	Annexin I
0760	Hs.78225	ANXA1	-0.0228	Annexin I
2506	Hs.217493	ANXA2	0.2223	Lipocotin (annexin II)
0772	Hs.217493	ANXA2	0.2080	Lipocotin (annexin II)
0723	Hs.217493	ANXA2	0.0701	Lipocotin
1239	Hs.93194	APOA1	0.1133	Apolipoprotein A1 (ApoA1)
1237	Hs.93194	APOA1	-0.0373	Apolipoprotein A1 (ApoA1)
1234	Hs.93194	APOA1	-0.0894	Apolipoprotein A1 (ApoA1)
0428	Hs.25	ATP5B	0.0080	ATP synthase β subunit precursor
0427	Hs.25	ATP5B	0.0122	ATP synthase β subunit precursor
0424	Hs.25	ATP5B	-0.0992	ATP synthase β subunit precursor
0863	Hs.75106	CLU	-0.0483	Apolipoprotein J (ApoJ)
0780	Hs.75106	CLU	-0.0443	Apolipoprotein J (ApoJ)
1527	Hs.119140	EIF5A	-0.0726	eIF-5A
1484	Hs.119140	EIF5A	-0.0376	eIF-5A
1728	Hs.5241	FABP1	-0.1916	L-FABP
1712	Hs.5241	FABP1	-0.0473	L-FABP
0947	Hs.169476	GAPD	0.1745	Glyceraldehyde-3-phosphate dehydrogenase
1232	Hs.75207	GLO1	0.2249	Glyoxalase-I
1229	Hs.75207	GLO1	0.0450	Glyoxalase-I
1595	Hs.158300	HAP1	-0.0137	Huntingtin-associated protein 1 (neuroan 1)
1810	Hs.75990	HP	-0.4672	α -Haptoglobin
1459	Hs.75990	HP	0.0802	α -Haptoglobin
1458	Hs.75990	HP	-0.0305	α -Haptoglobin
0619	Hs.75990	HP	0.0461	B-haptoglobin
0615	Hs.75990	HP	-0.0034	B-haptoglobin
1250	Hs.41707	HSPB3	-0.1024	Hsp27
0549	Hs.79037	HSPD1	0.1074	Hsp60
0338	Hs.79037	HSPD1	0.2265	Hsp60
0333	Hs.79037	HSPD1	0.1383	Hsp60
0331	Hs.79037	HSPD1	0.1803	Hsp60
2381	Hs.65114	KRT18	0.2016	Cytokeratin 18
0535	Hs.65114	KRT18	0.1106	Cytokeratin 18

Protein and mRNA Correlation in Lung Adenocarcinomas

TABLE II—continued

Correlation coefficients of protein and mRNA where multiple isoforms were present on 2D gels

 r , correlation coefficient value > 0.2445 ; $p < 0.05$. Values in boldface are significant at $p < 0.05$.

Spot	Unigene	Gene name	r	Protein name
0529	Hs.65114	KRT18	0.1279	Cytokeratin 18
0528	Hs.65114	KRT18	0.0414	Cytokeratin 18
0527	Hs.65114	KRT18	0.0436	Cytokeratin 18
0514	Hs.65114	KRT18	0.0733	Cytokeratin 18
0451	Hs.242463	KRT8	-0.0111	Cytokeratin 8
0446	Hs.242463	KRT8	0.0347	Cytokeratin 8
0444	Hs.242463	KRT8	-0.1311	Cytokeratin 8
0443	Hs.242463	KRT8	0.0942	Cytokeratin 8
1488	Hs.81915	LAP18	0.0495	QP18 (Stathmin)
0321	Hs.75655	P4HB	-0.0546	PDI (proly-4-OH-B)
0320	Hs.75655	P4HB	-0.0041	PDI (proly-4-OH-B)
1063	Hs.75323	PHB	0.0441	Prohibitin
0837	Hs.75323	PHB	0.1402	Prohibitin
0326	Hs.297681	SERPINA1	-0.0227	α -1-Antitrypsin
0322	Hs.297681	SERPINA1	-0.0277	α -1-Antitrypsin
0241	Hs.297681	SERPINA1	-0.0148	α -1-Antitrypsin
1280	Hs.301254	SFTPA1	-0.1488	Pulmonary surfactant-associated protein
1278	Hs.301254	SFTPA1	-0.2040	Pulmonary surfactant-associated protein
0866	Hs.73980	TNNT1	0.1162	Troponin T
0778	Hs.73980	TNNT1	0.0740	Troponin T
1213	Hs.83848	TPI1	0.0024	Triose phosphate isomerase (TPI)
1210	Hs.83848	TPI1	0.0490	Triose phosphate isomerase (TPI)
1207	Hs.83848	TPI1	-0.1615	Triose phosphate isomerase (TPI)
1204	Hs.83848	TPI1	0.0209	Triose phosphate isomerase (TPI)
1202	Hs.83848	TPI1	0.0721	Triose phosphate isomerase (TPI)
1161	Hs.83848	TPI1	0.2265	Triose phosphate isomerase (TPI)
1052	Hs.77899	TPM1	-0.1040	Tropomyosin clean-product
1039	Hs.77899	TPM1	-0.2999	Cytoskeletal tropomyosin
1035	Hs.77899	TPM1	-0.3821	Tropomyosin
0783	Hs.77899	TPM1	0.0757	Tropomyosins 1-5
1574	Hs.194366	TTR	-0.0065	Transthyretin
0809	Hs.194366	TTR	0.0399	Transthyretin multimer
2202	Hs.76118	UCHL1	-0.0220	Ubiquitin carboxyl-terminal hydrolase isozyme L1
1246	Hs.76118	UCHL1	-0.1261	Ubiquitin carboxyl-terminal hydrolase isozyme L1
1242	Hs.76118	UCHL1	0.1473	Ubiquitin carboxyl-terminal hydrolase isozyme L1
0606	Hs.297753	VIM	0.0951	Vimentin
0594	Hs.297753	VIM	-0.2664	Vimentin-derived protein (vid4)
0508	Hs.297753	VIM	0.1008	Vimentin-derived protein (vid2)
0419	Hs.297753	VIM	0.0032	Vimentin-derived protein (vid1)
1279	Hs.75544	YWHAH	0.0059	14-3-3 η

such that $p_p(i)$ denotes the i th largest correlation coefficient for p th permutation. Hence, the expected correlation coefficient, $p_E(i)$, was the average over the 60 permutations, $p_E(i) = \sum_{p=1}^{60} p_p(i)/60$. A scatter plot of observed correlations ($p(i)$) versus the expected correlations is shown in Fig. 2D. For this study, we chose threshold $\Delta = 0.115$ so that correlation would be considered significant if absolute value of difference between $p(i)$ and $p_E(i)$ was greater than the threshold. Twenty-nine (including one with observed correlation coefficient -0.4672) of 165 pairs of gene and protein expression were called significant in such criteria, and the permuted data generated an average of 5.1 falsely significant pairs of gene and protein expression. This provided an estimated false discovery rate (the percentage of pairs of gene and protein expression identified by chance) for our data set.

RESULTS

Correlation of Individual Proteins and mRNA Expression within Each Tumor—We have examined quantitatively 165

protein spots on 2D gels representing 98 genes and compared protein levels with mRNA levels for a cohort of 85 lung adenocarcinomas and normal lung samples. Of the 165 protein spots, 69 proteins were represented by only one known spot on 2D gels for an individual gene, whereas 96 protein spots showed multiple protein products from 29 different genes. 2D Western blotting verified the proteins identified by mass spectrometry when specific antibodies were available. Spearman correlation coefficients of the proteins and their associated mRNA for each protein spot were generated using all 76 lung adenocarcinomas and nine non-neoplastic lung tissues (see Tables I and II, and see Figs. 1 and 2). The correlation coefficients (r) ranged from -0.467 to 0.442 (Fig. 2D). A total of 28 protein spots (21 genes) were found to have a statistically significant correlation between expression of

Protein and mRNA Correlation in Lung Adenocarcinomas




Fig. 1. A, digital image of a silver-stained 2D-PAGE separation of a stage I lung adenocarcinoma showing protein spots separated by molecular mass (MW) and isoelectric point (PI). Twenty-eight protein spots whose expression levels are correlated with mRNA abundance are indicated by the black arrows. B, the outlined areas of A showing protein GRP58. C, 2D Western blot of GRP58 from the A549 lung adenocarcinoma cell line. D, the outlined areas of A showing the protein isoforms of Op18. E, 2D Western blot of Op18 from A549 cells.

their protein and mRNA ($r > 0.2445$; $p < 0.05$). This accounts for 17% (28/165) of the 165 protein spots. Among the 69 genes for which only a single protein spot was known (Table I), nine genes (9/69, 13%) were observed to show a statistically significant relationship between protein and mRNA abundance ($r > 0.2445$; $p < 0.05$). The proteins whose expression levels were correlated with their mRNA abundance included those involved in signal transduction, carbohydrate metabolism, apoptosis, protein post-translational modification, structural proteins, and heat shock proteins (Table III).

Individual Isoforms of the Same Protein Have Different Protein/mRNA Correlation Coefficients—Of the 165 protein spots, 96 represent protein products of 29 genes with at least two isoforms. Among these 96 protein spots, 19 (19/96 protein spots, 20%) showed a statistically significant correlation between their protein and mRNA expression ($r > 0.2445$; $p < 0.05$) (Table II) and represented 12 genes (12/29, 41%). Individual isoforms of the same protein demonstrated different protein/mRNA correlation coefficients. For example, 2D-PAGE/Western analysis revealed four isoforms of OP18 differing in regards to isoelectric point but similar in molecular weight. Three of the four isoforms (spots 1492, 1493, and 1494) showed a statistically significant correlation between their protein and mRNA abundance ($r = 0.3234$, 0.3154 , and 0.4003 , respectively). The fourth isoform (spot 1488) showed no correlation be-

tween protein and mRNA expression ($r = 0.0495$). Similarly, just one of five quantified isoforms of cytokeratin 8 (spot 439) demonstrated a statistically significant correlation between protein and mRNA abundance ($r = 0.3049$; $p < 0.05$) (Table II).

In addition to differences in the relationship between mRNA levels and protein expression among separate isoforms, some genes with very comparable mRNA levels showed a 24-fold difference in their protein expression. Genes with comparable protein expression levels also showed up to a 28-fold variance in their mRNA levels.

Lack of Correlation for mRNA and Protein Expression when Using Average Tumor Values across All 165 Protein Spots (98 Genes)—The relationship between mRNA and protein expression was also examined by using the average expression values for all samples. To analyze this relationship using this approach, the average value for each protein or mRNA was generated using all 85 lung tissue samples. The range of normalized average protein values ranged from -0.0646 to 0.0979 (raw value 0.0036 to 4.1947), and the range for mRNA was from 0 to 15260.5 for all 165 individual protein spots. The Spearman correlation coefficient for the whole data set (165 protein spots/98 genes) was -0.025 (Fig. 3A). Even for the 28 protein spots (Fig. 2D) that were found to have a statistically significant correlation between their mRNA and protein, use of

Protein and mRNA Correlation in Lung Adenocarcinomas




Fig. 2. A-C, plots showing the correlation between mRNA and protein for the three selected genes Op18, Annexin IV, and GAPD for all 76 lung adenocarcinomas and nine non-neoplastic lung samples ($p < 0.05$). D, distribution of all 165 Spearman correlation coefficients (r) and verification analysis using SAM. A more detailed description of the method is provided under "Experimental Procedures." Approximately 17% of the 165 proteins demonstrate a significant correlation between mRNA and protein levels as demonstrated by the values shown beyond the outer range of threshold $\Delta = 0.115$. Normalized protein values were used, thus negative values for some proteins are observed.

the average value resulted in a correlation coefficient value of -0.035 , which was not significant (Fig. 3B).

Lack of a Relationship between Protein/mRNA Correlation Coefficients and Average Protein Abundance—To determine whether an absolute protein level might influence the correlation with mRNA, the mean value of each protein (relative abundance) and the Spearman protein/mRNA correlation coefficients among all 85 samples were examined. No relationship between the protein abundance and the correlation coefficients was observed ($r = 0.039$; $p > 0.05$). A detailed analysis of separate subsets of proteins with differing levels of abundance (less than -0.0014 , larger than -0.0014 , or larger than 0.0077) also showed a lack of correlation between mRNA and protein expression among the 83 (50%), 82 (50%), and 41 (25%) of 165 total protein spots, respectively ($r = 0.016$, 0.08 , and 0.172 , respectively).

Stage-related Changes in the Protein/mRNA Correlation Coefficients—To determine whether the 21 genes (28 protein spots) showing a significant correlation between the protein and mRNA expression among all samples demonstrate changes in this relationship during tumor progression, the correlations were examined separately for stage I ($n = 57$) and

stage III ($n = 19$) lung adenocarcinomas (Table III). The number of non-neoplastic lung samples ($n = 9$) was insufficient for a separate correlation analysis of this group. Many of the protein spots represent one of several known protein isoforms for a given gene. The majority of genes (16/21) did not differ in the protein/mRNA correlation between stage I and stage III tumors indicating a similar regulatory relationship between the mRNA and protein spot. GRP-58, PSMC, SOD1, TPI1, and VIM, however, were found to demonstrate significant differences in the correlation coefficients between stage I and stage III lung adenocarcinomas. For GRP-58, PSMC, and VIM the change in the correlation coefficient was because of a relative increase in protein expression in stage III tumors. For SOD and TPI the change resulted from a relative decrease in expression of this specific protein in stage III tumors.

DISCUSSION

Relatively little is known about the regulatory mechanisms controlling the complex patterns of protein abundance and post-translational modification in tumors. Most reports concerning the regulation of protein translation have focused on

Protein and mRNA Correlation in Lung Adenocarcinomas

TABLE III
Stage-dependent analysis of protein-mRNA correlation coefficients

r, correlation coefficient. Values in boldface indicate a significant difference between stage I and stage III.

Spot	Gene name	r (Stage I)	r (Stage III)	Function
1874	AKR1B1	0.269	0.106	Carbohydrate metabolism; electron transporter
2524	ANXA1	0.184	0.572	Phospholipase inhibitor; signal transduction
0994	ANXA4	0.660	0.362	Phospholipase inhibitor
0963	ANXA5	0.241	0.390	Phospholipase inhibitor; calcium binding; phospholipid binding
1314	DJ-1	0.363	0.354	Signal transduction
1405	FTL	0.126	0.358	Iron storage protein
0855	GAPD	0.243	0.581	Carbohydrate metabolism (glycolysis regulation)
0350	GRP58	0.327	-0.087	Signal transduction; protein disulfide isomerase
0264	HNRPK	0.360	0.243	RNA-binding protein (RNA processing/modification)
1192	HSPB3	0.457	0.633	Heat shock protein
0523	KRT18	0.115	0.371	Structural protein
0439	KRT8	0.323	0.436	Structural protein
1492	LAP18	0.483	0.663	Signal transduction; cell growth and maintenance
1638	LGALS1	0.200	0.528	Apoptosis; cell adhesion; cell size control
1252	PSMC	0.253	0.060	Protein degradation
1104	SFN	0.465	0.475	Signal transduction (protein kinase C inhibitor)
1454	SOD1	0.352	0.079	Oxidoreductase
1203	TP11	0.378	0.009	Carbohydrate metabolism
0957	TPM1	0.475	0.225	Structural protein (muscle); control of heart
0593	VIM	-0.054	0.556	Structural protein
0935	YWHAH	0.283	0.210	Signal transduction

one or several protein products (18). Celis *et al.* (19) found a good correlation between transcript and protein levels among 40 well resolved, abundant proteins using a proteomic and microarray study of bladder cancer. By comparing the mRNA and protein expression levels within the same tumor samples, we found that 17% (28/165) of the protein spots (21/98 genes) show a statistically significant correlation between mRNA and protein. These proteins appear to represent a diverse group of gene products and include those involved in signal transduction, carbohydrate metabolism, protein modification, cell structure, heat shock, and apoptosis. These results suggest that expression of this subset of 165 proteins is likely to be regulated at the transcriptional level in these tissues. The majority of the protein isoforms, however, did not correlate with mRNA levels, and thus their expression is regulated by other mechanisms. We also observed a subset of proteins that demonstrated a negative correlation with the mRNA expression values; for example α -haptoglobin demonstrated a strong negative correlation with its mRNA expression values. This may reflect negative feedback on the mRNA or the protein or the presence of other regulatory influences that are not understood currently.

Post-translational modification or processing will result in individual protein products of the same gene migrating to different locations on 2D-PAGE gels (20). Because the identity of all possible isoforms for each protein examined has not been characterized completely, this may influence the correlation analyses performed in this study. This is partly because of limitations of the 2D-PAGE and mass spectrometry technologies (21, 22). Potential inconsistencies between mRNA and protein correlations that have been reported may also be because of differences, even in the same gene, in the mechanisms


of protein translation among different cells or as measured in different laboratories (23).

In this study, we examined 165 protein spots identified in lung adenocarcinomas. Ninety-six protein spots, representing the products of 29 genes, contained at least two protein isoforms. Nineteen of 96 protein spots, representing 12 genes, were shown to have a statistically significant correlation between their protein and mRNA expression, suggesting that the levels of these proteins reflects the transcription of the corresponding genes. Differences in protein/mRNA correlations were found among the individual isoforms of a given protein. For example, of the four OP18 isoforms, three showed a statistically significant correlation between the protein and mRNA expression levels. The lack of relationship for the one isoform, however, indicates that individual protein isoforms of the same gene product can be regulated differentially. This is not unexpected and likely reflects other post-translational mechanisms that can influence isoform abundance in tissues and cancer.

In addition to the analyses of the correlation of mRNA/protein within the same tumor samples, we also tested the global relationship between mRNA and the corresponding protein abundance across all 165 protein spots in the lung samples. A protein and mRNA average value for each gene was generated using all 85 lung tissues samples. We observed a very wide range of normalized average protein and mRNA values. The correlation coefficient generated using this average value data set was -0.025, and even for the 28 protein spots that showed a statistically significant correlation between individual mRNA and proteins, the correlation value was only -0.035. This suggests that it is not possible to predict overall protein expression levels based on average

Protein and mRNA Correlation in Lung Adenocarcinomas

Fig. 3. The overall correlation of mRNA and protein levels across all 165 protein spots (A) and across 28 protein spots that contained individual r values larger than 0.244 (B) are shown. Each protein or mRNA mean value was calculated based on all 76 lung adenocarcinomas and nine non-neoplastic lung samples using quantitative 2D-PAGE and Affymetrix oligonucleotide microarrays. The Spearman correlation coefficients for the two data sets (A and B) were -0.025 and -0.035 , respectively, indicating a lack of correlation if mean values for mRNA and protein for all samples is used.



mRNA abundance in lung cancer samples. This conclusion is also supported by previous results from Anderson and Seilhamer (24), who examined 19 genes in human liver cells, and by Gygi *et al.* (25), who examined 106 genes in yeast. Both studies found a lack of correlation between mRNA and protein expression when average or overall levels were used.

A good correlation was reported when the 11 most abundant proteins were examined in yeast (25), suggesting that the level of protein abundance may be a factor that may influence the correlation between mRNA and protein. In the present study, a fairly wide range of mean protein values among 165 protein spots in lung adenocarcinomas was observed, and the correlation coefficients also varied from -0.467 to 0.442 .

A comparison between the mean value of each protein and the correlation coefficient generated using all 85 tissue samples did not reveal a strong relationship between the overall protein abundance and the correlation coefficients ($r = 0.039$; $p > 0.05$). Detailed analysis of different subsets of protein abundance also failed to show a correlation between mRNA and protein expression. Thus in contrast to yeast, a relationship between mRNA/protein correlation coefficient and protein abundance in human lung adenocarcinomas was not observed.

The results of this study indicate that the level of protein abundance in lung adenocarcinomas is associated with the corresponding levels of mRNA in 17% (28 proteins) of the total 165 protein spots examined. This was substantially

Protein and mRNA Correlation in Lung Adenocarcinomas

higher than the amount predicted to result by chance alone (which was 5.1) and suggests that a transcriptional mechanism likely underlies the abundance of these proteins in lung adenocarcinomas. We also demonstrate that the expression of individual isoforms of the same protein may or may not correlate with the mRNA, indicating that separate and likely post-translational mechanisms account for the regulation of isoform abundance. These mechanisms may also account for the differences in the correlation coefficients observed between stage I and stage III tumors, indicating that specific protein isoforms show regulatory changes during tumor progression. Further studies in lung adenocarcinomas will examine the relationship between the expression of individual protein isoforms and specific clinical-pathological features of these tumors, such as the presence of angiolymphatic invasion, and nodal or pleural surface involvement. The potential to identify specific protein isoforms associated with biological behavior in lung adenocarcinomas would be of considerable interest and will add to our understanding of the regulation of gene products by transcriptional, translational, and post-translational mechanisms.

Acknowledgments—We thank Kerby A. Shedden, Rork D. Kuick, Eric Puravs, Robert Hinderer, Melissa C. Krause, and Christopher Wood for assistance in this study.

* This work was supported by NCI, National Institutes of Health Grant U19 CA-85953. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

†† To whom correspondence should be addressed: General Thoracic Surgery, SRB II, B560, Box 0686, University of Michigan Medical School, Ann Arbor, MI 48109-0686; E-mail: dgbeer@umich.edu.

REFERENCES

- Ideker, T., Thorsson, V., Ranish, J. A., Christmas, R., Buhler, J., Eng, J. K., Bumgarner, R., Goodlett, D. R., Aebersold, R., Hood, L. (2001) Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. *Science* 292, 929–934
- Liang, P., Pardee, A. B. (1998) Differential display. A general protocol. *Mol. Biotechnol.* 10, 261–267
- Porter, D. A., Krop, I. E., Nasser, S., Sgroi, D., Kaelin, C. M., Marks, J. R., Riggins, G., Polyak, K. (2001) A sage (serial analysis of gene expression) view of breast tumor progression. *Cancer Res.* 61, 5697–5702
- Blitner, M., Meltzer, P., Chen, Y., Jiang, Y., Sefter, E., Hendrix, M., Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., Sampas, N., Dougherty, E., Wang, E., Marincola, F., Gooden, C., Lueders, J., Glatfelter, A., Pollock, P., Capten, J., Gillanders, E., Leja, D., Dietrich, K., Beaudry, C., Berens, M., Alberts, D., Sondak, V. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. *Nature* 406, 536–540
- Fung, E. T., Wright, G. L., Jr., Dalmasso, E. A. (2000) Proteomic strategies for biomarker identification: progress and challenges. *Curr. Opin. Mol. Ther.* 2, 643–650
- Davidson, D., Baldock, R. (2001) Bioinformatics beyond sequence: mapping gene function in the embryo. *Nat. Rev. Genet.* 2, 409–417
- Chee, M., Yang, R., Hubbell, E., Bemo, A., Huang, X. C., Stern, D., Winkler, J., Lockhart, D. J., Morris, M. S., Fodor, S. P. (1996) Accessing genetic information with high-density DNA arrays. *Science* 274, 610–614
- Wang, D. G., Fan, J. B., Siao, C. J., Bemo, A., Young, P., Sapolsky, R., Ghandour, G., Perkins, N., Winchester, E., Spencer, J., Kruglyak, L., Stein, L., Hsie, L., Topaloglou, T., Hubbell, E., Robinson, E., Mittmann, M., Morris, M. S., Shen, N., Kilburn, D., Rioux, J., Nusbaum, C., Rozen, S., Hudson, T. J., Lander, E. S. (1998) Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. *Science* 280, 1077–1082
- Pease, A. C., Solas, D., Sullivan, E. J., Cronin, M. T., Holmes, C. P., Fodor, S. P. (1994) Light-generated oligonucleotide arrays for rapid DNA sequence analysis. *Proc. Natl. Acad. Sci. U. S. A.* 91, 5022–5026
- Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., Loda, M., Weber, G., Mark, E. J., Lander, E. S., Wong, W., Johnson, B. E., Golub, T. R., Sugarbaker, D. J., Meyerson, M. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. *Proc. Natl. Acad. Sci. U. S. A.* 98, 13790–13795
- Giordano, T. J., Shedden, K. A., Schwartz, D. R., Kuick, R., Taylor, J. M. G., Lee, N., Misek, D. E., Graesson, J. K., Kardis, S. L. R., Beer, D. G., Rennert, G., Cho, K. R., Gnibler, S. B., Fearon, E. R., Hanash, S. (2001) Organ-specific molecular classification of lung, colon and ovarian adenocarcinomas using gene expression profiles. *Am. J. Pathol.* 159, 1231–1238
- Strahler, J. R., Kuick, R., Hanash, S. M. (1989) in *Protein Structure: A Practical Approach* (Creighton, T., ed) pp. 65–92, IRL Press, Oxford
- Merril, C. R., Dunau, M. L., Goldman, D. (1981) A rapid sensitive silver stain for polypeptides in polyacrylamide gels. *Anal. Biochem.* 101, 201–207
- Hanash, S. M., Strahler, J. R., Chan, Y., Kuick, R., Teichrow, D., Neel, J. V., Hallet, N., Kelm, D. R., Gratiot-Deans, J., Ungar, D., Richardson, B. C. (1993) Data base-analysis of protein expression patterns during T-cell ontogeny and activation. *Proc. Natl. Acad. Sci. U. S. A.* 90, 3314–3318
- Brichory, F. M., Misek, D. E., Yim, A. M., Krause, M. C., Giordano, T. J., Beer, D. G., Hanash, S. M. (2001) An immune response manifested by the common occurrence of annexins-I and II autoantibodies and high circulating levels of IL-6 in lung cancer. *Proc. Natl. Acad. Sci. U. S. A.* 98, 9824–9829
- Lavens-Phillips, S. E., MacGlashan, D. W., Jr. (2000) The tyrosine kinases p53/56lyn and p72syk are differentially expressed at the protein level but not at the messenger RNA level in nonreleasing human basophils. *Am. J. Respir. Cell Mol. Biol.* 23, 566–571
- Tusher, V. G., Tibshirani, R., Chu, G. (2001) Significance analysis of microarrays applied to the ionizing radiation response. *Proc. Natl. Acad. Sci. U. S. A.* 98, 5116–5121
- Tew, K. D., Monks, A., Barone, L., Rosser, D., Akerman, G., Montali, J. A., Wheatley, J. B., Schmidt, D. E., Jr. (1996) Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. *Mol. Pharmacol.* 50, 149–159
- Celis, J. E., Kruhoffer, M., Gromova, I., Frederiksen, C., Ostergaard, M., Thykjaer, T., Gromov, P., Yu, J., Palsdottir, H., Magnusson, N., Orntoft, T. F. (2000) Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. *FEBS Lett.* 480, 2–16
- Anderson, N. L., Anderson, N. G. (1998) Proteome and proteomics: new technologies, new concepts, and new words. *Electrophoresis* 19, 1853–1861
- Gygi, S. P., Corthals, G. L., Zhang, Y., Rochon, Y., Aebersold, R. (2000) Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. *Proc. Natl. Acad. Sci. U. S. A.* 97, 9390–9395
- Fey, S. J., Larsen, P. M. (2001) 2D or not 2D. Two-dimensional gel electrophoresis. *Curr. Opin. Chem. Biol.* 5, 26–33
- McBride, S., Walsh, D., Meleady, P., Daly, N., Clynes, M. (1999) Bromodeoxyuridine induces keratin protein synthesis at a posttranscriptional level in human lung tumor cell lines. *Differentiation* 64, 185–193
- Anderson, L., Seilhamer, J. (1997) A comparison of selected mRNA and protein abundances in human liver. *Electrophoresis* 18, 533–537
- Gygi, S. P., Rochon, Y., Franz, B. R., Aebersold, R. (1999) Correlation between protein and mRNA abundance in yeast. *Mol. Cell. Biol.* 19, 1720–1730

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Eaton, et al.
Appl. No.	:	10/063,557
Filed	:	May 2, 2002
For	:	SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
Examiner	:	David J. Blanchard
Group Art Unit	:	1642

DECLARATION OF J. CHRISTOPHER GRIMALDI, UNDER 37 CFR §1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, J. Christopher Grimaldi, declare and state as follows:

1. I am a Senior Research Associate in the Molecular Biology Department of Genentech, Inc., South San Francisco, CA 94080.
2. My scientific Curriculum Vitae, including my list of publications, is attached to and forms part of this Declaration (Exhibit A).
3. I joined Genentech in January of 1999. From 1999 to 2003, I directed the Cloning Laboratory in the Molecular Biology Department. During this time I directed or performed numerous molecular biology techniques including semi-quantitative Polymerase Chain Reaction (PCR) analyses. I am currently involved, among other projects, in the isolation of genes coding for membrane associated proteins which can be used as targets for antibody therapeutics against cancer. In connection with the above-identified patent application, I personally performed or directed the semi-quantitative PCR gene expression analyses in the assay entitled "Tumor Versus Normal Differential Tissue Expression Distribution," which is described in EXAMPLE 18 in the specification. These studies were used to identify differences in gene expression between tumor tissue and their normal counterparts.
4. EXAMPLE 18 reports the results of the PCR analyses conducted as part of the investigating of several newly discovered DNA sequences. This process included developing

Appl. No. : 10/063,557
Filed : May 2, 2002

primers and analyzing expression of the DNA sequences of interest in normal and tumor tissues. The analyses were designed to determine whether a difference exists between gene expression in normal tissues as compared to tumor in the same tissue type.

5. The DNA libraries used in the gene expression studies were made from pooled samples of normal and of tumor tissues. Data from pooled samples is more likely to be accurate than data obtained from a sample from a single individual. That is, the detection of variations in gene expression is likely to represent a more generally relevant condition when pooled samples from normal tissues are compared with pooled samples from tumors in the same tissue type.

6. In differential gene expression studies, one looks for genes whose expression levels differ significantly under different conditions, for example, in normal versus diseased tissue. Thus, I conducted a semi-quantitative analysis of the expression of the DNA sequences of interest in normal versus tumor tissues. Expression levels were graded according to a scale of +, -, and +/- to indicate the amount of the specific signal detected. Using the widely accepted technique of PCR, it was determined whether the polynucleotides tested were more highly expressed, less expressed, or whether expression remained the same in tumor tissue as compared to its normal counterpart. Because this technique relies on the visual detection of ethidium bromide staining of PCR products on agarose gels, it is reasonable to assume that any detectable differences seen between two samples will represent at least a two fold difference in cDNA.

7. The results of the gene expression studies indicate that the genes of interest can be used to differentiate tumor from normal. The precise levels of gene expression are irrelevant; what matters is that there is a relative difference in expression between normal tissue and tumor tissue. The precise type of tumor is also irrelevant; again, the assay was designed to indicate whether a difference exists between normal tissue and tumor tissue of the same type. If a difference is detected, this indicates that the gene and its corresponding polypeptide and antibodies against the polypeptide are useful for diagnostic purposes, to screen samples to differentiate between normal and tumor. Additional studies can then be conducted if further information is desired.

8. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By:


J. Christopher Grimaldi

Date:

8/10/2004

EXHIBIT A

J. Christopher Grimaldi

1434-36th Ave.
San Francisco, CA 94122
(415) 681-1639 (Home)

EDUCATION

University of California, Berkeley
Bachelor of Arts in Molecular Biology, 1984

EMPLOYMENT EXPERIENCE

SRA

Genentech Inc., South San Francisco; 1/99 to present

Previously, was responsible to direct and manage the Cloning Lab. Currently focused on isolating cancer specific genes for the Tumor Antigen (TAP), and Secreted Tumor Protein (STOP) projects for the Oncology Department as well as Immunologically relevant genes for the Immunology Department. Directed a lab of 6 scientists focused on a company-wide team effort to identify and isolate secreted proteins for potential therapeutic use (SPDI). For the SPDI project my duties were, among other things, the critically important coordination of the cloning of thousands of putative genes, by developing a smooth process of communication between the Bioinformatics, Cloning, Sequencing, and Legal teams. Collaborated with several groups to discover novel genes through the Curagen project, a unique differential display methodology. Interacted extensively with the Legal team providing essential data needed for filing patents on novel genes discovered through the SPDI, TAP and Curagen projects. My group has developed, implemented and patented high throughput cloning methodologies that have proven to be essential for the isolation of hundreds of novel genes for the SPDI, TAP and Curagen projects as well as dozens of other smaller projects.

Scientist

DNAX Research Institute, Palo Alto; 9/91 to 1/99

Involved in multiple projects aimed at understanding novel genes discovered through bioinformatics studies and functional assays. Developed and patented a method for the specific depletion of eosinophils in vivo using monoclonal antibodies. Developed and implemented essential technical methodologies and provided strategic direction in the areas of expression, cloning, protein purification, general molecular biology, and monoclonal antibody production. Trained and supervised numerous technical staff.

Facilities

Manager

Corixa, Redwood City; 5/89 - 7/91.

Directed plant-related activities, which included expansion planning, maintenance, safety, purchasing, inventory control, shipping and receiving, and laboratory management. Designed and implemented the safety program. Also served as liaison to regulatory agencies at the local, state and federal level. Was in charge of property leases, leasehold improvements, etc. Negotiated vendor contracts and directed the purchasing department. Trained and supervised personnel to carry out the above-mentioned duties.

SRA University of California, San Francisco
Cancer Research Institute; 2/87-4/89.

Was responsible for numerous cloning projects including: studies of somatic hypermutation, studies of AIDS-associated lymphomas, and cloning of t(5;14), t(11;14), and t(8;14) translocations. Focused on the activation of hemopoietic growth factors involved in the t(5;14) translocation in leukemia patients..

Research Berlex Biosciences, South San Francisco; 7/85-2/87.
Technician

Worked on a subunit porcine vaccine directed against Mycoplasma hyopneumoniae. Was responsible for generating genomic libraries, screening with degenerate oligonucleotides, and characterizing and expressing clones in E. coli. Also constructed a general purpose expression vector for use by other scientific teams.

PUBLICATIONS

1. Hilary F. Clark, et al. "The Secreted Protein Discovery Initiative (SPDI), a Large-scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: a bioinformatics assessment." *Genome Res.* Vol 13(10), 2265-2270, 2003
2. Sean H. Adams, Clarissa Chui, Sarah L. Schilbach, Xing Xian Yu, Audrey D. Goddard, J. Christopher Grimaldi, James Lee, Patrick Dowd, David A. Lewin, & Steven Colman "BFTT, a Unique Acyl-CoA Thioesterase Induced in Thermogenic Brown Adipose Tissue: Cloning, organization of the human gene and assessment of a potential link to obesity" *Biochemical Journal*, Vol 360, 135-142, 2001
3. Szeto W, Jiang W, Tice DA, Rubinfeld B, Hollingshead PG, Fong SE, Dugger DL, Pham T, Yansura D, Wong TA, Grimaldi JC, Corpuz RT, Singh JS, Frantz GD, Devaux B, Crowley CW, Schwall RH, Eberhard DA, Rastelli L, Polakis P, and Pennica D. "Overexpression of the Retinoic Acid-Responsive Gene Stra6 in Human Cancers and its Synergistic Activation by Wnt-1 and Retinoic Acid." *Cancer Research* Vol. 61(10), 4197-4205, 2001
4. Jeanne Kahn, Fuad Mehraban, Gladdys Ingle, Xiaohua Xin, Juliet E. Bryant, Gordon Vehar, Jill Schoenfeld, J. Christopher Grimaldi (incorrectly named as "Grimaldi, CJ"), Franklin Peale, Aparna Draksharapu, David A. Lewin, and Mary E. Gerritsen. "Gene Expression Profiling in an in Vitro Model of Angiogenesis." *American Journal of Pathology* Vol 156(6), 1887-1900, 2000.
5. Grimaldi JC, Yu NX, Grunig G, Seymour BW, Cottrez F, Robinson DS, Hosken N, Ferlin WG, Wu X, Soto H, O'Garra A, Howard MC, Coffman RL. "Depletion of eosinophils in mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3). *Journal of Leukocyte Biology*; Vol. 65(6), 846-53, 1999
6. Oliver AM, Grimaldi JC, Howard MC, Kearney JF. "Independently ligating CD38 and Fc gammaRIIB relays a dominant negative signal to B cells." *Hybridoma* Vol. 18(2), 113-9, 1999

7. Cockayne DA, Muchamuel T, Grimaldi JC, Muller-Steffner H, Randall TD, Lund FE, Murray R, Schuber F, Howard MC. "Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses." *Blood* Vol. 92(4), 1324-33, 1998
8. Frances E. Lund, Nanette W. Solvason, Michael P. Cooke, Andrew W. Heath, J. Christopher Grimaldi, Troy D. Randall, R. M. E. Parkhouse, Christopher C Goodnow and Maureen C. Howard. "Signaling through murine CD38 is impaired in antigen receptor unresponsive B cells." *European Journal of Immunology*, Vol. 25(5), 1338-1345, 1995
9. M. J. Guimaraes, J. F. Bazan, A. Zolotnik, M. V. Wiles, J. C. Grimaldi, F. Lee, T. McClanahan. "A new approach to the study of haematopoietic development in the yolk sac and embryoid body." *Development*, Vol. 121(10), 3335-3346, 1995
10. J. Christopher Grimaldi, Sriram Balasubramanian, J. Fernando Bazan, Armen Shanafelt, Gerard Zurawski and Maureen Howard. "CD38-mediated protein ribosylation." *Journal of Immunology*, Vol. 155(2), 811-817, 1995
11. Leopoldo Santos-Argumedo, Frances F. Lund, Andrew W. Heath, Nanette Solvason, Wei Wei Wu, J. Christopher Grimaldi, R. M. E. Parkhouse and Maureen Howard. "CD38 unresponsiveness of xid B cells implicates Bruton's tyrosine kinase (btk) as a regulator of CD38 induced signal transduction." *International Immunology*, Vol 7(2), 163-170, 1995
12. Frances Lund, Nanette Solvason, J. Christopher Grimaldi, R. M. E. Parkhouse and Maureen Howard. "Murine CD38: An immunoregulatory ectoenzyme." *Immunology Today*, Vol. 16(10), 469-473, 1995
13. Maureen Howard, J. Christopher Grimaldi, J. Fernando Bazan, Frances E. Lund, Leopoldo Santos-Argumedo, R. M. E. Parkhouse, Timothy F. Walseth, and Hon Cheung Lee. "Formation and Hydrolysis of Cyclic ADP-Ribose Catalyzed by Lymphocyte Antigen CD38." *Science*, Vol. 262, 1056-1059, 1993
14. Nobuyuki Harada, Leopoldo Santos-Argumedo, Ray Chang, J. Christopher Grimaldi, Frances Lund, Camilynn I. Brannan, Neal G. Copeland, Nancy A. Jenkins, Andrew Heath, R. M. E. Parkhouse and Maureen Howard. "Expression Cloning of a cDNA Encoding a Novel Murine B Cell Activation Marker: Homology to Human CD38." *The Journal of Immunology*, Vol. 151, 3111-3118, 1993
15. David J. Rawlings, Douglas C. Saffran, Satoshi Tsukada, David A. Largaespada, J. Christopher Grimaldi, Lucie Cohen Randolph N. Mohr, J. Fernando Bazan, Maureen Howard, Neal G. Copeland, Nancy A. Jenkins, Owen Witte. "Mutation of Unique Region of Bruton's Tyrosine Kinase in Immunodeficient XID Mice." *Science*, Vol. 261, 358-360, 1993
16. J. Christopher Grimaldi, Raul Torres, Christine A. Kozak, Ray Chang, Edward Clark, Maureen Howard, and Debra A. Cockayne. "Genomic Structure and Chromosomal Mapping of the Murine CD40 Gene." *The Journal of Immunology*, Vol 149, 3921-3926, 1992
17. Timothy C. Meeker, Bruce Shiramizu, Lawrence Kaplan, Brian Herndier, Henry Sanchez, J. Christopher Grimaldi, James Baumgartner, Jacob Rachlin, Ellen Feigal, Mark Rosenblum and Michael S. McGrath. "Evidence for Molecular Subtypes of HIV-Associated Lymphoma:

Division into Peripheral Monoclonal, Polyclonal and Central Nervous System Lymphoma." AIDS, Vol. 5, 669-674, 1991

18. Ann Grimaldi and Chris Grimaldi. "Small-Scale Lambda DNA Prep." Contribution to Current Protocols in Molecular Biology, Supplement 5, Winter 1989
19. J. Christopher Grimaldi, Timothy C. Meeker. "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene." Blood, Vol. 73, 2081-2085, 1989
20. Timothy C. Meeker, J. Christopher Grimaldi, et al. "An Additional Breakpoint Region in the BCL-1 Locus Associated with the t(11;14) (q13;q32) Translocation of B-Lymphocytic Malignancy." Blood, Vol. 74, 1801-1806, 1989
21. Timothy C. Meeker, J. Christopher Grimaldi, Robert O'Rourke, et al. "Lack of Detectable Somatic Hypermutation in the V Region of the Ig H Chain Gene of a Human Chronic B Lymphocytic Leukemia." The Journal of Immunology, Vol. 141, 3994-3998, 1988

MANUSCRIPTS IN PREPARATION

1. Sriram Balasubramanian, J. Christopher Grimaldi, J. Fernando Bazan, Gerard Zurawski and Maureen Howard. "Structural and functional characterization of CD38: Identification of active site residues"

PATENTS

1. "Methods for Eosinophil Depletion with Antibody to CCR3 Receptor" (US 6,207,155 B1).
2. "Amplification Based Cloning Method." (US 6,607,899)
3. Ashkenazi et al., "Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same." (this patent covers several hundred genes)
4. "IL-17 Homologous Polypeptides and Therapeutic Uses Thereof"
5. "Method of Diagnosing and Treating Cartilaginous Disorders."

MEMBERSHIPS AND ACTIVITIES

Editor	Frontiers in Bioscience
Member	DNAX Safety Committee 1991-1999
	Biological Safety Affairs Forum (BSAF) 1990-1991
	Environmental Law Foundation (ELF) 1990-1991

8 8
GNE2930R1C3

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Botstein, et al.
Appl. No. : 10/032,996
Filed : December 27, 2001
For : SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME
Examiner : Fredman, J.
Group Art Unit : 1634

COPY

DECLARATION OF PAUL POLAKIS, PH.D. UNDER 37 C.F.R. § 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Attached is the Declaration of Paul Polakis, Ph.D.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 16, 2004

By: AnneMarie Kaiser

AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550

S:\DOCS\BSG\BSG-1215.DOC
-061404

DECLARATION OF PAUL POLAKIS, Ph.D.

I, Paul Polakis, Ph.D., declare and say as follows:

1. I was awarded a Ph.D. by the Department of Biochemistry of the Michigan State University in 1984. My scientific Curriculum Vitae is attached to and forms part of this Declaration (Exhibit A).
2. I am currently employed by Genentech, Inc. where my job title is Staff Scientist. Since joining Genentech in 1999, one of my primary responsibilities has been leading Genentech's Tumor Antigen Project, which is a large research project with a primary focus on identifying tumor cell markers that find use as targets for both the diagnosis and treatment of cancer in humans.
3. As part of the Tumor Antigen Project, my laboratory has been analyzing differential expression of various genes in tumor cells relative to normal cells. The purpose of this research is to identify proteins that are abundantly expressed on certain tumor cells and that are either (i) not expressed, or (ii) expressed at lower levels, on corresponding normal cells. We call such differentially expressed proteins "tumor antigen proteins". When such a tumor antigen protein is identified, one can produce an antibody that recognizes and binds to that protein. Such an antibody finds use in the diagnosis of human cancer and may ultimately serve as an effective therapeutic in the treatment of human cancer.
4. In the course of the research conducted by Genentech's Tumor Antigen Project, we have employed a variety of scientific techniques for detecting and studying differential gene expression in human tumor cells relative to normal cells, at genomic DNA, mRNA and protein levels. An important example of one such technique is the well known and widely used technique of microarray analysis which has proven to be extremely useful for the identification of mRNA molecules that are differentially expressed in one tissue or cell type relative to another. In the course of our research using microarray analysis, we have identified approximately 200 gene transcripts that are present in human tumor cells at significantly higher levels than in corresponding normal human cells. To date, we have generated antibodies that bind to about 30 of the tumor antigen proteins expressed from these differentially expressed gene transcripts and have used these antibodies to quantitatively determine the level of production of these tumor antigen proteins in both human cancer cells and corresponding normal cells. We have then compared the levels of mRNA and protein in both the tumor and normal cells analyzed.
5. From the mRNA and protein expression analyses described in paragraph 4 above, we have observed that there is a strong correlation between changes in the level of mRNA present in any particular cell type and the level of protein

expressed from that mRNA in that cell type. In approximately 80% of our observations we have found that increases in the level of a particular mRNA correlates with changes in the level of protein expressed from that mRNA when human tumor cells are compared with their corresponding normal cells.

6. Based upon my own experience accumulated in more than 20 years of research, including the data discussed in paragraphs 4 and 5 above and my knowledge of the relevant scientific literature, it is my considered scientific opinion that for human genes, an increased level of mRNA in a tumor cell relative to a normal cell typically correlates to a similar increase in abundance of the encoded protein in the tumor cell relative to the normal cell. In fact, it remains a central dogma in molecular biology that increased mRNA levels are predictive of corresponding increased levels of the encoded protein. While there have been published reports of genes for which such a correlation does not exist, it is my opinion that such reports are exceptions to the commonly understood general rule that increased mRNA levels are predictive of corresponding increased levels of the encoded protein.

7. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Dated: 5/07/04

By: Paul Polakis

Paul Polakis, Ph.D.

EXHIBIT A

CURRICULUM VITAE

PAUL G. POLAKIS
Staff Scientist
Genentech, Inc
1 DNA Way, MS#40
S. San Francisco, CA 94080

EDUCATION:

Ph.D., Biochemistry, Department of Biochemistry,
Michigan State University (1984)

B.S., Biology. College of Natural Science, Michigan State University (1977)

PROFESSIONAL EXPERIENCE:

2002-present	Staff Scientist, Genentech, Inc S. San Francisco, CA
1999- 2002	Senior Scientist, Genentech, Inc., S. San Francisco, CA
1997 -1999	Research Director Onyx Pharmaceuticals, Richmond, CA
1992- 1996	Senior Scientist, Project Leader, Onyx Pharmaceuticals, Richmond, CA
1991-1992	Senior Scientist, Chiron Corporation, Emeryville, CA.
1989-1991	Scientist, Cetus Corporation, Emeryville CA.
1987-1989	Postdoctoral Research Associate, Genentech, Inc., South San Francisco, CA.
1985-1987	Postdoctoral Research Associate, Department of Medicine, Duke University Medical Center, Durham, NC

1984-1985

Assistant Professor, Department of Chemistry,
Oberlin College, Oberlin, Ohio

1980-1984

Graduate Research Assistant, Department of
Biochemistry, Michigan State University
East Lansing, Michigan

PUBLICATIONS:

1. Polakis, P. G. and Wilson, J. E. 1982 Purification of a Highly Bindable Rat Brain Hexokinase by High Performance Liquid Chromatography. **Biochem. Biophys. Res. Commun.** 107, 937-943.
2. Polakis, P. G. and Wilson, J. E. 1984 Proteolytic Dissection of Rat Brain Hexokinase: Determination of the Cleavage Pattern during Limited Digestion with Trypsin. **Arch. Biochem. Biophys.** 234, 341-352.
3. Polakis, P. G. and Wilson, J. E. 1985 An Intact Hydrophobic N-Terminal Sequence is Required for the Binding Rat Brain Hexokinase to Mitochondria. **Arch. Biochem. Biophys.** 236, 328-337.
4. Uhing, R. J., Polakis, P. G. and Snyderman, R. 1987 Isolation of GTP-binding Proteins from Myeloid HL60 Cells. **J. Biol. Chem.** 262, 15575-15579.
5. Polakis, P. G., Uhing, R. J. and Snyderman, R. 1988 The Formylpeptide Chemoattractant Receptor Copurifies with a GTP-binding Protein Containing a Distinct 40 kDa Pertussis Toxin Substrate. **J. Biol. Chem.** 263, 4969-4979.
6. Uhing, R. J., Dillon, S., Polakis, P. G., Truett, A. P. and Snyderman, R. 1988 Chemoattractant Receptors and Signal Transduction Processes in Cellular and Molecular Aspects of Inflammation (Poste, G. and Crooke, S. T. eds.) pp 335-379.
7. Polakis, P. G., Evans, T. and Snyderman 1989 Multiple Chromatographic Forms of the Formylpeptide Chemoattractant Receptor and their Relationship to GTP-binding Proteins. **Biochem. Biophys. Res. Commun.** 161, 276-283.
8. Polakis, P. G., Snyderman, R. and Evans, T. 1989 Characterization of G25K, a GTP-binding Protein Containing a Novel Putative Nucleotide Binding Domain. **Biochem. Biophys. Res. Commun.** 160, 25-32.
9. Polakis, P., Weber, R. F., Nevins, B., Didsbury, J. Evans, T. and Snyderman, R. 1989 Identification of the *rac1* and *rac1* Gene Products, Low Molecular Mass GTP-binding Proteins from Human Platelets. **J. Biol. Chem.** 264, 16383-16389.
10. Snyderman, R., Perianin, A., Evans, T., Polakis, P. and Didsbury, J. 1989 G Proteins and Neutrophil Function. In ADP-Ribosylating Toxins and G Proteins: Insights into Signal Transduction. (J. Moss and M. Vaughn, eds.) Amer. Soc. Microbiol. pp. 295-323.

11. Hart, M.J., Polakis, P.G., Evans, T. and Cerrione, R.A. 1990 The Identification and Characterization of an Epidermal Growth Factor-Stimulated Phosphorylation of a Specific Low Molecular Mass GTP-binding Protein in a Reconstituted Phospholipid Vesicle System. *J. Biol. Chem.* 265, 5990-6001.
12. Yatani, A., Okabe, K., Polakis, P., Halenbeck, R., McCormick, F. and Brown, A. M. 1990 ras p21 and GAP Inhibit Coupling of Muscarinic Receptors to Atrial K⁺ Channels. *Cell*. 61, 769-776.
13. Munemitsu, S., Innis, M.A., Clark, R., McCormick, F., Ullrich, A. and Polakis, P.G. 1990 Molecular Cloning and Expression of a G25K cDNA, the Human Homolog of the Yeast Cell Cycle Gene CDC42. *Mol. Cell. Biol.* 10, 5977-5982.
14. Polakis, P.G., Rubinfeld, B., Evans, T. and McCormick, F. 1991 Purification of Plasma Membrane-Associated GTPase Activating Protein (GAP) Specific for rap-1/krev-1 from HL60 Cells. *Proc. Natl. Acad. Sci. USA* 88, 239-243.
15. Moran, M. F., Polakis, P., McCormick, F., Pawson, T. and Ellis, C. 1991 Protein Tyrosine Kinases Regulate the Phosphorylation, Protein Interactions, Subcellular Distribution, and Activity of p21ras GTPase Activating Protein. *Mol. Cell. Biol.* 11, 1804-1812.
16. Rubinfeld, B., Wong, G., Bekesi, E., Wood, A., McCormick, F. and Polakis, P. G. 1991 A Synthetic Peptide Corresponding to a Sequence in the GTPase Activating Protein Inhibits p21^{ras} Stimulation and Promotes Guanine Nucleotide Exchange. *Internatl. J. Peptide and Prot. Res.* 38, 47-53.
17. Rubinfeld, B., Munemitsu, S., Clark, R., Conroy, L., Watt, K., Crosier, W., McCormick, F., and Polakis, P. 1991 Molecular Cloning of a GTPase Activating Protein Specific for the Krev-1 Protein p21^{rap1}. *Cell* 65, 1033-1042.
18. Zhang, K., Papageorge, A., G., Martin, P., Vass, W. C., Olah, Z., Polakis, P., McCormick, F. and Lowy, D. R. 1991 Heterogenous Amino Acids in RAS and Rap1A Specifying Sensitivity to GAP Proteins. *Science* 254, 1630-1634.
19. Martin, G., Yatani, A., Clark, R., Polakis, P., Brown, A. M. and McCormick, F. 1992 GAP Domains Responsible for p21^{ras}-dependent Inhibition of Muscarinic Atrial K⁺ Channel Currents. *Science* 255, 192-194.
20. McCormick, F., Martin, G. A., Clark, R., Bollag, G. and Polakis, P. 1992 Regulation of p21^{ras} by GTPase Activating Proteins. *Cold Spring Harbor Symposia on Quantitative Biology*: Vol. 56, 237-241.
21. Pronk, G. B., Polakis, P., Wong, G., deVries-Smits, A. M., Bos J. L. and McCormick, F. 1992 p60^{v-src} Can Associate with and Phosphorylate the p21^{ras} GTPase Activating Protein. *Oncogene* 7, 389-394.
22. Polakis P. and McCormick, F. 1992 Interactions Between p21^{ras} Proteins and Their GTPase Activating Proteins. In Cancer Surveys (Franks, L. M., ed.) 12, 25-42.

23. Wong, G., Muller, O., Clark, R., Conroy, L., Moran, M., Polakis, P. and McCormick, F. 1992 Molecular cloning and nucleic acid binding properties of the GAP-associated tyrosine phosphoprotein p62. *Cell* 69, 551-558.
24. Polakis, P., Rubinfeld, B. and McCormick, F. 1992 Phosphorylation of rap1GAP in vivo and by cAMP-dependent Kinase and the Cell Cycle p34^{cdc2} Kinase in vitro. *J. Biol. Chem.* 267, 10780-10785.
25. McCabe, P.C., Haubrauck, H., Polakis, P., McCormick, F., and Innis, M. A. 1992 Functional Interactions Between p21^{rap1A} and Components of the Budding pathway of *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* 12, 4084-4092.
26. Rubinfeld, B., Crosier, W.J., Albert, I., Conroy, L., Clark, R., McCormick, F. and Polakis, P. 1992 Localization of the rap1GAP Catalytic Domain and Sites of Phosphorylation by Mutational Analysis. *Mol. Cell. Biol.* 12, 4634-4642.
27. Ando, S., Kaibuchi, K., Sasaki, K., Hiraoka, T., Nishiyama, T., Mizuno, T., Asada, M., Nunoi, H., Matsuda, I., Matsuura, Y., Polakis, P., McCormick, F. and Takai, Y. 1992 Post-translational processing of rac p21s is important both for their interaction with the GDP/GTP exchange proteins and for their activation of NADPH oxidase. *J. Biol. Chem.* 267, 25709-25713.
28. Janoueix-Lerosey, I., Polakis, P., Tavittian, A. and deGunzburg, J. 1992 Regulation of the GTPase activity of the ras-related rap2 protein. *Biochem. Biophys. Res. Commun.* 189, 455-464.
29. Polakis, P. 1993 GAPs Specific for the rap1/Krev-1 Protein. in GTP-binding Proteins: the ras-superfamily. (J.C. LaCale and F. McCormick, eds.) 445-452.
30. Polakis, P. and McCormick, F. 1993 Structural requirements for the interaction of p21^{ras} with GAP, exchange factors, and its biological effector target. *J. Biol. Chem.* 268, 9157-9160.
31. Rubinfeld, B., Souza, B., Albert, I., Muller, O., Chamberlain, S., Masiarz, F., Munemitsu, S. and Polakis, P. 1993 Association of the APC gene product with beta-catenin. *Science* 262, 1731-1734.
32. Weiss, J., Rubinfeld, B., Polakis, P., McCormick, F., Cavenee, W. A. and Arden, K. 1993 The gene for human rap1-GTPase activating protein (rap1GAP) maps to chromosome 1p35-1p36.1. *Cytogenet. Cell Genet.* 66, 18-21.
33. Sato, K. Y., Polakis, P., Haubruck, H., Fasching, C. L., McCormick, F. and Stanbridge, E. J. 1994 Analysis of the tumor suppressor activity of the K-rev gene in human tumor cell lines. *Cancer Res.* 54, 552-559.
34. Janoueix-Lerosey, I., Fontenay, M., Tobelem, G., Tavittian, A., Polakis, P. and DeGunzburg, J. 1994 Phosphorylation of rap1GAP during the cell cycle. *Biochem. Biophys. Res. Commun.* 202, 967-975.
35. Munemitsu, S., Souza, B., Mueller, O., Albert, I., Rubinfeld, B., and Polakis, P. 1994 The APC gene product associates with microtubules in vivo and affects their assembly in vitro. *Cancer Res.* 54, 3676-3681.

36. Rubinfeld, B. and Polakis, P. 1995 Purification of baculovirus produced rap1GAP. *Methods Enz.* 255,31
37. Polakis, P. 1995 Mutations in the APC gene and their implications for protein structure and function. *Current Opinions in Genetics and Development* 5, 66-71
38. Rubinfeld, B., Souza, B., Albert, I., Munemitsu, S. and Polakis P. 1995 The APC protein and E-cadherin form similar but independent complexes with α -catenin, β -catenin and Plakoglobin. *J. Biol. Chem.* 270, 5549-5555
39. Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B., and Polakis, P. 1995 Regulation of intracellular β -catenin levels by the APC tumor suppressor gene. *Proc. Natl. Acad. Sci.* 92, 3046-3050.
40. Lock, P., Fumagalli, S., Polakis, P. McCormick, F. and Courtneidge, S. A. 1996 The human p62 cDNA encodes Sam68 and not the rasGAP-associated p62 protein. *Cell* 84, 23-24.
41. Papkoff, J., Rubinfeld, B., Schryver, B. and Polakis, P. 1996 Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes. *Mol. Cell. Biol.* 16, 2128-2134.
42. Rubinfeld, B., Albert, I., Porfiri, E., Fiol, C., Munemitsu, S. and Polakis, P. 1996 Binding of GSK3 β to the APC- β -catenin complex and regulation of complex assembly. *Science* 272, 1023-1026.
43. Munemitsu, S., Albert, I., Rubinfeld, B. and Polakis, P. 1996 Deletion of amino-terminal structure stabilizes β -catenin in vivo and promotes the hyperphosphorylation of the APC tumor suppressor protein. *Mol. Cell. Biol.* 16, 4088-4094.
44. Hart, M. J., Callow, M. G., Sousa, B. and Polakis P. 1996 IQGAP1, a calmodulin binding protein with a rasGAP related domain, is a potential effector for cdc42Hs. *EMBO J.* 15, 2997-3005.
45. Nathke, I. S., Adams, C. L., Polakis, P., Sellin, J. and Nelson, W. J. 1996 The adenomatous polyposis coli (APC) tumor suppressor protein is localized to plasma membrane sites involved in active epithelial cell migration. *J. Cell. Biol.* 134, 165-180.
46. Hart, M. J., Sharma, S., elMasry, N., Qui, R-G., McCabe, P., Polakis, P. and Bollag, G. 1996 Identification of a novel guanine nucleotide exchange factor for the rho GTPase. *J. Biol. Chem.* 271, 25452.
47. Thomas JE, Smith M, Rubinfeld B, Gutowski M, Beckmann RP, and Polakis P. 1996 Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1. *J. Biol. Chem.* 1996 271, 28630-28635
48. Hayashi, S., Rubinfeld, B., Souza, B., Polakis, P., Wieschaus, E., and Levine, A. 1997 A Drosophila homolog of the tumor suppressor adenomatous polyposis coli

down-regulates β -catenin but its zygotic expression is not essential for the regulation of armadillo. *Proc. Natl. Acad. Sci.* 94, 242-247.

49. Vleminckx, K., Rubinfeld, B., Polakis, P. and Gumbiner, B. 1997 The APC tumor suppressor protein induces a new axis in *Xenopus* embryos. *J. Cell. Biol.* 136, 411-420.

50. Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, P. and Polakis, P. 1997 Stabilization of β -catenin by genetic defects in melanoma cell lines. *Science* 275, 1790-1792.

51. Polakis, P. The adenomatous polyposis coli (APC) tumor suppressor. 1997 *Biochem. Biophys. Acta*, 1332, F127-F147.

52. Rubinfeld, B., Albert, I., Porfiri, E., Munemitsu, S., and Polakis, P. 1997 Loss of β -catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. *Cancer Res.* 57, 4624-4630.

53. Porfiri, E., Rubinfeld, B., Albert, I., Hovanes, K., Waterman, M., and Polakis, P. 1997 Induction of a β -catenin-LEF-1 complex by wnt-1 and transforming mutants of β -catenin. *Oncogene* 15, 2833-2839.

54. Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, and Polakis P., 1997 Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. *Cell Growth Differ.* 8, 801-809.

55. Hart, M., de los Santos, R., Albert, I., Rubinfeld, B., and Polakis P., 1998 Down regulation of β -catenin by human Axin and its association with the adenomatous polyposis coli (APC) tumor suppressor, β -catenin and glycogen synthase kinase 3 β . *Current Biology* 8, 573-581.

56. Polakis, P. 1998 The oncogenic activation of β -catenin. *Current Opinions in Genetics and Development* 9, 15-21

57. Matt Hart, Jean-Paul Concordet, Irina Lassot, Iris Albert, Rico del los Santos, Herve Durand, Christine Perret, Bonnee Rubinfeld, Florence Margottin, Richard Benarous and Paul Polakis. 1999 The F-box protein β -TrCP associates with phosphorylated β -catenin and regulates its activity in the cell. *Current Biology* 9, 207-10.

58. Howard C. Crawford, Barbara M. Fingleton, Bonnee Rubinfeld, Paul Polakis and Lynn M. Matrisian 1999 The metalloproteinase matrilysin is a target of β -catenin transactivation in intestinal tumours. *Oncogene* 18, 2883-91.

59. Meng J, Glick JL, Polakis P, Casey PJ. 1999 Functional interaction between Galpha(z) and Rap1GAP suggests a novel form of cellular cross-talk. *J Biol Chem.* 17, 36663-9

60. Vijayasurian Easwaran, Virginia Song, Paul Polakis and Steve Byers 1999 The ubiquitin-proteasome pathway and serine kinase activity modulate APC mediated regulation of β -catenin-LEF signaling. **J. Biol. Chem.** 274(23):16641-5.
61. Polakis P, Hart M and Rubinfeld B. 1999 Defects in the regulation of beta-catenin in colorectal cancer. **Adv Exp Med Biol.** 470, 23-32
62. Shen Z, Batzer A, Koehler JA, Polakis P, Schlessinger J, Lydon NB, Moran MF. 1999 Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src. **Oncogene.** 18, 4647-53
64. Thomas GM, Frame S, Goedert M, Nathke I, Polakis P, Cohen P. 1999 A GSK3- binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. **FEBS Lett.** 458, 247-51.
65. Peifer M, Polakis P. 2000 Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus. **Science** 287,1606-9,
66. Polakis P. 2000 Wnt signaling and cancer. **Genes Dev**;14, 1837-1851.
67. Spink KE, Polakis P, Weis WI 2000 Structural basis of the Axin-adenomatous polyposis coli interaction. **EMBO J** 19, 2270-2279.
68. Szeto, W., Jiang, W., Tice, D.A., Rubinfeld, B., Hollingshead, P.G., Fong, S.E., Dugger, D.L., Pham, T., Yansura, D.E., Wong, T.A., Grimaldi, J.C., Corpuz, R.T., Singh J.S., Frantz, G.D., Devaux, B., Crowley, C.W., Schwall, R.H., Eberhard, D.A., Rastelli, L., Polakis, P. and Pennica, D. 2001 Overexpression of the Retinoic Acid-Responsive Gene Stra6 in Human Cancers and its Synergistic Induction by Wnt-1 and Retinoic Acid. **Cancer Res** 61, 4197-4204.
69. Rubinfeld B, Tice DA, Polakis P. 2001 Axin dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase 1 epsilon. **J Biol Chem** 276, 39037-39045.
70. Polakis P. 2001 More than one way to skin a catenin. **Cell** 2001 105, 563-566.
71. Tice DA, Soloviev I, Polakis P. 2002 Activation of the Wnt Pathway Interferes with Serum Response Element-driven Transcription of Immediate Early Genes. **J Biol. Chem.** 277, 6118-6123.
72. Tice DA, Szeto W, Soloviev I, Rubinfeld B, Fong SE, Dugger DL, Winer J,

Williams PM, Wieand D, Smith V, Schwall RH, Pennica D, Polakis P. 2002 Synergistic activation of tumor antigens by wnt-1 signaling and retinoic acid revealed by gene expression profiling. **J Biol Chem.** 277,14329-14335.

73. Polakis, P. 2002 Casein kinase I: A wnt'er of disconnect. **Curr. Biol.** 12, R499.

74. Mao, W., Luis, E., Ross, S., Silva, J., Tan, C., Crowley, C., Chui, C., Franz, G., Senter, P., Koeppen, H., Polakis, P. 2004 EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. **Cancer Res.** 64, 781-788.

75. Shibamoto, S., Winer, J., Williams, M., Polakis, P. 2003 A Blockade in Wnt signaling is activated following the differentiation of F9 teratocarcinoma cells. **Exp. Cell Res.** 29211-20.

76. Zhang Y, Eberhard DA, Frantz GD, Dowd P, Wu TD, Zhou Y, Watanabe C, Luoh SM, Polakis P, Hillan KJ, Wood WI, Zhang Z. 2004 GEPIS--quantitative gene expression profiling in normal and cancer tissues. **Bioinformatics**, April 8

MOLECULAR BIOLOGY OF
THE CELL
THIRD EDITION

Text Editor: Miranda Robertson
Managing Editor: Ruth Adams
Illustrator: Nigel Orme
Molecular Model Drawings: Kate Hesketh-Moore
Director of Electronic Publishing: John M. Roblin
Computer Specialist: Chuck Bartelt
Disk Preparation: Carol Winter
Copy Editor: Shirley M. Cobert
Production Editor: Douglas Goertzen
Production Coordinator: Perry Bessas
Indexer: Maija Hinkle

Bruce Alberts received his Ph.D. from Harvard University and is currently President of the National Academy of Sciences and Professor of Biochemistry and Biophysics at the University of California, San Francisco. *Dennis Bray* received his Ph.D. from the Massachusetts Institute of Technology and is currently a Medical Research Council Fellow in the Department of Zoology, University of Cambridge.

Julian Lewis received his D.Phil. from the University of Oxford and is currently a Senior Scientist in the Imperial Cancer Research Fund Developmental Biology Unit, University of Oxford. *Martin Raff* received his M.D. from McGill University and is currently a Professor in the MRC Laboratory for Molecular Cell Biology and the Biology Department, University College London. *Keith Roberts* received his Ph.D. from the University of Cambridge and is currently Head of the Department of Cell Biology, the John Innes Institute, Norwich. *James D. Watson* received his Ph.D. from Indiana University and is currently Director of the Cold Spring Harbor Laboratory. He is the author of *Molecular Biology of the Gene* and, with Francis Crick and Maurice Wilkins, won the Nobel Prize in Medicine and Physiology in 1962.

© 1983, 1989, 1994 by Bruce Alberts, Dennis Bray, Julian Lewis, Martin Raff, Keith Roberts, and James D. Watson.

All rights reserved. No part of this book covered by the copyright hereon may be reproduced or used in any form or by any means—graphic, electronic, or mechanical, including photocopying, recording, taping, or information storage and retrieval systems—without permission of the publisher.

Library of Congress Cataloging-in-Publication Data

Molecular biology of the cell / Bruce Alberts . . . [et al.].—3rd ed.
p. cm.

Includes bibliographical references and index.

ISBN 0-8153-1619-4 (hard cover).—ISBN 0-8153-1620-8 (pbk.)

1. Cytology. 2. Molecular biology. I. Alberts, Bruce.

[DNLM: 1. Cells. 2. Molecular Biology. QH 581.2 M718 1994]

QH581.2.M64 1994

574.87—dc20

DNLM/DLC

for Library of Congress

93-45907

CIP

Published by Garland Publishing, Inc.
717 Fifth Avenue, New York, NY 10022

Printed in the United States of America

15 14 13 12 10 9 8 7

Front cover: The photograph shows a rat nerve cell in culture. It is labeled (*yellow*) with a fluorescent antibody that stains its cell body and dendritic processes. Nerve terminals (*green*) from other neurons (not visible), which have made synapses on the cell, are labeled with a different antibody. (Courtesy of Olaf Mundigl and Pietro de Camilli.)

Dedication page: Gavin Borden, late president of Garland Publishing, weathered in during his mid-1980s climb near Mount McKinley with MBoC author Bruce Alberts and famous mountaineer guide Mugs Stump (1940–1992).

Back cover: The authors, in alphabetical order, crossing Abbey Road in London on their way to lunch. Much of this third edition was written in a house just around the corner. (Photograph by Richard Olivier.)

extracts. If these minor cell proteins differ among cells to the same extent as the more abundant proteins, as is commonly assumed, only a small number of protein differences (perhaps several hundred) suffice to create very large differences in cell morphology and behavior.

A Cell Can Change the Expression of Its Genes in Response to External Signals³

Most of the specialized cells in a multicellular organism are capable of altering their patterns of gene expression in response to extracellular cues. If a liver cell is exposed to a glucocorticoid hormone, for example, the production of several specific proteins is dramatically increased. Glucocorticoids are released during periods of starvation or intense exercise and signal the liver to increase the production of glucose from amino acids and other small molecules; the set of proteins whose production is induced includes enzymes such as tyrosine aminotransferase, which helps to convert tyrosine to glucose. When the hormone is no longer present, the production of these proteins drops to its normal level.

Other cell types respond to glucocorticoids in different ways. In fat cells, for example, the production of tyrosine aminotransferase is reduced, while some other cell types do not respond to glucocorticoids at all. These examples illustrate a general feature of cell specialization—different cell types often respond in different ways to the same extracellular signal. Underlying this specialization are features that do not change, which give each cell type its permanently distinctive character. These features reflect the persistent expression of different sets of genes.

Gene Expression Can Be Regulated at Many of the Steps in the Pathway from DNA to RNA to Protein⁴

If differences between the various cell types of an organism depend on the particular genes that the cells express, at what level is the control of gene expression exercised? There are many steps in the pathway leading from DNA to protein, and all of them can in principle be regulated. Thus a cell can control the proteins it makes by (1) controlling when and how often a given gene is transcribed (**transcriptional control**), (2) controlling how the primary RNA transcript is spliced or otherwise processed (**RNA processing control**), (3) selecting which completed mRNAs in the cell nucleus are exported to the cytoplasm (**RNA transport control**), (4) selecting which mRNAs in the cytoplasm are translated by ribosomes (**translational control**), (5) selectively destabilizing certain mRNA molecules in the cytoplasm (**mRNA degradation control**), or (6) selectively activating, inactivating, or compartmentalizing specific protein molecules after they have been made (**protein activity control**) (Figure 9-2).

For most genes transcriptional controls are paramount. This makes sense because, of all the possible control points illustrated in Figure 9-2, only transcriptional control ensures that no superfluous intermediates are synthesized. In the




Figure 9-2 Six steps at which eucaryote gene expression can be controlled. Only controls that operate at steps 1 through 5 are discussed in this chapter. The regulation of protein activity (step 6) is discussed in Chapter 5; this includes reversible activation or inactivation by protein phosphorylation as well as irreversible inactivation by proteolytic degradation.

following sections we discuss the DNA and protein components that regulate the initiation of gene transcription. We return at the end of the chapter to the other ways of regulating gene expression.

Summary

The genome of a cell contains in its DNA sequence the information to make many thousands of different protein and RNA molecules. A cell typically expresses only a fraction of its genes, and the different types of cells in multicellular organisms arise because different sets of genes are expressed. Moreover, cells can change the pattern of genes they express in response to changes in their environment, such as signals from other cells. Although all of the steps involved in expressing a gene can in principle be regulated, for most genes the initiation of RNA transcription is the most important point of control.

DNA-binding Motifs in Gene Regulatory Proteins⁵

How does a cell determine which of its thousands of genes to transcribe? As discussed in Chapter 8, the transcription of each gene is controlled by a regulatory region of DNA near the site where transcription begins. Some regulatory regions are simple and act as switches that are thrown by a single signal. Other regulatory regions are complex and act as tiny microprocessors, responding to a variety of signals that they interpret and integrate to switch the neighboring gene on or off. Whether complex or simple, these switching devices consist of two fundamental types of components: (1) short stretches of DNA of defined sequence and (2) *gene regulatory proteins* that recognize and bind to them.

We begin our discussion of gene regulatory proteins by describing how these proteins were discovered.

Gene Regulatory Proteins Were Discovered Using Bacterial Genetics⁶

Genetic analyses in bacteria carried out in the 1950s provided the first evidence of the existence of **gene regulatory proteins** that turn specific sets of genes on or off. One of these regulators, the *lambda repressor*, is encoded by a bacterial virus, *bacteriophage lambda*. The repressor shuts off the viral genes that code for the protein components of new virus particles and thereby enables the viral genome to remain a silent passenger in the bacterial chromosome, multiplying with the bacterium when conditions are favorable for bacterial growth (see Figure 6-80). The lambda repressor was among the first gene regulatory proteins to be characterized, and it remains one of the best understood, as we discuss later. Other bacterial regulators respond to nutritional conditions by shutting off genes encoding specific sets of metabolic enzymes when they are not needed. The *lac repressor*, for example, the first of these bacterial proteins to be recognized, turns off the production of the proteins responsible for lactose metabolism when this sugar is absent from the medium.

The first step toward understanding gene regulation was the isolation of mutant strains of bacteria and bacteriophage lambda that were unable to shut off specific sets of genes. It was proposed at the time, and later proved, that most of these mutants were deficient in proteins acting as specific repressors for these sets of genes. Because these proteins, like most gene regulatory proteins, are present in small quantities, it was difficult and time-consuming to isolate them. They were eventually purified by fractionating cell extracts on a series of standard chromatography columns (see pp. 166-169). Once isolated, the proteins were shown to bind to specific DNA sequences close to the genes that they




Figure 9-3 Double-helical structure of DNA. The major and minor grooves on the outside of the double helix are indicated. The atoms are colored as follows: carbon, dark blue; nitrogen, light blue; hydrogen, white; oxygen, red; phosphorus, yellow.




Figure 9-71 A mechanism to explain both the marked deficiency of CG sequences and the presence of CG islands in vertebrate genomes. A black line marks the location of an unmethylated CG dinucleotide in the DNA sequence, while a red line marks the location of a methylated CG dinucleotide.

Summary

The many types of cells in animals and plants are created largely through mechanisms that cause different genes to be transcribed in different cells. Since many specialized animal cells can maintain their unique character when grown in culture, the gene regulatory mechanisms involved in creating them must be stable once established and heritable when the cell divides, endowing the cell with a memory of its developmental history. Prokaryotes and yeasts provide unusually accessible model systems in which to study gene regulatory mechanisms, some of which may be relevant to the creation of specialized cell types in higher eucaryotes. One such mechanism involves a competitive interaction between two (or more) gene regulatory proteins, each of which inhibits the synthesis of the other; this can create a flip-flop switch that switches a cell between two alternative patterns of gene expression. Direct or indirect positive feedback loops, which enable gene regulatory proteins to perpetuate their own synthesis, provide a general mechanism for cell memory.

In eucaryotes gene transcription is generally controlled by combinations of gene regulatory proteins. It is thought that each type of cell in a higher eucaryotic organism contains a specific combination of gene regulatory proteins that ensures the expression of only those genes appropriate to that type of cell. A given gene regulatory protein may be expressed in a variety of circumstances and typically is involved in the regulation of many genes.

In addition to diffusible gene regulatory proteins, inherited states of chromatin condensation are also utilized by eucaryotic cells to regulate gene expression. In vertebrates DNA methylation also plays a part, mainly as a device to reinforce decisions about gene expression that are made initially by other mechanisms.

Posttranscriptional Controls

Although controls on the initiation of gene transcription are the predominant form of regulation for most genes, other controls can act later in the pathway from RNA to protein to modulate the amount of gene product that is made. Although these posttranscriptional controls, which operate after RNA polymerase has bound to the gene's promoter and begun RNA synthesis, are less common than transcriptional control, for many genes they are crucial. It seems that every step in gene expression that could be controlled in principle is likely to be regulated under some circumstances for some genes.

We consider the varieties of posttranscriptional regulation in temporal order, according to the sequence of events that might be experienced by an RNA molecule after its transcription has begun (Figure 9-72).




Figure 9-72 Possible posttranscriptional controls on gene expression. Only a few of these controls are likely to be used for any one gene.

MOLECULAR BIOLOGY OF
THE CELL

fourth edition

Bruce Alberts

Alexander Johnson

Julian Lewis

Martin Raff

Keith Roberts

Peter Walter

 **Garland Science**
Taylor & Francis Group

Garland

Vice President: Denise Schanck
Managing Editor: Sarah Gibbs
Senior Editorial Assistant: Kirsten Jenner
Managing Production Editor: Emma Hunt
Proofreader and Layout: Emma Hunt
Production Assistant: Angela Bennett
Text Editors: Marjorie Singer Anderson and Betsy Dileria
Copy Editor: Bruce Goatly
Word Processors: Fran Dependahl, Misty Landers and Carol Winter
Designer: Blink Studio, London
Illustrator: Nigel Orme
Indexer: Janine Ross and Sherry Granum
Manufacturing: Nigel Eyre and Marion Morrow

Cell Biology Interactive

Artistic and Scientific Direction: Peter Walter
Narrated by: Julie Theriot
Production, Design, and Development: Mike Morales

Bruce Alberts received his Ph.D. from Harvard University and is President of the National Academy of Sciences and Professor of Biochemistry and Biophysics at the University of California, San Francisco. **Alexander Johnson** received his Ph.D. from Harvard University and is a Professor of Microbiology and Immunology at the University of California, San Francisco. **Julian Lewis** received his D.Phil. from the University of Oxford and is a Principal Scientist at the Imperial Cancer Research Fund, London. **Martin Raff** received his M.D. from McGill University and is at the Medical Research Council Laboratory for Molecular Cell Biology and Cell Biology Unit and in the Biology Department at University College London. **Keith Roberts** received his Ph.D. from the University of Cambridge and is Associate Research Director at the John Innes Centre, Norwich. **Peter Walter** received his Ph.D. from The Rockefeller University in New York and is Professor and Chairman of the Department of Biochemistry and Biophysics at the University of California, San Francisco, and an Investigator of the Howard Hughes Medical Institute.

© 2002 by Bruce Alberts, Alexander Johnson, Julian Lewis, Martin Raff, Keith Roberts, and Peter Walter.
© 1983, 1989, 1994 by Bruce Alberts, Dennis Bray, Julian Lewis, Martin Raff, Keith Roberts, and James D. Watson.

All rights reserved. No part of this book covered by the copyright hereon may be reproduced or used in any format in any form or by any means—graphic, electronic, or mechanical, including photocopying, recording, taping, or information storage and retrieval systems—without permission of the publisher.

Library of Congress Cataloging-in-Publication Data

Molecular biology of the cell / Bruce Alberts ... [et al.]. -- 4th ed.
p. cm
Includes bibliographical references and index.
ISBN 0-8153-3218-1 (hardbound) -- ISBN 0-8153-4072-9 (pbk.)
1. Cytology. 2. Molecular biology. I. Alberts, Bruce.
[DNLM: 1. Cells. 2. Molecular Biology.]
QH581.2 .M64 2002
571.6--dc21

2001054471 CIP

Published by Garland Science, a member of the Taylor & Francis Group,
29 West 35th Street, New York, NY 10001-2299

Printed in the United States of America

15 14 13 12 11 10 9 8 7 6 5 4 3 2 1

Front cover Human Genome: Reprinted by permission from *Nature*, International Human Genome Sequencing Consortium, 409:860-921, 2001 © Macmillan Magazines Ltd. Adapted from an image by Francis Collins, NHGRI; Jim Kent, UCSC; Ewan Birney, EBI; and Darryl Leja, NHGRI; showing a portion of Chromosome 1 from the initial sequencing of the human genome.

Back cover In 1967, the British artist Peter Blake created a design classic. Nearly 35 years later Nigel Orme (illustrator), Richard Denyer (photographer), and the authors have together produced an affectionate tribute to Mr Blake's image. With its gallery of icons and influences, its assembly created almost as much complexity, intrigue and mystery as the original. *Drosophila*, *Arabidopsis*, Dolly and the assembled company tempt you to dip inside where, as in the original, "a splendid time is guaranteed for all." (Gunter Blobel, courtesy of The Rockefeller University; Marie Curie, Keystone Press Agency Inc; Darwin bust, by permission of the President and Council of the Royal Society; Rosalind Franklin, courtesy of Cold Spring Harbor Laboratory Archives; Dorothy Hodgkin, © The Nobel Foundation, 1964; James Joyce, etching by Peter Blake; Robert Johnson, photo booth self-portrait early 1930s, © 1986 Delta Haze Corporation all rights reserved, used by permission; Albert L. Lehninger, (unidentified photographer) courtesy of The Alan Mason Chesney Medical Archives of The Johns Hopkins Medical Institutions; Linus Pauling, from Ava Helen and Linus Pauling Papers, Special Collections, Oregon State University; Nicholas Poussin, courtesy of ArtToday.com; Barbara McClintock, © David Micklos, 1983; Andrei Sakharov, courtesy of Elena Bonner; Frederick Sanger, © The Nobel Foundation, 1958.)




Figure 6-3 Genes can be expressed with different efficiencies. Gene A is transcribed and translated much more efficiently than gene B. This allows the amount of protein A in the cell to be much greater than that of protein B.

FROM DNA TO RNA

Transcription and translation are the means by which cells read out, or express, the genetic instructions in their genes. Because many identical RNA copies can be made from the same gene, and each RNA molecule can direct the synthesis of many identical protein molecules, cells can synthesize a large amount of protein rapidly when necessary. But each gene can also be transcribed and translated with a different efficiency, allowing the cell to make vast quantities of some proteins and tiny quantities of others (Figure 6-3). Moreover, as we see in the next chapter, a cell can change (or regulate) the expression of each of its genes according to the needs of the moment—most obviously by controlling the production of its RNA.

Portions of DNA Sequence Are Transcribed into RNA

The first step a cell takes in reading out a needed part of its genetic instructions is to copy a particular portion of its DNA nucleotide sequence—a gene—into an RNA nucleotide sequence. The information in RNA, although copied into another chemical form, is still written in essentially the same language as it is in DNA—the language of a nucleotide sequence. Hence the name **transcription**.

Like DNA, RNA is a linear polymer made of four different types of nucleotide subunits linked together by phosphodiester bonds (Figure 6-4). It differs from DNA chemically in two respects: (1) the nucleotides in RNA are *ribonucleotides*—that is, they contain the sugar ribose (hence the name *ribonucleic acid*) rather than deoxyribose; (2) although, like DNA, RNA contains the bases adenine (A), guanine (G), and cytosine (C), it contains the base uracil (U) instead of the thymine (T) in DNA. Since U, like T, can base-pair by hydrogen-bonding with A (Figure 6-5), the complementary base-pairing properties described for DNA in Chapters 4 and 5 apply also to RNA (in RNA, G pairs with C, and A pairs with U). It is not uncommon, however, to find other types of base pairs in RNA: for example, G pairing with U occasionally.

Despite these small chemical differences, DNA and RNA differ quite dramatically in overall structure. Whereas DNA always occurs in cells as a double-stranded helix, RNA is single-stranded. RNA chains therefore fold up into a variety of shapes, just as a polypeptide chain folds up to form the final shape of a protein (Figure 6-6). As we see later in this chapter, the ability to fold into complex three-dimensional shapes allows some RNA molecules to have structural and catalytic functions.

Transcription Produces RNA Complementary to One Strand of DNA

All of the RNA in a cell is made by DNA transcription, a process that has certain similarities to the process of DNA replication discussed in Chapter 5.




Figure 6-89 Protein aggregates that cause human disease. (A) Schematic illustration of the type of conformational change in a protein that produces material for a cross-beta filament. (B) Diagram illustrating the self-infectious nature of the protein aggregation that is central to prion diseases. PrP is highly unusual because the misfolded version of the protein, called PrP^{*}, induces the normal PrP protein it contacts to change its conformation, as shown. Most of the human diseases caused by protein aggregation are caused by the overproduction of a variant protein that is especially prone to aggregation, but because this structure is not infectious in this way, it cannot spread from one animal to another. (C) Drawing of a cross-beta filament, a common type of protease-resistant protein aggregate found in a variety of human neurological diseases. Because the hydrogen-bond interactions in a β sheet form between polypeptide backbone atoms (see Figure 3-9), a number of different abnormally folded proteins can produce this structure. (D) One of several possible models for the conversion of PrP to PrP^{*}, showing the likely change of two α -helices into four β -strands. Although the structure of the normal protein has been determined accurately, the structure of the infectious form is not yet known with certainty because the aggregation has prevented the use of standard structural techniques. (C, courtesy of Louise Serpell, adapted from M. Sunde et al., *J. Mol. Biol.* 273:729-739, 1997; D, adapted from S.B. Prusiner, *Trends Biochem. Sci.* 21:482-487, 1996.)

animals and humans. It can be dangerous to eat the tissues of animals that contain PrP^{*}, as witnessed most recently by the spread of BSE (commonly referred to as the "mad cow disease") from cattle to humans in Great Britain.

Fortunately, in the absence of PrP^{*}, PrP is extraordinarily difficult to convert to its abnormal form. Although very few proteins have the potential to misfold into an infectious conformation, a similar transformation has been discovered to be the cause of an otherwise mysterious "protein-only inheritance" observed in yeast cells.

There Are Many Steps From DNA to Protein

We have seen so far in this chapter that many different types of chemical reactions are required to produce a properly folded protein from the information contained in a gene (Figure 6-90). The final level of a properly folded protein in a cell therefore depends upon the efficiency with which each of the many steps is performed.

We discuss in Chapter 7 that cells have the ability to change the levels of their proteins according to their needs. In principle, any or all of the steps in Fig-




Figure 6-90 The production of a protein by a eucaryotic cell. The final level of each protein in a eucaryotic cell depends upon the efficiency of each step depicted.

ure 6-90) could be regulated by the cell for each individual protein. However, as we shall see in Chapter 7, the initiation of transcription is the most common point for a cell to regulate the expression of each of its genes. This makes sense, inasmuch as the most efficient way to keep a gene from being expressed is to block the very first step—the transcription of its DNA sequence into an RNA molecule.

Summary

The translation of the nucleotide sequence of an mRNA molecule into protein takes place in the cytoplasm on a large ribonucleoprotein assembly called a ribosome. The amino acids used for protein synthesis are first attached to a family of tRNA molecules, each of which recognizes, by complementary base-pair interactions, particular sets of three nucleotides in the mRNA (codons). The sequence of nucleotides in the mRNA is then read from one end to the other in sets of three according to the genetic code.

To initiate translation, a small ribosomal subunit binds to the mRNA molecule at a start codon (AUG) that is recognized by a unique initiator tRNA molecule. A large ribosomal subunit binds to complete the ribosome and begin the elongation phase of protein synthesis. During this phase, aminoacyl tRNAs—each bearing a specific amino acid bind sequentially to the appropriate codon in mRNA by forming complementary base pairs with the tRNA anticodon. Each amino acid is added to the C-terminal end of the growing polypeptide by means of a cycle of three sequential




Figure 7-5 Six steps at which eucaryotic gene expression can be controlled. Controls that operate at steps 1 through 5 are discussed in this chapter. Step 6, the regulation of protein activity, includes reversible activation or inactivation by protein phosphorylation (discussed in Chapter 3) as well as irreversible inactivation by proteolytic degradation (discussed in Chapter 6).

Gene Expression Can Be Regulated at Many of the Steps in the Pathway from DNA to RNA to Protein

If differences among the various cell types of an organism depend on the particular genes that the cells express, at what level is the control of gene expression exercised? As we saw in the last chapter, there are many steps in the pathway leading from DNA to protein, and all of them can in principle be regulated. Thus a cell can control the proteins it makes by (1) controlling when and how often a given gene is transcribed (**transcriptional control**), (2) controlling how the RNA transcript is spliced or otherwise processed (**RNA processing control**), (3) selecting which completed mRNAs in the cell nucleus are exported to the cytosol and determining where in the cytosol they are localized (**RNA transport and localization control**), (4) selecting which mRNAs in the cytoplasm are translated by ribosomes (**translational control**), (5) selectively destabilizing certain mRNA molecules in the cytoplasm (**mRNA degradation control**), or (6) selectively activating, inactivating, degrading, or compartmentalizing specific protein molecules after they have been made (**protein activity control**) (Figure 7-5).

For most genes transcriptional controls are paramount. This makes sense because, of all the possible control points illustrated in Figure 7-5, only transcriptional control ensures that the cell will not synthesize superfluous intermediates. In the following sections we discuss the DNA and protein components that perform this function by regulating the initiation of gene transcription. We shall return at the end of the chapter to the additional ways of regulating gene expression.

Summary

The genome of a cell contains in its DNA sequence the information to make many thousands of different protein and RNA molecules. A cell typically expresses only a fraction of its genes, and the different types of cells in multicellular organisms arise because different sets of genes are expressed. Moreover, cells can change the pattern of genes they express in response to changes in their environment, such as signals from other cells. Although all of the steps involved in expressing a gene can in principle be regulated, for most genes the initiation of RNA transcription is the most important point of control.

DNA-BINDING MOTIFS IN GENE REGULATORY PROTEINS

How does a cell determine which of its thousands of genes to transcribe? As mentioned briefly in Chapters 4 and 6, the transcription of each gene is controlled by a regulatory region of DNA relatively near the site where transcription begins. Some regulatory regions are simple and act as switches that are thrown by a single signal. Many others are complex and act as tiny microprocessors, responding to a variety of signals that they interpret and integrate to switch the neighboring gene on or off. Whether complex or simple, these switching devices

occur in the germ line, the cell lineage that gives rise to sperm or eggs. Most of the DNA in vertebrate germ cells is inactive and highly methylated. Over long periods of evolutionary time, the methylated CG sequences in these inactive regions have presumably been lost through spontaneous deamination events that were not properly repaired. However promoters of genes that remain active in the germ cell lineages (including most housekeeping genes) are kept unmethylated, and therefore spontaneous deaminations of Cs that occur within them can be accurately repaired. Such regions are preserved in modern day vertebrate cells as CG islands. In addition, any mutation of a CG sequence in the genome that destroyed the function or regulation of a gene in the adult would be selected against, and some CG islands are simply the result of a higher than normal density of critical CG sequences.

The mammalian genome contains an estimated 20,000 CG islands. Most of the islands mark the 5' ends of transcription units and thus, presumably, of genes. The presence of CG islands often provides a convenient way of identifying genes in the DNA sequences of vertebrate genomes.

Summary

The many types of cells in animals and plants are created largely through mechanisms that cause different genes to be transcribed in different cells. Since many specialized animal cells can maintain their unique character through many cell division cycles and even when grown in culture, the gene regulatory mechanisms involved in creating them must be stable once established and heritable when the cell divides. These features endow the cell with a memory of its developmental history. Bacteria and yeasts provide unusually accessible model systems in which to study gene regulatory mechanisms. One such mechanism involves a competitive interaction between two gene regulatory proteins, each of which inhibits the synthesis of the other; this can create a flip-flop switch that switches a cell between two alternative patterns of gene expression. Direct or indirect positive feedback loops, which enable gene regulatory proteins to perpetuate their own synthesis, provide a general mechanism for cell memory. Negative feedback loops with programmed delays form the basis for cellular clocks.

In eucaryotes the transcription of a gene is generally controlled by combinations of gene regulatory proteins. It is thought that each type of cell in a higher eucaryotic organism contains a specific combination of gene regulatory proteins that ensures the expression of only those genes appropriate to that type of cell. A given gene regulatory protein may be active in a variety of circumstances and typically is involved in the regulation of many genes.

In addition to diffusible gene regulatory proteins, inherited states of chromatin condensation are also used by eucaryotic cells to regulate gene expression. An especially dramatic case is the inactivation of an entire X chromosome in female mammals. In vertebrates DNA methylation also functions in gene regulation, being used mainly as a device to reinforce decisions about gene expression that are made initially by other mechanisms. DNA methylation also underlies the phenomenon of genomic imprinting in mammals, in which the expression of a gene depends on whether it was inherited from the mother or the father.

POSTTRANSCRIPTIONAL CONTROLS

In principle, every step required for the process of gene expression could be controlled. Indeed, one can find examples of each type of regulation, although any one gene is likely to use only a few of them. Controls on the initiation of gene transcription are the predominant form of regulation for most genes. But other controls can act later in the pathway from DNA to protein to modulate the amount of gene product that is made. Although these **posttranscriptional controls**, which operate after RNA polymerase has bound to the gene's promoter and begun RNA synthesis, are less common than *transcriptional control*, for many genes they are crucial.




Figure 7-86 A mechanism to explain both the marked overall deficiency of CG sequences and their clustering into CG islands in vertebrate genomes. A black line marks the location of a CG dinucleotide in the DNA sequence, while a red "lollipop" indicates the presence of a methyl group on the CG dinucleotide. CG sequences that lie in regulatory sequences of genes that are transcribed in germ cells are unmethylated and therefore tend to be retained in evolution. Methylated CG sequences, on the other hand, tend to be lost through deamination of 5-methyl C to T, unless the CG sequence is critical for survival.

CHAPTER 29

Regulation of transcription

Genes VII (1997) CH 29, pp. 847-848.
Benjamin Lewin

The phenotypic differences that distinguish the various kinds of cells in a higher eukaryote are largely due to differences in the expression of genes that code for proteins, that is, those transcribed by RNA polymerase II. In principle, the expression of these genes might be regulated at any one of several stages. The concept of the "level of control" implies that gene expression is not necessarily an automatic process once it has begun. It could be regulated in a gene-specific way at any one of several sequential steps. We can distinguish (at least) five potential control points, forming the series:

Activation of gene structure
↓
Initiation of transcription
↓
Processing the transcript
↓
Transport to cytoplasm
↓
Translation of mRNA

The existence of the first step is implied by the discovery that genes may exist in either of two structural conditions. Relative to the state of most of the genome, genes are found in an "active" state in the cells in which they are expressed (see Chapter 27). The change of structure is distinct from the act of transcription, and indicates that the gene is "transcribable." This suggests that acquisition of the "active" structure must be the first step in gene expression.

Transcription of a gene in the active state is

controlled at the stage of initiation, that is, by the interaction of RNA polymerase with its promoter. This is now becoming susceptible to analysis in the *in vitro* systems (see Chapter 28). For most genes, this is a major control point; probably it is the most common level of regulation.

There is at present no evidence for control at subsequent stages of transcription in eukaryotic cells, for example, via antitermination mechanisms.

The primary transcript is modified by capping at the 5' end, and usually also by polyadenylation at the 3' end. Introns must be spliced out from the transcripts of interrupted genes. The mature RNA must be exported from the nucleus to the cytoplasm. Regulation of gene expression by selection of sequences at the level of nuclear RNA might involve any or all of these stages, but the one for which we have most evidence concerns changes in splicing; some genes are expressed by means of alternative splicing patterns whose regulation controls the type of protein product (see Chapter 30).

Finally, the translation of an mRNA in the cytoplasm can be specifically controlled. There is little evidence for the employment of this mechanism in adult somatic cells, but it does occur in some embryonic situations, as described in Chapter 7. The mechanism is presumed to involve the blocking of initiation of translation of some mRNAs by specific protein factors.

But having acknowledged that control of gene expression can occur at multiple stages, and that production of RNA cannot inevitably be equated with production of protein, it is clear

that the overwhelming majority of regulatory events occur at the initiation of transcription. Regulation of tissue-specific gene transcription lies at the heart of eukaryotic differentiation; indeed, we see examples in Chapter 38 in which proteins that regulate embryonic development prove to be transcription factors. A regulatory transcription factor serves to provide

common control of a large number of target genes, and we seek to answer two questions about this mode of regulation: what identifies the common target genes to the transcription factor; and how is the activity of the transcription factor itself regulated in response to intrinsic or extrinsic signals?

Response elements identify genes under common regulation

The principle that emerges from characterizing groups of genes under common control is that they share a promoter element that is recognized by a regulatory transcription factor. An element that causes a gene to respond to such a factor is called a response element; examples are the HSE (heat shock response element), GRE (glucocorticoid response element), SRE (serum response element).

The properties of some inducible transcription factors and the elements that they recognize are summarized in Table 29.1. Response elements have the same general characteristics as upstream elements of promoters or enhancers. They contain short consensus sequences, and copies of the response elements found in different genes are closely related, but not necessarily identical. The region bound by the factor extends for a short distance on either side of

the consensus sequence. In promoters, the elements are not present at fixed distances from the startpoint, but are usually <200 bp upstream of it. The presence of a single element usually is sufficient to confer the regulatory response, but sometimes there are multiple copies.

Response elements may be located in promoters or in enhancers. Some types of elements are typically found in one rather than the other: usually an HSE is found in a promoter, while a GRE is found in an enhancer. We assume that all response elements function by the same general principle. A gene is regulated by a sequence at the promoter or enhancer that is recognized by a specific protein. The protein functions as a transcription factor needed for RNA polymerase to initiate. Active protein is available only under conditions when the gene is to be expressed; its absence means that the promoter is not activated by this particular circuit.

An example of a situation in which many genes are controlled by a single factor is provided by the heat shock response. This is common to a wide range of prokaryotes and eukaryotes and involves multiple controls of gene expression: an increase in temperature turns off transcription of some genes, turns on transcription of the heat shock genes, and causes changes in the translation of mRNAs. The control of the heat shock genes illustrates the differences between prokaryotic and eukaryotic modes of control. In bacteria, a new sigma factor is synthesized that directs RNA polymerase holoenzyme to recognize an alter-

Table 29.1 Inducible transcription factors bind to response elements that identify groups of promoters or enhancers subject to coordinate control.

Regulatory Agent	Module	Consensus	Factor
Heat shock	HSE	CNNGAANNTCGNG	HSTF
Glucocorticoid	GRE	TGGTACAAATGTTCT	Receptor
Phorbol ester	TRE	TGACTCA	AP1
Serum	SRE	CCATATTAGC	SRE

Research

Open Access

Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer

Zhao Zhigang*¹ and Shen Wenlv²

Address: ¹Department of Urology, Shantou University Medical College, Shantou, Guangdong, China and ²Department of Urology, No 2. Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China

Email: Zhao Zhigang* - zgzhao@yaho.com.cn; Shen Wenlv - wshen99@hotmail.com

* Corresponding author

Published: 10 May 2004

Received: 30 March 2004

World Journal of Surgical Oncology 2004, 2:13

Accepted: 10 May 2004

This article is available from: <http://www.wjso.com/content/2/1/13>

© 2004 Zhigang and Wenlv; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: Prostate stem cell antigen (PSCA) is a recently defined homologue of the Thy-1/Ly-6 family of glycosylphosphatidylinositol (GPI)-anchored cell surface antigens. The purpose of the present study was to examine the expression status of PSCA protein and mRNA in clinical specimens of human prostate cancer (Pca) and to validate it as a potential molecular target for diagnosis and treatment of Pca.

Materials and Methods: Immunohistochemical (IHC) and *in situ* hybridization (ISH) analyses of PSCA expression were simultaneously performed on paraffin-embedded sections from 20 benign prostatic hyperplasia (BPH), 20 prostatic intraepithelial neoplasm (PIN) and 48 prostate cancer (Pca) tissues, including 9 androgen-independent prostate cancers. The level of PSCA expression was semiquantitatively scored by assessing both the percentage and intensity of PSCA-positive staining cells in the specimens. Then compared PSCA expression between BPH, PIN and Pca tissues and analysed the correlations of PSCA expression level with pathological grade, clinical stage and progression to androgen-independence in Pca.

Results: In BPH and low grade PIN, PSCA protein and mRNA staining were weak or negative and less intense and uniform than that seen in HGPIN and Pca. There were moderate to strong PSCA protein and mRNA expression in 8 of 11 (72.7%) HGPIN and in 40 of 48 (83.4%) Pca specimens examined by IHC and ISH analyses, with statistical significance compared with BPH (20%) and low grade PIN (22.2%) samples ($p < 0.05$, respectively). The expression level of PSCA increased with high Gleason grade, advanced stage and progression to androgen-independence ($p < 0.05$, respectively). In addition, IHC and ISH staining showed a high degree of correlation between PSCA protein and mRNA overexpression.

Conclusions: Our data demonstrate that PSCA as a new cell surface marker is overexpressed by a majority of human Pca. PSCA expression correlates positively with adverse tumor characteristics, such as increasing pathological grade (poor cell differentiation), worsening clinical stage and androgen-independence, and speculatively with prostate carcinogenesis. PSCA protein overexpression results from upregulated transcription of PSCA mRNA. PSCA may have prognostic utility and may be a promising molecular target for diagnosis and treatment of Pca.

Introduction

Prostate cancer (Pca) is the second leading cause of cancer-related death in American men and is becoming a common cancer increasing in China. Despite recently great progress in the diagnosis and management of localized disease, there continues to be a need for new diagnostic markers that can accurately discriminate between indolent and aggressive variants of Pca. There also continues to be a need for the identification and characterization of potential new therapeutic targets on Pca cells. Current diagnostic and therapeutic modalities for recurrent and metastatic Pca have been limited by a lack of specific target antigens of Pca.

Although a number of prostate-specific genes have been identified (i.e. prostate specific antigen, prostatic acid phosphatase, glandular kallikrein 2), the majority of these are secreted proteins not ideally suited for many immunological strategies. So, the identification of new cell surface antigens is critical to the development of new diagnostic and therapeutic approaches to the management of Pca.

Reiter RE et al [1] reported the identification of prostate stem cell antigen (PSCA), a cell surface antigen that is predominantly prostate specific. The PSCA gene encodes a 123 amino acid glycoprotein, with 30% homology to stem cell antigen 2 (Sca 2). Like Sca-2, PSCA also belongs to a member of the Thy-1/Ly-6 family and is anchored by a glycosylphosphatidylinositol (GPI) linkage. mRNA *in situ* hybridization (ISH) localized PSCA expression in normal prostate to the basal cell epithelium, the putative stem cell compartment of prostatic epithelium, suggesting that PSCA may be a marker of prostate stem/progenitor cells.

In order to examine the status of PSCA protein and mRNA expression in human Pca and validate it as a potential diagnostic and therapeutic target for Pca, we used immunohistochemistry (IHC) and *in situ* hybridization (ISH) simultaneously, and conducted PSCA protein and mRNA expression analyses in paraffin-embedded tissue specimens of benign prostatic hyperplasia (BPH, n = 20), prostate intraepithelial neoplasm (PIN, n = 20) and prostate cancer (Pca, n = 48). Furthermore, we evaluated the possible correlation of PSCA expression level with Pca tumorigenesis, grade, stage and progression to androgen-independence.

Materials and methods

Tissue samples

All of the clinical tissue specimens studied herein were obtained from 80 patients of 57–84 years old by prostatectomy, transurethral resection of prostate (TURP) or biopsies. The patients were classified as 20 cases of BPH, 20 cases of PIN, 40 cases of primary Pca, including 9 patients

with recurrent Pca and a history of androgen ablation therapy (orchiectomy and/or hormonal therapy), who were referred to as androgen-independent prostate cancers. Eight specimens were harvested from these androgen-independent Pca patients prior to androgen ablation treatment. Each tissue sample was cut into two parts, one was fixed in 10% formalin for IHC and the other treated with 4% paraformaldehyde/0.1 M PBS PH 7.4 in 0.1% DEPC for 1 h for ISH analysis, and then embedded in paraffin. All paraffin blocks examined were then cut into 5 μ m sections and mounted on the glass slides specific for IHC and ISH respectively in the usual fashion. H&E-stained section of each Pca was evaluated and assigned a Gleason score by the experienced urological pathologist at our institution based on the criteria of Gleason score [2]. The Gleason sums are summarized in Table 1. Clinical staging was performed according to Jewett-whitmore-prout staging system, as shown in Table 2. In the category of PIN, we graded the specimens into two groups, i.e. low grade PIN (grade I – II) and high grade PIN (HGPN, grade III) on the basis of literatures [3,4].

Immunohistochemical (IHC) analysis

Briefly, tissue sections were deparaffinized, dehydrated, and subjected to microwaving in 10 mmol/L citrate buffer, PH 6.0 (Boshide, Wuhan, China) in a 900 W oven for 5 min to induce epitope retrieval. Slides were allowed to cool at room temperature for 30 min. A primary mouse antibody specific to human PSCA (Boshide, Wuhan, China) with a 1:100 dilution was applied to incubate with the slides at room temperature for 2 h. Labeling was detected by sequentially adding biotinylated secondary antibodies and streptavidin-peroxidase, and localized using 3,3'-diaminobenzidine reaction. Sections were then counterstained with hematoxylin. Substitution of the primary antibody with phosphate-buffered-saline (PBS) served as a negative-staining control.

mRNA *in situ* hybridization (ISH)

Five- μ m-thick tissue sections were deparaffinized and dehydrated, then digested in pepsin solution (4 mg/ml in 3% citric acid) for 20 min at 37.5°C, and further processed for ISH. Digoxigenin-labeled sense and antisense human PSCA RNA probes (obtained from Boshide, Wuhan, China) were hybridized to the sections at 48°C overnight. The posthybridization wash with a high stringency was performed sequentially at 37°C in 2 \times standard saline citrate (SSC) for 10 min, in 0.5 \times SSC for 15 min and in 0.2 \times SSC for 30 min. The slides were then incubated to biotinylated mouse anti-digoxigenin antibody at 37.5°C for 1 h followed by washing in 1 \times PBS for 20 min at room temperature, and then to streptavidin-peroxidase at 37.5°C for 20 min followed by washing in 1 \times PBS for 15 min at room temperature. Subsequently, the slides were developed with diaminobenzidine and then coun-

Table 1: Correlation of PSCA expression with Gleason score

Gleason score	Intensity × frequency	
	0-6 (%)	9 (%)
2-4	5 (83)	1 (17)
5-7	19 (79)	5 (21)
8-10	5 (28)	13 (72)

Table 2: Correlation of PSCA expression with clinical stage

Tumor stage	Intensity × frequency	
	0-6 (%)	9 (%)
≤B	27 (67.5)	13 (32.5)
≥C	2 (25)	6 (75)

terstained with hematoxylin to localize the hybridization signals. Sections hybridized with the sense control probes routinely did not show any specific hybridization signal above background. All slides were hybridized with PBS to substitute for the probes as a negative control.

Scoring methods

To determine the correlation between the results of PSCA immunostaining and mRNA *in situ* hybridization, the same scoring manners are taken in the present study for PSCA protein staining by IHC and PSCA mRNA staining by ISH. Each slide was read and scored by two independently experienced urological pathologists using Olympus BX-41 light microscopes. The evaluation was done in a blinded fashion. For each section, five areas of similar grade were analyzed semiquantitatively for the fraction of cells staining. Fifty percent of specimens were randomly chosen and rescored to determine the degree of interobserver and intraobserver concordance. There was greater than 95% intra- and interobserver agreement.

The intensity of PSCA expression evaluated microscopically was graded on a scale of 0 to 3+ with 3 being the highest expression observed (0, no staining; 1+, mildly intense; 2+, moderately intense; 3+, severely intense). The staining density was quantified as the percentage of cells staining positive for PSCA with the primary antibody or hybridization probe, as follows: 0 = no staining; 1 = positive staining in <25% of the sample; 2 = positive staining in 25%-50% of the sample; 3 = positive staining in >50%

of the sample. Intensity score (0 to 3+) was multiplied by the density score (0-3) to give an overall score of 0-9 [1,5]. In this way, we were able to differentiate specimens that may have had focal areas of increased staining from those that had diffuse areas of increased staining [6]. The overall score for each specimen was then categorically assigned to one of the following groups: 0 score, negative expression; 1-2 scores, weak expression; 3-6 scores, moderate expression; 9 score, strong expression.

Statistical analysis

Intensity and density of PSCA protein and mRNA expression in BPH, PIN and Pca tissues were compared using the Chi-square and Student's *t*-test. Univariate associations between PSCA expression and Gleason score, clinical stage and progression to androgen-independence were calculated using Fisher's Exact Test. For all analyses, *p* < 0.05 was considered statistically significant.

Results

PSCA expression in BPH

In general, PSCA protein and mRNA were expressed weakly in individual samples of BPH. Some areas of prostate expressed weak levels (composite score 1-2), whereas other areas were completely negative (composite score 0). Four cases (20%) of BPH had moderate expression of PSCA protein and mRNA (composite score 4-6) by IHC and ISH. In 2/20 (10%) BPH specimens, PSCA mRNA expression was moderate (composite score 3-6), but PSCA protein expression was weak (composite score

2) in one and negative (composite score 0) in the other. PSCA expression was localized to the basal and secretory epithelial cells, and prostatic stroma was almost negative staining for PSCA protein and mRNA in all cases examined.

PSCA expression in PIN

In this study, we detected weak or negative expression of PSCA protein and mRNA (≤ 2 scores) in 7 of 9 (77.8%) low grade PIN and in 2 of 11 (18.2%) HGPIN, and moderate expression (3–6 scores) in the rest 2 low grade PIN and 5 of 11 (45.5%) HGPIN. One HGPIN with moderate PSCA mRNA expression (6 score) was found weak staining for PSCA protein (2 score) by IHC. Strong PSCA protein and mRNA expression (9 score) were detected in the remaining 3 of 11 (27.3%) HGPIN. There was a statistically significant difference of PSCA protein and mRNA expression levels observed between HGPIN and BPH ($p < 0.05$), but no statistical difference reached between low grade PIN and BPH ($p > 0.05$).

PSCA expression in Pca

In order to determine if PSCA protein and mRNA can be detected in prostate cancers and if PSCA expression levels are increased in malignant compared with benign glands, Forty-eight paraffin-embedded Pca specimens were analysed by IHC and ISH. It was shown that 19 of 48 (39.6%) Pca samples stained very strongly for PSCA protein and mRNA with a score of 9 and another 21 (43.8%) specimens displayed moderate staining with scores of 4–6 (Figure 1). In addition, 4 specimens with moderate to strong PSCA mRNA expression (scores of 4–9) had weak protein staining (a score of 2) by IHC analyses. Overall, Pca expressed a significantly higher level of PSCA protein and mRNA than any other specimen category in this study ($p < 0.05$, compared with BPH and PIN respectively). The result demonstrates that PSCA protein and mRNA are overexpressed by a majority of human Pca.

Correlation of PSCA expression with Gleason score in Pca

Using the semi-quantitative scoring method as described in Materials and Methods, we compared the expression level of PSCA protein and mRNA with Gleason grade of Pca, as shown in Table 1. Prostate adenocarcinomas were graded by Gleason score as 2–4 scores = well-differentiation, 5–7 scores = moderate-differentiation and 8–10 scores = poor-differentiation [7]. Seventy-two percent of Gleason scores 8–10 prostate cancers had very strong staining of PSCA compared to 21% with Gleason scores 5–7 and 17% with 2–4 respectively, demonstrating that poorly differentiated Pca had significantly stronger expression of PSCA protein and mRNA than moderately and well differentiated tumors ($p < 0.05$). As depicted in Figure 1, IHC and ISH analyses showed that PSCA protein and mRNA expression in several cases of poorly differen-

tiated Pca were particularly prominent, with more intense and uniform staining. The results indicate that PSCA expression increases significantly with higher tumor grade in human Pca.

Correlation of PSCA expression with clinical stage in Pca

With regards to PSCA expression in every stage of Pca, we showed the results in Table 2. Seventy-five percent of locally advanced and node positive cancers (i.e. C-D stages) expressed statistically high levels of PSCA versus 32.5% that were organ confined (i.e. A-B stages) ($p < 0.05$). The data demonstrate that PSCA expression increases significantly with advanced tumor stage in human Pca.

Correlation of PSCA expression with androgen-independent progression of Pca

All 9 specimens of androgen-independent prostate cancers stained positive for PSCA protein and mRNA. Eight specimens were obtained from patients managed prior to androgen ablation therapy. Seven of eight (87.5%) of these androgen-independent prostate cancers were in the strongest staining category (score = 9), compared with three out of eight (37.5%) of patients with androgen-dependent cancers ($p < 0.05$). The results demonstrate that PSCA expression increases significantly with progression to androgen-independence of human Pca.

It is evident from the results above that within a majority of human prostate cancers the level of PSCA protein and mRNA expression correlates significantly with increasing grade, worsening stage and progression to androgen-independence.

Correlation of PSCA immunostaining and mRNA in situ hybridization

In all 88 specimens surveyed herein, we compared the results of PSCA IHC staining with mRNA ISH analysis. Positive staining areas and its intensity and density scores evaluated by IHC were identical to those seen by ISH in 79 of 88 (89.8%) specimens (18/20 BPH, 19/20 PIN and 42/48 Pca respectively). Importantly, 27/27 samples with PSCA mRNA composite scores of 0–2, 32/36 samples with scores of 3–6 and 22/24 samples with a score of 9 also had PSCA protein expression scores of 0–2, 3–6 and 9 respectively. However, in 5 samples with PSCA mRNA overall scores of 3–6 and in 2 with scores of 9 there were less or negative PSCA protein expression (i.e. scores of 0–4), suggesting that this may reflect posttranscriptional modification of PSCA or that the epitopes recognized by PSCA mAb may be obscured in some cancers. The data demonstrate that the results of PSCA immunostaining were consistent with those of mRNA ISH analysis, showing a high degree of correlation between PSCA protein and mRNA expression.




Figure 1

Representatives of PSCA IHC and ISH staining in Pca (A. IHC staining, B. ISH staining, $\times 200$ magnification). A₁, B₁: negative control of IHC and ISH. PBS replacing the primary antibody (A₁) and hybridization with a sense PSCA probe (B₁) showed no background staining. A₂, B₂: a moderately differentiated Pca (Gleason score = $3+3 = 6$) with moderate staining (composite score = 6) in all malignant cells; A₂: IHC shows not only cell surface but also apparent cytoplasmic staining of PSCA protein. A₃, B₃: a poorly differentiated Pca (Gleason score = $4+4 = 8$) with very strong staining (composite score = 9) in all malignant cells.

Discussion

PSCA is homologous to a group of cell surface proteins that mark the earliest phase of hematopoietic development. PSCA mRNA expression is prostate-specific in normal male tissues and is highly up-regulated in both androgen-dependent and-independent Pca xenografts (LAPC-4 tumors). We hypothesize that PSCA may play a role in Pca tumorigenesis and progression, and may serve as a target for Pca diagnosis and treatment. In this study, IHC and ISH showed that in general there were weak or absent PSCA protein and mRNA expression in BPH and low grade PIN tissues. However, PSCA protein and mRNA are widely expressed in HGPIN, the putative precursor of invasive Pca, suggesting that up-regulation of PSCA is an early event in prostate carcinogenesis. Recently, Reiter RE et al [1], using ISH analysis, reported that 97 of 118 (82%) HGPIN specimens stained strongly positive for PSCA mRNA. A very similar finding was seen on mouse PSCA (mPSCA) expression in mouse HGPIN tissues by Tran C. P et al [8]. These data suggest that PSCA may be a new marker associated with transformation of prostate cells and tumorigenesis.

We observed that PSCA protein and mRNA are highly expressed in a large percentage of human prostate cancers, including advanced, poorly differentiated, androgen-independent and metastatic cases. Fluorescence-activated cell sorting and confocal/ immunofluorescent studies demonstrated cell surface expression of PSCA protein in Pca cells [9]. Our IHC expression analysis of PSCA shows not only cell surface but also apparent cytoplasmic staining of PSCA protein in Pca specimens (Figure 1). One possible explanation for this is that anti-PSCA antibody can recognize PSCA peptide precursors that reside in the cytoplasm. Also, it is possible that the positive staining that appears in the cytoplasm is actually from the overlying cell membrane [5]. These data seem to indicate that PSCA is a novel cell surface marker for human Pca.

Our results show that elevated level of PSCA expression correlates with high grade (i.e. poor differentiation), increased tumor stage and progression to androgen-independence of Pca. These findings support the original IHC analyses by Gu Z et al [9], who reported that PSCA protein expressed in 94% of primary Pca and the intensity of PSCA protein expression increased with tumor grade, stage and progression to androgen-independence. Our results also collaborate the recent work of Han KR et al [10], in which the significant association between high PSCA expression and adverse prognostic features such as high Gleason score, seminal vesicle invasion and capsular involvement in Pca was found. It is suggested that PSCA overexpression may be an adverse predictor for recurrence, clinical progression or survival of Pca. Hara H et al [11] used RT-PCR detection of PSA, PSMA and PSCA in 1

ml of peripheral blood to evaluate Pca patients with poor prognosis. The results showed that among 58 Pca patients, each PCR indicated the prognostic value in the hierarchy of PSCA>PSA>PSMA RT-PCR, and extraprostatic cases with positive PSCA PCR indicated lower disease-progression-free survival than those with negative PSCA PCR, demonstrating that PSCA can be used as a prognostic factor. Dubey P et al [12] reported that elevated numbers of PSCA + cells correlate positively with the onset and development of prostate carcinoma over a long time span in the prostates of the TRAMP and PTEN +/- models compared with its normal prostates. Taken together with our present findings, in which PSCA is overexpressed from HGPIN to almost frank carcinoma, it is reasonable and possible to use increased PSCA expression level or increased numbers of PSCA-positive cells in the prostate samples as a prognostic marker to predict the potential onset of this cancer. These data raise the possibility that PSCA may have diagnostic utility or clinical prognostic value in human Pca.

The cause of PSCA overexpression in Pca is not known. One possible mechanism is that it may result from PSCA gene amplification. In humans, PSCA is located on chromosome 8q24.2 [1], which is often amplified in metastatic and recurrent Pca and considered to indicate a poor prognosis [13-15]. Interestingly, PSCA is in close proximity to the c-myc oncogene, which is amplified in >20% of recurrent and metastatic prostate cancers [16,17]. Reiter RE et al [18] reported that PSCA and MYC gene copy numbers were co-amplified in 25% of tumors (five out of twenty), demonstrating that PSCA overexpression is associated with PSCA and MYC coamplification in Pca. Gu Z et al [9] recently reported that in 102 specimens available to compare the results of PSCA immunostaining with their previous mRNA ISH analysis, 92 (90.2%) had identically positive areas of PSCA protein and mRNA expression. Taken together with our findings, in which we detected moderate to strong expression of PSCA protein and mRNA in 34 of 40 (85%) Pca specimens examined simultaneously by IHC and ISH analyses, it is demonstrated that PSCA protein and mRNA overexpressed in human Pca, and that the increased protein level of PSCA was resulted from the upregulated transcription of its mRNA.

At present, the regulation mechanisms of human PSCA expression and its biological function are yet to be elucidated. PSCA expression may be regulated by multiple factors [18]. Watabe T et al [19] reported that transcriptional control is a major component regulating PSCA expression levels. In addition, induction of PSCA expression may be regulated or mediated through cell-cell contact and protein kinase C (PKC) [20]. Homologues of PSCA have diverse activities, and have themselves been involved in

carcinogenesis. Signalling through SCA-2 has been demonstrated to prevent apoptosis in immature thymocytes [21]. Thy-1 is involved in T cell activation and transduces signals through src-like tyrosine kinases [22]. Ly-6 genes have been implicated both in tumorigenesis and in cell-cell adhesion [23-25]. Cell-cell or cell-matrix interaction is critical for local tumor growth and spread to distal sites. From its restricted expression in basal cells of normal prostate and its homology to SCA-2, PSCA may play a role in stem/progenitor cell function, such as self-renewal (i.e. anti-apoptosis) and/or proliferation [1]. Taken together with the results in the present study, we speculate that PSCA may play a role in tumorigenesis and clinical progression of Pca through affecting cell transformation and proliferation. From our results, it is also suggested that PSCA as a new cell surface antigen may have a number of potential uses in the diagnosis, therapy and clinical prognosis of human Pca. PSCA overexpression in prostate biopsies could be used to identify patients at high risk to develop recurrent or metastatic disease, and to discriminate cancers from normal glands in prostatectomy samples. Similarly, the detection of PSCA-overexpressing cells in bone marrow or peripheral blood may identify and predict metastatic progression better than current assays, which identify only PSA-positive or PSMA-positive prostate cells.

In summary, we have shown in this study that PSCA protein and mRNA are maintained in expression from HGPIN through all stages of Pca in a majority of cases, which may be associated with prostate carcinogenesis and correlate positively with high tumor grade (poor cell differentiation), advanced stage and androgen-independent progression. PSCA protein overexpression is due to the upregulation of its mRNA transcription. The results suggest that PSCA may be a promising molecular marker for the clinical prognosis of human Pca and a valuable target for diagnosis and therapy of this tumor.

Competing interests

None declared.

References

- Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, David E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. *Proc Natl Acad Sci USA* 1998, 95:1735-1740.
- Gleason DF: Histologic grading and clinical staging of prostatic carcinoma. In: *Urologic Pathology: The Prostate* Edited by: Tannebaum M, Philadelphia, Lea & Febiger; 1977:171-197.
- Brawer MK: Prostatic intraepithelial neoplasia: a premalignant lesion. *Hum Pathol* 1992, 23:242-248.
- Amin MB, Ro JY, Ayala AC: Prostatic intraepithelial neoplasia: relationship to adenocarcinoma of prostate. *Pathol Annu* 1994, 29:1-30.
- Amara N, Palapattu GS, Schrage M, Gu Z, Thomas GV, Dorey F, Said J, Reiter RE: Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. *Cancer Res* 2001, 61:4660-4665.
- Hanas JS, Lerner MR, Lightfoot SA, Raczkowski C, Kastens DJ, Brackett DJ, Postier RG: Expression of the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus. *Cancer (Phila)* 1999, 86:756-763.
- Egevad L, Gramfors T, Karlberg L: Prognostic value of the Gleason score in prostate cancer. *BJU Int* 2002, 89:538-542.
- Tran CP, Lin C, Yamashiro J, Reiter RE: Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. *Mol Cancer Res* 2002, 1:113-121.
- Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE: Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. *Oncogene* 2000, 19:1288-1296.
- Han KR, Sellgren DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE: Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. *J Urol* 2004, 171:1117-1121.
- Hara H, Kasahara T, Kawasaki T, Bilim V, Obara K, Takahashi K, Tomita Y: Reverse Transcription-Polymerase Chain Reaction Detection of Prostate-specific Antigen, Prostate-specific Membrane Antigen, and Prostate Stem Cell Antigen in One Milliliter of Peripheral Blood. *Clin Cancer Res* 2002, 8:1794-1799.
- Dubey P, Wu H, Reiter RE, Witte ON: Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. *Cancer Res* 2001, 61:3256-3261.
- Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytiäinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP: Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. *Cancer Res* 1995, 55:342-347.
- Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstrahl EJ, Jenkins RB: Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. *J Natl Cancer Inst* 1999, 91:1574-1580.
- Van Den Berg C, Guan XY, Von Hoff D, Jenkins R, Bittner J, Griffin C, Kallioniemi O, Visakorpi T, McGill J, Herath J, Epstein J, Sarosdy M, Meltzer P, Trent J: DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. *Clin Cancer Res* 1995, 1:11-18.
- Jenkins RB, Qian J, Lieber MM, Bostwick DG: Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. *Cancer Res* 1997, 57:524-531.
- Nupponen NN, Kakkola L, Koivisto P, Visakorpi T: Genetic alterations in hormone-refractory recurrent prostate carcinomas. *Am J Pathol* 1998, 153:141-148.
- Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins RB: Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. *Genes Chromosomes Cancer* 2000, 27:95-103.
- Watabe T, Lin M, Donjacour AA, Cunha GR, Witte ON, Reiter RE: Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. *Proc Natl Acad Sci USA* 2002, 99:401-406.
- Bahrenberg G, Brauers A, Joost HG, Jakse G: PSCA expression is regulated by phorbol ester and cell adhesion in the bladder carcinoma cell line RT112. *Cancer Lett* 2001, 168:37-43.
- Noda S, Kosugi A, Saitoh S, Narumiya S, Hamaoka T: Protection from anti-TCR/CD3-induced apoptosis in immature thymocytes by a signal through thymic shared antigen-1/stem cell antigen-2. *J Exp Med* 1996, 183:2355-2360.
- Thomas PM, Samelson LE: The glycosphosphatidylinositol-anchored Thy-1 molecule interacts with the p60fyn protein tyrosine kinase in T cells. *J Biol Chem* 1992, 267:12317-12322.
- Bamezai A, Rock KL: Overexpressed Ly-6A.2 mediated cell-cell adhesion by binding a ligand expressed on lymphoid cells. *Proc Natl Acad Sci USA* 1995, 92:4294-4298.
- Katz BZ, Eshel R, Sagi-Assif O, Witz IP: An association between high Ly-6A/E expression on tumor cells and a highly malignant phenotype. *Int J Cancer* 1994, 59:684-691.
- Brakenhoff RH, Gerretsen M, Knippels EM, van Dijk M, van Essen H, Weghuis DO, Sinke RJ, Snow GB, van Dongen GA: The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. *J Cell Biol* 1995, 129:1677-1689.

Review

Translation Initiation in Cancer: A Novel Target for Therapy¹

Funda Meric² and Kelly K. Hunt

Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Abstract

Translation initiation is regulated in response to nutrient availability and mitogenic stimulation and is coupled with cell cycle progression and cell growth. Several alterations in translational control occur in cancer. Variant mRNA sequences can alter the translational efficiency of individual mRNA molecules, which in turn play a role in cancer biology. Changes in the expression or availability of components of the translational machinery and in the activation of translation through signal transduction pathways can lead to more global changes, such as an increase in the overall rate of protein synthesis and translational activation of the mRNA molecules involved in cell growth and proliferation. We review the basic principles of translational control, the alterations encountered in cancer, and selected therapies targeting translation initiation to help elucidate new therapeutic avenues.

Introduction

The fundamental principle of molecular therapeutics in cancer is to exploit the differences in gene expression between cancer cells and normal cells. With the advent of cDNA array technology, most efforts have concentrated on identifying differences in gene expression at the level of mRNA, which can be attributable either to DNA amplification or to differences in transcription. Gene expression is quite complicated, however, and is also regulated at the level of mRNA stability, mRNA translation, and protein stability.

The power of translational regulation has been best recognized among developmental biologists, because transcription does not occur in early embryogenesis in eukaryotes. For example, in *Xenopus*, the period of transcriptional quiescence continues until the embryo reaches midblastula transition, the 4000-cell stage. Therefore, all necessary mRNA molecules are transcribed during oogenesis and stockpiled in a translationally inactive, masked form. The mRNA are translationally activated at appropriate times during oocyte maturation, fertilization, and

early embryogenesis and thus, are under strict translational control.

Translation has an established role in cell growth. Basically, an increase in protein synthesis occurs as a consequence of mitogenesis. Until recently, however, little was known about the alterations in mRNA translation in cancer, and much is yet to be discovered about their role in the development and progression of cancer. Here we review the basic principles of translational control, the alterations encountered in cancer, and selected therapies targeting translation initiation to elucidate potential new therapeutic avenues.

Basic Principles of Translational Control

Mechanism of Translation Initiation

Translation initiation is the main step in translational regulation. Translation initiation is a complex process in which the initiator tRNA and the 40S and 60S ribosomal subunits are recruited to the 5' end of a mRNA molecule and assembled by eukaryotic translation initiation factors into an 80S ribosome at the start codon of the mRNA (Fig. 1). The 5' end of eukaryotic mRNA is capped, i.e., contains the cap structure m⁷GpppN (7-methyl-guanosine-triphospho-5'-ribonucleoside). Most translation in eukaryotes occurs in a cap-dependent fashion, i.e., the cap is specifically recognized by the eIF4E,³ which binds the 5' cap. The eIF4F translation initiation complex is then formed by the assembly of eIF4E, the RNA helicase eIF4A, and eIF4G, a scaffolding protein that mediates the binding of the 40S ribosomal subunit to the mRNA molecule through interaction with the eIF3 protein present on the 40S ribosome. eIF4A and eIF4B participate in melting the secondary structure of the 5' UTR of the mRNA. The 43S initiation complex (40S/eIF2/Met-tRNA/GTP complex) scans the mRNA in a 5'→3' direction until it encounters an AUG start codon. This start codon is then base-paired to the anticodon of initiator tRNA, forming the 48S initiation complex. The initiation factors are then displaced from the 48S complex, and the 60S ribosome joins to form the 80S ribosome.

Unlike most eukaryotic translation, translation initiation of certain mRNAs, such as the picornavirus RNA, is cap independent and occurs by internal ribosome entry. This mechanism does not require eIF4E. Either the 43S complex can bind the initiation codon directly through interaction with the IRES in the 5' UTR such as in the encephalomyocarditis virus, or it can

Received 5/16/02; revised 7/12/02; accepted 7/22/02.

¹ F. M. is supported by The University of Texas M. D. Anderson Cancer Center Physician-Scientist Program and by NIH Grant 1K08-CA 91895-01. K. K. H. is supported by Department of Defense Award DAMD-17-97-1-7162.

² To whom requests for reprints should be addressed, at Department of Surgical Oncology, Box 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 745-4453; Fax: (713) 745-4926; E-mail: fmeric@mdanderson.org.

³ The abbreviations used are: eIF4E, eukaryotic initiation factor 4E; UTR, untranslated region; IRES, internal ribosome entry site; 4E-BP1, eukaryotic initiation factor 4E-binding protein 1; S6K, ribosomal p70 S6 kinase; mTOR, mammalian target of rapamycin; ATM, ataxia telangiectasia mutated; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog deleted from chromosome 10; PP2A, protein phosphatase 2A; TGF- β 3, transforming growth factor- β 3; PAP, poly(A) polymerase; EPA, eicosapentaenoic acid; mda-7, melanoma differentiation-associated gene 7.




Fig. 1. Translation initiation in eukaryotes. The 4E-BPs are hyperphosphorylated to release eIF4E so that it can interact with the 5' cap, and the eIF4F initiation complex is assembled. The interaction of poly(A) binding protein with the initiation complex and circularization of the mRNA is not depicted in the diagram. The secondary structure of the 5' UTR is melted, the 40S ribosomal subunit is bound to eIF3, and the ternary complex consisting of eIF2, GTP, and the Met-tRNA are recruited to the mRNA. The ribosome scans the mRNA in a 5'→3' direction until an AUG start codon is found in the appropriate sequence context. The initiation factors are released, and the large ribosomal subunit is recruited.

Initially attach to the IRES and then reach the initiation codon by scanning or transfer, as is the case with the poliovirus (1).

Regulation of Translation Initiation

Translation initiation can be regulated by alterations in the expression or phosphorylation status of the various factors involved. Key components in translational regulation that may provide potential therapeutic targets follow.

eIF4E. eIF4E plays a central role in translation regulation. It is the least abundant of the initiation factors and is considered the rate-limiting component for initiation of cap-dependent translation. eIF4E may also be involved in mRNA splicing, mRNA 3' processing, and mRNA nucleocytoplasmic transport (2). eIF4E expression can be increased at the transcriptional level in response to serum or growth factors (3). eIF4E overexpression may cause preferential translation of mRNAs containing excessive secondary structure in their 5' UTR that are normally discriminated against by the trans-

lational machinery and thus are inefficiently translated (4–7). As examples of this, overexpression of eIF4E promotes increased translation of vascular endothelial growth factor, fibroblast growth factor-2, and cyclin D1 (2, 8, 9).

Another mechanism of control is the regulation of eIF4E phosphorylation. eIF4E phosphorylation is mediated by the mitogen-activated protein kinase-interacting kinase 1, which is activated by the mitogen-activated pathway activating extracellular signal-related kinases and the stress-activated pathway acting through p38 mitogen-activated protein kinase (10–13). Several mitogens, such as serum, platelet-derived growth factor, epidermal growth factor, insulin, angiotensin II, src kinase overexpression, and ras overexpression, lead to eIF4E phosphorylation (14). The phosphorylation status of eIF4E is usually correlated with the translational rate and growth status of the cell; however, eIF4E phosphorylation has also been observed in response to some cellular stresses when translational rates actually decrease (15). Thus, further study is needed to understand the effects of eIF4E phosphorylation on eIF4E activity.

Another mechanism of regulation is the alteration of eIF4E availability by the binding of eIF4E to the eIF4E-binding proteins (4E-BP, also known as PHAS-I). 4E-BPs compete with eIF4G for a binding site in eIF4E. The binding of eIF4E to the best characterized eIF4E-binding protein, 4E-BP1, is regulated by 4E-BP1 phosphorylation. Hypophosphorylated 4E-BP1 binds to eIF4E, whereas 4E-BP1 hyperphosphorylation decreases this binding. Insulin, angiotensin, epidermal growth factor, platelet-derived growth factor, hepatocyte growth factor, nerve growth factor, insulin-like growth factors I and II, interleukin 3, granulocyte-macrophage colony-stimulating factor + steel factor, gastrin, and the adenovirus have all been reported to induce phosphorylation of 4E-BP1 and to decrease the ability of 4E-BP1 to bind eIF4E (15, 16). Conversely, deprivation of nutrients or growth factors results in 4E-BP1 dephosphorylation, an increase in eIF4E binding, and a decrease in cap-dependent translation.

p70 S6 Kinase. Phosphorylation of ribosomal 40S protein S6 by S6K is thought to play an important role in translational regulation. S6K $-/-$ mouse embryonic cells proliferate more slowly than do parental cells, demonstrating that S6K has a positive influence on cell proliferation (17). S6K regulates the translation of a group of mRNAs possessing a 5' terminal oligopyrimidine tract (5' TOP) found at the 5' UTR of ribosomal protein mRNAs and other mRNAs coding for components of the translational machinery. Phosphorylation of S6K is regulated in part based on the availability of nutrients (18, 19) and is stimulated by several growth factors, such as platelet-derived growth factor and insulin-like growth factor I (20).

eIF2 α Phosphorylation. The binding of the initiator tRNA to the small ribosomal unit is mediated by translation initiation factor eIF2. Phosphorylation of the α -subunit of eIF2 prevents formation of the eIF2/GTP/Met-tRNA complex and inhibits global protein synthesis (21, 22). eIF2 α is phosphorylated under a variety of conditions, such as viral infection, nutrient deprivation, heme deprivation, and apoptosis (22). eIF2 α is phosphorylated by heme-regulated inhibitor, nutrient-regulated protein kinase, and the IFN-induced, double-stranded RNA-activated protein kinase (PKR; Ref. 23).

The mTOR Signaling Pathway. The macrolide antibiotic rapamycin (Siralimus; Wyeth-Ayerst Research, Collegeville, PA) has been the subject of intensive study because it inhibits signal transduction pathways involved in T-cell activation. The rapamycin-sensitive component of these pathways is mTOR (also called FRAP or RAFT1). mTOR is the mammalian homologue of the yeast TOR proteins that regulate G₁ progression and translation in response to nutrient availability (24). mTOR is a serine-threonine kinase that modulates translation initiation by altering the phosphorylation status of 4E-BP1 and S6K (Fig. 2; Ref. 25).

4E-BP1 is phosphorylated on multiple residues. mTOR phosphorylates the Thr-37 and Thr-46 residues of 4E-BP1 *in vitro* (26); however, phosphorylation at these sites is not associated with a loss of eIF4E binding. Phosphorylation of Thr-37 and Thr-46 is required for subsequent phosphorylation at several COOH-terminal, serum-sensitive sites; a combination of these phosphorylation events appears to be needed to inhibit the binding of 4E-BP1 to eIF4E (25). The product of the *ATM* gene, p38/MSK1 pathway, and protein kinase C α also play a role in 4E-BP1 phosphorylation (27–29).

S6K and 4E-BP1 are also regulated, in part, by PI3K and its downstream protein kinase Akt. PTEN is a phosphatase that negatively regulates PI3K signaling. PTEN null cells have constitutively active Akt, with increased S6K activity and S6 phosphorylation (30). S6K activity is inhibited both by PI3K inhibitors wortmannin and LY294002 and by mTOR inhibitor rapamycin (24). Akt phosphorylates Ser-2448 in mTOR *in vitro*, and this site is phosphorylated upon Akt activation *in vivo* (31–33). Thus, mTOR is regulated by the PI3K/Akt pathway; however, this does not appear to be the only mode of regulation of mTOR activity. Whether the PI3K pathway also regulates S6K and 4E-BP1 phosphorylation independent of mTOR is controversial.

Interestingly, mTOR autophosphorylation is blocked by wortmannin but not by rapamycin (34). This seeming inconsistency suggests that mTOR-responsive regulation of 4E-BP1 and S6K activity occurs through a mechanism other than intrinsic mTOR kinase activity. An alternate pathway for 4E-BP1 and S6K phosphorylation by mTOR activity is by the inhibition of a phosphatase. Treatment with calyculin A, an inhibitor of phosphatases 1 and 2A, reduces rapamycin-induced dephosphorylation of 4E-BP1 and S6K by rapamycin (35). PP2A interacts with full-length S6K but not with a S6K mutant that is resistant to dephosphorylation resulting from rapamycin. mTOR phosphorylates PP2A *in vitro*; however, how this process alters PP2A activity is not known. These results are consistent with the model that phosphorylation of a phosphatase by mTOR prevents dephosphorylation of 4E-BP1 and S6K, and conversely, that nutrient deprivation and rapamycin block inhibition of the phosphatase by mTOR.

Polyadenylation. The poly(A) tail in eukaryotic mRNA is important in enhancing translation initiation and mRNA stability. Polyadenylation plays a key role in regulating gene expression during oogenesis and early embryogenesis. Some mRNA that are translationally inactive in the oocyte are polyadenylated concomitantly with translational activation in oocyte maturation, whereas other mRNAs that are translationally active during oogenesis are deadenylated and trans-




Fig. 2. Regulation of translation initiation by signal transduction pathways. Signaling via p38, extracellular signal-related kinase, PI3K, and mTOR can all activate translation initiation.

lationally silenced (36–38). Thus, control of poly(A) tail synthesis is an important regulatory step in gene expression. The 5' cap and poly(A) tail are thought to function synergistically to regulate mRNA translational efficiency (39, 40).

RNA Packaging. Most RNA-binding proteins are assembled on a transcript at the time of transcription, thus determining the translational fate of the transcript (41). A highly conserved family of Y-box proteins is found in cytoplasmic messenger ribonucleoprotein particles, where the proteins are thought to play a role in restricting the recruitment of mRNA to the translational machinery (41–43). The major mRNA-associated protein, YB-1, destabilizes the interaction of eIF4E and the 5' mRNA cap *in vitro*, and overexpression of YB-1 results in translational repression *in vivo* (44). Thus, alterations in RNA packaging can also play an important role in translational regulation.

Translation Alterations Encountered in Cancer

Three main alterations at the translational level occur in cancer: variations in mRNA sequences that increase or decrease translational efficiency, changes in the expression or availability of components of the translational machinery, and activation of translation through aberrantly activated signal transduction pathways. The first alteration affects the translation of an individual mRNA that may play a role in carcinogenesis. The second and third alterations can lead to more global changes, such as an increase in the overall rate of protein synthesis, and the translational activation of several mRNA species.

Variations in mRNA Sequence

Variations in mRNA sequence affect the translational efficiency of the transcript. A brief description of these variations and examples of each mechanism follow.

Mutations. Mutations in the mRNA sequence, especially in the 5' UTR, can alter its translational efficiency, as seen in the following examples.

c-myc. Salto *et al.* proposed that translation of full-length *c-myc* is repressed, whereas in several Burkitt lymphomas that have deletions of the mRNA 5' UTR, translation of *c-myc* is more efficient (45). More recently, it was reported that the 5' UTR of *c-myc* contains an IRES, and thus *c-myc* translation can be initiated by a cap-independent as well as a cap-dependent mechanism (46, 47). In patients with multiple myeloma, a C→T mutation in the *c-myc* IRES was identified (48) and found to cause an enhanced initiation of translation via internal ribosomal entry (49).

BRCA1. A somatic point mutation (117 G→C) in position -3 with respect to the start codon of the *BRCA1* gene was identified in a highly aggressive sporadic breast cancer (50). Chimeric constructs consisting of the wild-type or mutated *BRCA1* 5' UTR and a downstream luciferase reporter demonstrated a decrease in the translational efficiency with the 5' UTR mutation.

Cyclin-dependent Kinase Inhibitor 2A. Some inherited melanoma kindreds have a G→T transversion at base -34 of cyclin-dependent kinase inhibitor-2A, which encodes a cyclin-dependent kinase 4/cyclin-dependent kinase 6 kinase inhibitor important in G₁ checkpoint regulation (51). This mutation gives rise to a novel AUG translation initiation codon, creating an upstream open reading frame that competes for scanning ribosomes and decreases translation from the wild-type AUG.

Alternate Splicing and Alternate Transcription Start Sites. Alterations in splicing and alternate transcription sites can lead to variations in 5' UTR sequence, length, and secondary structure, ultimately impacting translational efficiency.

ATM. The *ATM* gene has four noncoding exons in its 5' UTR that undergo extensive alternative splicing (52). The contents of 12 different 5' UTRs that show considerable diversity in length and sequence have been identified. These divergent 5' leader sequences play an important role in the translational regulation of the *ATM* gene.

mdm. In a subset of tumors, overexpression of the oncoprotein *mdm2* results in enhanced translation of the *mdm2* mRNA. Use of different promoters leads to two *mdm2* transcripts that differ only in their 5' leaders (53). The longer 5' UTR contains two upstream open reading frames, and this mRNA is loaded with ribosomes inefficiently compared with the short 5' UTR.

BRCA1. In a normal mammary gland, *BRCA1* mRNA is expressed with a shorter leader sequence (5'UTRa), whereas in sporadic breast cancer tissue, *BRCA1* mRNA is expressed with a longer leader sequence (5' UTRb); the translational efficiency of transcripts containing 5' UTRb is 10 times lower than that of transcripts containing 5' UTRa (54).

TGF- β 3. *TGF- β 3* mRNA includes a 1.1-kb 5' UTR, which exerts an inhibitory effect on translation. Many human breast cancer cell lines contain a novel *TGF- β 3* transcript with a 5' UTR that is 870 nucleotides shorter and has a 7-fold greater translational efficiency than the normal *TGF- β 3* mRNA (55).

Alternate Polyadenylation Sites. Multiple polyadenylation signals leading to the generation of several transcripts with differing 3' UTR have been described for several mRNA species, such as the *RET* proto-oncogene (56), *ATM* gene (52), tissue inhibitor of metalloproteinases-3 (57), *RHOA*

proto-oncogene (58), and calmodulin-1 (59). Although the effect of these alternate 3' UTRs on translation is not yet known, they may be important in RNA-protein interactions that affect translational recruitment. The role of these alterations in cancer development and progression is unknown.

Alterations in the Components of the Translation Machinery

Alterations in the components of translation machinery can take many forms.

Overexpression of eIF4E. Overexpression of eIF4E causes malignant transformation in rodent cells (60) and the deregulation of HeLa cell growth (61). Polunovsky *et al.* (62) found that eIF4E overexpression substitutes for serum and individual growth factors in preserving viability of fibroblasts, which suggests that eIF4E can mediate both proliferative and survival signaling.

Elevated levels of eIF4E mRNA have been found in a broad spectrum of transformed cell lines (63). eIF4E levels are elevated in all ductal carcinoma *in situ* specimens and invasive ductal carcinomas, compared with benign breast specimens evaluated with Western blot analysis (64, 65). Preliminary studies suggest that this overexpression is attributable to gene amplification (66).

There are accumulating data suggesting that eIF4E overexpression can be valuable as a prognostic marker. eIF4E overexpression was found in a retrospective study to be a marker of poor prognosis in stages I to III breast carcinoma (67). Verification of the prognostic value of eIF4E in breast cancer is now under way in a prospective trial (67). However, in a different study, eIF4E expression was correlated with the aggressive behavior of non-Hodgkin's lymphomas (68). In a prospective analysis of patients with head and neck cancer, elevated levels of eIF4E in histologically tumor-free surgical margins predicted a significantly increased risk of local-regional recurrence (9). These results all suggest that eIF4E overexpression can be used to select patients who might benefit from more aggressive systemic therapy. Furthermore, the head and neck cancer data suggest that eIF4E overexpression is a field defect and can be used to guide local therapy.

Alterations in Other Initiation Factors. Alterations in a number of other initiation factors have been associated with cancer. Overproduction of eIF4G, similar to eIF4E, leads to malignant transformation *in vitro* (69). eIF-2 α is found in increased levels in bronchioloalveolar carcinomas of the lung (3). Initiation factor eIF-4A1 is overexpressed in melanoma (70) and hepatocellular carcinoma (71). The p40 subunit of translation initiation factor 3 is amplified and overexpressed in breast and prostate cancer (72), and the eIF3-p110 subunit is overexpressed in testicular seminoma (73). The role that overexpression of these initiation factors plays on the development and progression of cancer, if any, is not known.

Overexpression of S6K. S6K is amplified and highly overexpressed in the MCF7 breast cancer cell line, compared with normal mammary epithelium (74). In a study by Barlund *et al.* (74), S6K was amplified in 59 of 668 primary breast tumors, and a statistically significant association was observed between amplification and poor prognosis.

Overexpression of PAP. PAP catalyzes 3' poly(A) synthesis. PAP is overexpressed in human cancer cells compared with normal and virally transformed cells (75). PAP enzymatic activity in breast tumors has been correlated with PAP protein levels (76) and, in mammary tumor cytosols, was found to be an independent factor for predicting survival (76). Little is known, however, about how PAP expression or activity affects the translational profile.

Alterations in RNA-binding Proteins. Even less is known about alterations in RNA packaging in cancer. Increased expression and nuclear localization of the RNA-binding protein YB-1 are indicators of a poor prognosis for breast cancer (77), non-small cell lung cancer (78), and ovarian cancer (79). However, this effect may be mediated at least in part at the level of transcription, because YB-1 increases chemoresistance by enhancing the transcription of a multidrug resistance gene (80).

Activation of Signal Transduction Pathways

Activation of signal transduction pathways by loss of tumor suppressor genes or overexpression of certain tyrosine kinases can contribute to the growth and aggressiveness of tumors. An important mutant in human cancers is the tumor suppressor gene *PTEN*, which leads to the activation of the PI3K/Akt pathway. Activation of PI3K and Akt induces the oncogenic transformation of chicken embryo fibroblasts. The transformed cells show constitutive phosphorylation of S6K and of 4E-BP1 (81). A mutant Akt that retains kinase activity but does not phosphorylate S6K or 4E-BP1 does not transform fibroblasts, which suggests a correlation between the oncogenicity of PI3K and Akt and the phosphorylation of S6K and 4E-BP1 (81).

Several tyrosine kinases such as platelet-derived growth factor, insulin-like growth factor, HER2/neu, and epidermal growth factor receptor are overexpressed in cancer. Because these kinases activate downstream signal transduction pathways known to alter translation initiation, activation of translation is likely to contribute to the growth and aggressiveness of these tumors. Furthermore, the mRNA for many of these kinases themselves are under translational control. For example, HER2/neu mRNA is translationally controlled both by a short upstream open reading frame that represses HER2/neu translation in a cell type-independent manner and by a distinct cell type-dependent mechanism that increases translational efficiency (82). HER2/neu translation is different in transformed and normal cells. Thus, it is possible that alterations at the translational level can in part account for the discrepancy between *HER2/neu* gene amplification detected by fluorescence *in situ* hybridization and protein levels detected by immunohistochemical assays.

Translation Targets of Selected Cancer Therapy

Components of the translation machinery and signal pathways involved in the activation of translation initiation represent good targets for cancer therapy.

Targeting the mTOR Signaling Pathway: Rapamycin and Temsirolumab

Rapamycin inhibits the proliferation of lymphocytes. It was initially developed as an immunosuppressive drug for organ

transplantation. Rapamycin with FKBP 12 (FK506-binding protein, *M*, 12,000) binds to mTOR to inhibit its function.

Rapamycin causes a small but significant reduction in the initiation rate of protein synthesis (83). It blocks cell growth in part by blocking S6 phosphorylation and selectively suppressing the translation of 5' TOP mRNAs, such as ribosomal proteins, and elongation factors (83–85). Rapamycin also blocks 4E-BP1 phosphorylation and inhibits cap-dependent but not cap-independent translation (17, 86).

The rapamycin-sensitive signal transduction pathway, activated during malignant transformation and cancer progression, is now being studied as a target for cancer therapy (87). Prostate, breast, small cell lung, glioblastoma, melanoma, and T-cell leukemia are among the cancer lines most sensitive to the rapamycin analogue CCI-779 (Wyeth-Ayerst Research; Ref. 87). In rhabdomyosarcoma cell lines, rapamycin is either cytostatic or cytotoxic, depending on the p53 status of the cell; p53 wild-type cells treated with rapamycin arrest in the G₁ phase and maintain their viability, whereas p53 mutant cells accumulate in G₁ and undergo apoptosis (88, 89). In a recently reported study using human primitive neuroectodermal tumor and medulloblastoma models, rapamycin exhibited more cytotoxicity in combination with cisplatin and camptothecin than as a single agent. *In vivo*, CCI-779 delayed growth of xenografts by 160% after 1 week of therapy and 240% after 2 weeks. A single high-dose administration caused a 37% decrease in tumor volume. Growth inhibition *in vivo* was 1.3 times greater, with cisplatin in combination with CCI-779 than with cisplatin alone (90). Thus, preclinical studies suggest that rapamycin analogues are useful as single agents and in combination with chemotherapy.

Rapamycin analogues CCI-779 and RAD001 (Novartis, Basel, Switzerland) are now in clinical trials. Because of the known effect of rapamycin on lymphocyte proliferation, a potential problem with rapamycin analogues is immunosuppression. However, although prolonged immunosuppression can result from rapamycin and CCI-779 administered on continuous-dose schedules, the immunosuppressive effects of rapamycin analogues resolve in ~24 h after therapy (91). The principal toxicities of CCI-779 have included dermatological toxicity, myelosuppression, infection, mucositis, diarrhea, reversible elevations in liver function tests, hyperglycemia, hypokalemia, hypocalcemia, and depression (87, 92–94). Phase II trials of CCI-779 have been conducted in advanced renal cell carcinoma and in stage III/IV breast carcinoma patients who failed with prior chemotherapy. In the results reported in abstract form, although there were no complete responses, partial responses were documented in both renal cell carcinoma and in breast carcinoma (94, 95). Thus, CCI-779 has documented preliminary clinical activity in a previously treated, unselected patient population.

Active investigation is under way into patient selection for mTOR inhibitors. Several studies have found an enhanced efficacy of CCI-779 in PTEN-null tumors (30, 96). Another study found that six of eight breast cancer cell lines were responsive to CCI-779, although only two of these lines lacked PTEN (97). There was, however, a positive correlation between Akt activation and CCI-779 sensitivity (97). This correlation suggests that activation of the PI3K-Akt pathway,

regardless of whether it is attributable to a PTEN mutation or to overexpression of receptor tyrosine kinases, makes cancer cell amenable to mTOR-directed therapy. In contrast, lower levels of the target of mTOR, 4E-BP1, are associated with rapamycin resistance; thus, a lower 4E-BP1/eIF4E ratio may predict rapamycin resistance (98).

Another mode of activity for rapamycin and its analogues appears to be through inhibition of angiogenesis. This activity may be both through direct inhibition of endothelial cell proliferation as a result of mTOR inhibition in these cells or by inhibition of translation of such proangiogenic factors as vascular endothelial growth factor in tumor cells (99, 100).

The angiogenesis inhibitor turostatin, another anticancer drug currently under study, was also found recently to inhibit translation in endothelial cells (101). Through a requisite interaction with Integrin, turostatin inhibits activation of the PI3K/Akt pathway and mTOR in endothelial cells and prevents dissociation of eIF4E from 4E-BP1, thereby inhibiting cap-dependent translation. These findings suggest that endothelial cells are especially sensitive to therapies targeting the mTOR-signaling pathway.

Targeting eIF2 α EPA, Clotrimazole, mda-7, and Flavonoids

EPA is an n-3 polyunsaturated fatty acid found in the fish-based diets of populations having a low incidence of cancer (102). EPA inhibits the proliferation of cancer cells (103), as well as in animal models (104, 105). It blocks cell division by inhibiting translation initiation (105). EPA releases Ca²⁺ from intracellular stores while inhibiting their refilling, thereby activating PKR. PKR, in turn phosphorylates and inhibits eIF2 α , resulting in the inhibition of protein synthesis at the level of translation initiation. Similarly, clotrimazole, a potent antiproliferative agent *in vitro* and *in vivo*, inhibits cell growth through depletion of Ca²⁺ stores, activation of PKR, and phosphorylation of eIF2 α (106). Consequently, clotrimazole preferentially decreases the expression of cyclins A, E, and D1, resulting in blockage of the cell cycle in G₁.

mda-7 is a novel tumor suppressor gene being developed as a gene therapy agent. Adenoviral transfer of mda-7 (Ad-mda7) induces apoptosis in many cancer cells including breast, colorectal, and lung cancer (107–109). Ad-mda7 also induces and activates PKR, which leads to phosphorylation of eIF2 α and induction of apoptosis (110).

Flavonoids such as genistein and quercetin suppress tumor cell growth. All three mammalian eIF2 α kinases, PKR, heme-regulated inhibitor, and PERK/PEK, are activated by flavonoids, with phosphorylation of eIF2 α and inhibition of protein synthesis (111).

Targeting eIF4A and eIF4E: Antisense RNA and Peptides

Antisense expression of eIF4A decreases the proliferation rate of melanoma cells (112). Sequestration of eIF4E by overexpression of 4E-BP1 is proapoptotic and decreases tumorigenicity (113, 114). Reduction of eIF4E with antisense RNA decreases soft agar growth, increases tumor latency, and increases the rates of tumor doubling times (7). Antisense eIF4E RNA treat-

ment also reduces the expression of angiogenic factors (115) and has been proposed as a potential adjuvant therapy for head and neck cancers, particularly when elevated eIF4E is found in surgical margins. Small molecule inhibitors that bind the eIF4G/4E-BP1-binding domain of eIF4E are proapoptotic (116) and are also being actively pursued.

Exploiting Selective Translation for Gene Therapy

A different therapeutic approach that takes advantage of the enhanced cap-dependent translation in cancer cells is the use of gene therapy vectors encoding suicide genes with highly structured 5' UTR. These mRNA would thus be at a competitive disadvantage in normal cells and not translate well, whereas in cancer cells, they would translate more efficiently. For example, the introduction of the 5' UTR of fibroblast growth factor-2 5' to the coding sequence of *herpes simplex virus type-1 thymidine kinase* gene, allows for selective translation of *herpes simplex virus type-1 thymidine kinase* gene in breast cancer cell lines compared with normal mammary cell lines and results in selective sensitivity to ganciclovir (117).

Toward the Future

Translation is a crucial process in every cell. However, several alterations in translational control occur in cancer. Cancer cells appear to need an aberrantly activated translational state for survival, thus allowing the targeting of translation initiation with surprisingly low toxicity. Components of the translational machinery, such as eIF4E, and signal transduction pathways involved in translation initiation, such as mTOR, represent promising targets for cancer therapy. Inhibitors of the mTOR have already shown some preliminary activity in clinical trials. It is possible that with the development of better predictive markers and better patient selection, response rates to single-agent therapy can be improved. Similar to other cytostatic agents, however, mTOR inhibitors are most likely to achieve clinical utility in combination therapy. In the interim, our increasing understanding of translation initiation and signal transduction pathways promise to lead to the identification of new therapeutic targets in the near future.

Acknowledgments

We thank Gayle Nesom from The University of Texas M. D. Anderson Cancer Center Department of Scientific Publications for editorial assistance and Dr. Elmer Bernstein for assistance with manuscript preparation.

References

1. Pestova, T. V., Kotupaeva, V. G., Lomakin, I. B., Pilipenko, E. V., Shatsky, I. N., Agol, V. I., and Hellen, C. U. Molecular mechanisms of translation initiation in eukaryotes. *Proc. Natl. Acad. Sci. USA*, 98: 7029–7036, 2001.
2. Rosenwald, I. B., Kasper, R., Rousseau, D., Gehrke, L., LeBoulch, P., Chen, J. J., Schmidt, E. V., Sonenberg, N., and London, I. M. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. *J. Biol. Chem.*, 270: 21176–21180, 1995.
3. Rosenwald, I. B., Hutzler, M. J., Wang, S., Savas, L., and Fraire, A. E. Expression of eukaryotic translation initiation factors 4E and 2 α is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. *Cancer (Phila.)*, 92: 2164–2171, 2001.

4. Darveau, A., Pelletier, J., and Sonenberg, N. Differential efficiencies of *in vitro* translation of mouse c-myc transcripts differing in the 5' untranslated region. *Proc. Natl. Acad. Sci. USA*, 82: 2315-2319, 1985.
5. Kozak, M. Influences of mRNA secondary structure on initiation by eukaryotic ribosomes. *Proc. Natl. Acad. Sci. USA*, 83: 2850-2854, 1986.
6. Koromilas, A. E., Lazaris-Karatzas, A., and Sonenberg, N. mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. *EMBO J.*, 11: 4153-4158, 1992.
7. Plinker-Schaeffer, C. W., Graff, J. R., De Benedetti, A., Zimmer, S. G., and Rhoads, R. E. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. *Int. J. Cancer*, 55: 841-847, 1993.
8. Kevil, C. G., De Benedetti, A., Payne, D. K., Coe, L. L., Laroux, F. S., and Alexander, J. S. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. *Int. J. Cancer*, 65: 785-790, 1996.
9. Nathan, C. A., Franklin, S., Abreo, F. W., Nassar, R., De Benedetti, A., and Glass, J. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. *J. Clin. Oncol.*, 17: 2909-2914, 1999.
10. Fukunaga, R., and Hunter, T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. *EMBO J.*, 16: 1821-1933, 1997.
11. Wasikiewicz, A. J., Flynn, A., Proud, C. G., and Cooper, J. A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. *EMBO J.*, 16: 1909-1920, 1997.
12. Wang, X., Flynn, A., Wasikiewicz, A. J., Webb, B. L., Vries, R. G., Balnes, L. A., Cooper, J. A., and Proud, C. G. The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways. *J. Biol. Chem.*, 273: 8373-8377, 1998.
13. Pyronnet, S., Imataka, H., Gingras, A. C., Fukunaga, R., Hunter, T., and Sonenberg, N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits Mnk1 to phosphorylate eIF4E. *EMBO J.*, 18: 270-279, 1999.
14. Kleijn, M., Scheper, G. C., Voorma, H. O., and Thomas, A. A. Regulation of translation initiation factors by signal transduction. *Eur. J. Biochem.*, 253: 531-544, 1999.
15. Raught, B., and Gingras, A. C. eIF4E activity is regulated at multiple levels. *Int. J. Biochem. Cell Biol.*, 31: 43-57, 1999.
16. Takeuchi, K., Shibamoto, S., Nagamine, K., Shigemori, I., Omura, S., Kitamura, N., and Ito, F. Signaling pathways leading to transcription and translation cooperatively regulate the transient increase in expression of c-Fos protein. *J. Biol. Chem.*, 276: 26077-26083, 2001.
17. Kawasome, H., Papst, P., Webb, S., Keller, G. M., Johnson, G. L., Gelfand, E. W., and Terada, N. Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sensitivity. *Proc. Natl. Acad. Sci. USA*, 95: 6033-6038, 1998.
18. Christie, G. R., Hajdich, E., Hundal, H. S., Proud, C. G., and Taylor, P. M. Intracellular sensing of amino acids in *Xenopus laevis* oocytes stimulates p70 S6 kinase in a target of rapamycin-dependent manner. *J. Biol. Chem.*, 277: 9952-9957, 2002.
19. Hara, K., Yonezawa, K., Weng, Q. P., Kozlowski, M. T., Belham, C., and Avruch, J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. *J. Biol. Chem.*, 273: 14484-14494, 1998.
20. Graves, L. M., Bornfeldt, K. E., Argast, G. M., Krebs, E. G., Kong, X., Lin, T. A., and Lawrence, J. C., Jr. cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-1 in aortic smooth muscle cells. *Proc. Natl. Acad. Sci. USA*, 92: 7222-7226, 1995.
21. Merrick, W. C., and Hershey, J. W. B. The pathway and mechanism of eukaryotic protein synthesis. In: J. W. B. Hershey and M. B. Matthews (eds.), *Translational Control*, pp. 31-69. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1998.
22. Kimball, S. R. Eukaryotic initiation factor eIF2. *Int. J. Biochem. Cell Biol.*, 31: 25-29, 1999.
23. Jagus, R., Joshi, B., and Barber, G. N. PKR, apoptosis and cancer. *Int. J. Biochem. Cell Biol.*, 31: 123-138, 1999.
24. Thomas, G., and Hall, M. N. TOR signalling and control of cell growth. *Curr. Opin. Cell Biol.*, 9: 782-787, 1997.
25. Gingras, A. C., Raught, B., and Sonenberg, N. Regulation of translation initiation by FRAP/mTOR. *Genes Dev.*, 15: 807-820, 2001.
26. Gingras, A. C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., and Sonenberg, N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. *Genes Dev.*, 13: 1422-1437, 1999.
27. Kumar, V., Pandey, P., Sabatini, D., Kumar, M., Majumder, P. K., Bharti, A., Carmichael, G., Kufe, D., and Karhanda, S. Functional interaction between RAFT1/FRAP/mTOR and protein kinase C δ in the regulation of cap-dependent initiation of translation. *EMBO J.*, 19: 1087-1097, 2000.
28. Yang, D. Q., and Kastan, M. B. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. *Nat. Cell Biol.*, 2: 893-898, 2000.
29. Liu, G., Zhang, Y., Bode, A. M., Ma, W. Y., and Dong, Z. Phosphorylation of 4E-BP1 is mediated by the p38/MSK1 pathway in response to UVB irradiation. *J. Biol. Chem.*, 277: 8810-8816, 2002.
30. Neshat, M. S., Mellingerhoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., and Sawyers, C. L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. *Proc. Natl. Acad. Sci. USA*, 98: 10314-10319, 2001.
31. Selak, A., Hudson, C. C., Homme, J. L., Yin, P., Ottaviano, D. M., Karnitz, L. M., and Abraham, R. T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. *Cancer Res.*, 60: 3504-3513, 2000.
32. Scott, P. H., and Lawrence, J. C., Jr. Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3-L1 adipocytes. *J. Biol. Chem.*, 273: 34496-34501, 1998.
33. Reynolds, J. T., Bodine, S. C., and Lawrence, J. C., Jr. Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. *J. Biol. Chem.*, 277: 17657-17662, 2002.
34. Peterson, R. T., Beal, P. A., Comb, M. J., and Schreiber, S. L. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. *J. Biol. Chem.*, 275: 7416-7423, 2000.
35. Peterson, R. T., Desai, B. N., Hardwick, J. S., and Schreiber, S. L. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycin-associated protein. *Proc. Natl. Acad. Sci. USA*, 96: 4438-4442, 1999.
36. McGrew, L. L., Dworkin-Rastl, E., Dworkin, M. B., and Richter, J. D. Poly(A) elongation during *Xenopus* oocyte maturation is required for translational recruitment and is mediated by a short sequence element. *Genes Dev.*, 3: 803-815, 1989.
37. Sheets, M. D., Wu, M., and Wickens, M. Polyadenylation of c-mos mRNA as a control point in *Xenopus* meiotic maturation. *Nature (Lond.)*, 374: 511-516, 1995.
38. Varnum, S. M., and Wormington, W. M. Deadenylation of maternal mRNAs during *Xenopus* oocyte maturation does not require specific cis-sequences: a default mechanism for translational control. *Genes Dev.*, 4: 2278-2286, 1990.
39. Gallie, D. R. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. *Genes Dev.*, 5: 2108-2116, 1991.
40. Sachs, A. B., and Varani, G. Eukaryotic translation initiation: there are (at least) two sides to every story. *Nat. Struct. Biol.*, 7: 358-361, 2000.
41. Wolffe, A. P., and Merlo, F. Coupling transcription to translation: a novel site for the regulation of eukaryotic gene expression. *Int. J. Biochem. Cell Biol.*, 28: 247-257, 1996.
42. Evdokimova, V. M., Wei, C. L., Sitkov, A. S., Simonenko, P. N., Lazarev, O. A., Vasilenko, K. S., Ustinov, V. A., Hershey, J. W., and Ovchinnikov, L. P. The major protein of messenger ribonucleoprotein particles in somatic cells is a member of the Y-box binding transcription factor family. *J. Biol. Chem.*, 270: 3188-3192, 1995.
43. Matsumoto, K., Merlo, F., and Wolffe, A. P. Translational repression dependent on the interaction of the *Xenopus* Y-box protein FRGY2 with mRNA. Role of the cold shock domain, tail domain, and selective RNA sequence recognition. *J. Biol. Chem.*, 271: 22706-22712, 1996.

44. Evdokimova, V., Ruzanov, P., Imataka, H., Raught, B., Svitkin, Y., Orshinnikov, L. P., and Sonenberg, N. The major mRNA-associated protein YB-1 is a potent 5' cap-dependent mRNA stabilizer. *EMBO J.*, 20: 5491-5502, 2001.
45. Saito, H., Hayday, A. C., Wiman, K., Hayward, W. S., and Tonegawa, S. Activation of the *c-myc* gene by translocation: a model for translational control. *Proc. Natl. Acad. Sci. USA*, 80: 7476-7480, 1983.
46. Nambu, C., Lafon, I., Audigier, S., Gensac, M. C., Vagner, S., Huez, G., and Prats, A. C. Alternative translation of the proto-oncogene *c-myc* by an internal ribosome entry site. *J. Biol. Chem.*, 272: 32061-32066, 1997.
47. Stoneley, M., Paulin, F. E., Le Quesne, J. P., Chappell, S. A., and Willis, A. E. *c-Myc* 5' untranslated region contains an internal ribosome entry segment. *Oncogene*, 16: 423-428, 1998.
48. Paulin, F. E., West, M. J., Sullivan, N. F., Whitney, R. L., Lyne, L., and Willis, A. E. Aberrant translational control of the *c-myc* gene in multiple myeloma. *Oncogene*, 13: 505-513, 1996.
49. Chappell, S. A., LeQuesne, J. P., Paulin, F. E., de Schoonebeester, M. L., Stoneley, M., Soutar, R. L., Ralston, S. H., Helfrich, M. H., and Willis, A. E. A mutation in the *c-myc*-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation. *Oncogene*, 18: 4437-4440, 2000.
50. Signori, E., Bagni, C., Papa, S., Primerano, B., Rinaldi, M., Amaldi, F., and Fazio, V. M. A. A somatic mutation in the 5'UTR of *BRCA1* gene in sporadic breast cancer causes down-modulation of translation efficiency. *Oncogene*, 20: 4596-4600, 2001.
51. Liu, L., Dillworth, D., Gao, L., Morzon, J., Summers, A., Lassam, N., and Hogg, D. Mutation of the *CDKN2A* 5' UTR creates an aberrant initiation codon and predisposes to melanoma. *Nat. Genet.*, 21: 128-132, 1999.
52. Savitsky, K., Platzer, M., Uziel, T., Gilad, S., Sartiel, A., Rosenthal, A., Brody-Stein, O., Shiloh, Y., and Rotman, G. Ataxia-telangiectasia: structural diversity of untranslated sequences suggests complex post-transcriptional regulation of *ATM* gene expression. *Nucleic Acids Res.*, 25: 1678-1684, 1997.
53. Brown, C. Y., Mize, G. J., Pineda, M., George, D. L., and Morris, D. R. Role of two upstream open reading frames in the translational control of oncogene *mdm2*. *Oncogene*, 18: 5631-5637, 1999.
54. Sobczak, K., and Krzyzosiak, W. J. Structural determinants of *BRCA1* translational regulation. *J. Biol. Chem.*, 277: 17349-17358, 2002.
55. Arnick, B. A., Grendell, R. L., and Griffin, L. A. Enhanced translational efficiency of a novel transforming growth factor β 3 mRNA in human breast cancer cells. *Mol. Cell. Biol.*, 14: 619-628, 1994.
56. Myers, S. M., Eng, C., Ponder, B. A., and Mulligan, L. M. Characterization of a novel *RET* proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for *RET*. *Oncogene*, 11: 2039-2045, 1995.
57. Byrne, J. A., Tomasello, C., Rouyer, N., Bellocq, J. P., Rio, M. C., and Basset, P. The tissue inhibitor of metalloproteinases-3 gene in breast carcinoma: identification of multiple polyadenylation sites and a stromal pattern of expression. *Mol. Med.*, 1: 418-427, 1995.
58. Moscow, J. A., He, R., Gudas, J. M., and Cowan, K. H. Utilization of multiple polyadenylation signals in the human *RHOA* protooncogene. *Gene (Amst.)*, 144: 229-236, 1994.
59. Sentenac-Lesentants, S., Alag, A. S., and Sobel, M. E. Multiple mRNA species are generated by alternate polyadenylation from the human *calmodulin-1* gene. *J. Cell. Biochem.*, 58: 445-454, 1995.
60. Lazaris-Karatzas, A., Montine, K. S., and Sonenberg, N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. *Nature (Lond.)*, 345: 544-547, 1990.
61. De Benedetti, A., and Rhoads, R. E. Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. *Proc. Natl. Acad. Sci. USA*, 87: 8212-8216, 1990.
62. Polunovsky, V. A., Rosenwald, I. B., Tan, A. T., White, J., Chiang, L., Sonenberg, N., and Blitterman, P. B. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or de-regulated *Myc*. *Mol. Cell. Biol.*, 16: 6573-6581, 1996.
63. Miyagi, Y., Sugiyama, A., Asai, A., Okazaki, T., Kuchino, Y., and Kerr, S. J. Elevated levels of eukaryotic translation initiation factor eIF-4E mRNA in a broad spectrum of transformed cell lines. *Cancer Lett.*, 91: 247-252, 1995.
64. Kerekatte, V., Smiley, K., Hu, B., Smith, A., Gelder, F., and De Benedetti, A. The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. *Int. J. Cancer*, 64: 27-31, 1995.
65. Li, B. D., Liu, L., Dawson, M., and De Benedetti, A. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. *Cancer (Phila.)*, 79: 2385-2390, 1997.
66. Sorrells, D. L., Black, D. R., Meschonat, C., Rhoads, R., De Benedetti, A., Gao, M., Williams, B. J., and Li, B. D. Detection of eIF4E gene amplification in breast cancer by competitive PCR. *Ann. Surg. Oncol.*, 6: 232-237, 1998.
67. Li, B. D., McDonald, J. C., Nassar, R., and De Benedetti, A. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. *Ann. Surg.*, 227: 756-761; discussion, 761-763, 1998.
68. Wang, S., Rosenwald, I. B., Hutzler, M. J., Pihan, G. A., Savas, L., Chen, J. J., and Woda, B. A. Expression of the eukaryotic translation initiation factors 4E and 2 α in non-Hodgkin's lymphomas. *Am. J. Pathol.*, 155: 247-255, 1999.
69. Fukuchi-Shimogori, T., Ishii, I., Kashiwagi, K., Mashiba, H., Ekimoto, H., and Igarashi, K. Malignant transformation by overproduction of translation initiation factor eIF4G. *Cancer Res.*, 57: 5041-5044, 1997.
70. Eberle, J., Krasagakis, K., and Orfanos, C. E. Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells *in vitro*. *Int. J. Cancer*, 71: 396-401, 1997.
71. Shuda, M., Kondoh, N., Tanaka, K., Ryo, A., Wakatsuki, T., Hada, A., Goseki, N., Igarashi, T., Matsuse, K., Aihara, T., Horuchi, S., Shichita, M., Yamamoto, N., and Yamamoto, M. Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. *Anticancer Res.*, 20: 2489-2494, 2000.
72. Nupponen, N. N., Porkka, K., Kakkola, L., Tanner, M., Persson, K., Borg, A., Isola, J., and Visakorpi, T. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. *Am. J. Pathol.*, 154: 1777-1783, 1999.
73. Rothe, M., Ko, Y., Albers, P., and Wemert, N. Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas. *Am. J. Pathol.*, 157: 1597-1604, 2000.
74. Berlund, M., Forozan, F., Kononen, J., Bubendorf, L., Chen, Y., Bittner, M. L., Thorhorst, J., Haas, P., Bucher, C., Sauter, G., Kallioniemi, O. P., and Kallioniemi, A. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. *J. Natl. Cancer Inst.* (Bethesda), 92: 1252-1259, 2000.
75. Topalian, S. L., Kaneko, S., Gonzales, M. I., Bond, G. L., Ward, Y., and Manley, J. L. Identification and functional characterization of neo-poly(A) polymerase, an RNA processing enzyme overexpressed in human tumors. *Mol. Cell. Biol.*, 21: 5614-5623, 2001.
76. Scorilas, A., Talieri, M., Aravanis, A., Courtis, N., Dimitriadis, E., Yotis, J., Tsiapalis, C. M., and Tringali, T. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: a new independent prognostic marker in primary breast cancer. *Cancer Res.*, 60: 5427-5433, 2000.
77. Jarz, M., Harbeck, N., Dettmar, P., Berger, U., Schmitt, A., Jurchott, K., Schmitt, M., and Royer, H. D. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. *Int. J. Cancer*, 97: 278-282, 2002.
78. Shibahara, K., Sugio, K., Osaki, T., Uchiyama, T., Maehara, Y., Kohno, K., Yasumoto, K., Sugimachi, K., and Kuwano, M. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. *Clin. Cancer Res.*, 7: 3151-3155, 2001.
79. Kamura, T., Yahata, H., Amada, S., Ogawa, S., Sonoda, T., Kobayashi, H., Mitsumoto, M., Kohno, K., Kuwano, M., and Nakano, H. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? *Cancer (Phila.)*, 85: 2450-2454, 1999.
80. Bargou, R. C., Jurchott, K., Wagener, C., Bergmann, S., Metzner, S., Bommer, K., Mapara, M. Y., Wenzel, K. J., Dietel, M., Dorkan, B., and Royer, H. D. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic *MDR1* gene expression. *Nat. Med.*, 3: 447-450, 1997.
81. Aoki, M., Blazek, E., and Vogt, P. K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3K and Akt. *Proc. Natl. Acad. Sci. USA*, 98: 136-141, 2001.
82. Child, S. J., Miller, M. K., and Geballe, A. P. Cell type-dependent and -independent control of HER-2/neu translation. *Int. J. Biochem. Cell Biol.*, 31: 201-213, 1999.

83. Jefferies, H. B., Reinhard, C., Kozma, S. C., and Thomas, G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. *Proc. Natl. Acad. Sci. USA*, 91: 4441-4445, 1994.
84. Terada, N., Patel, H. R., Takase, K., Kohno, K., Nairn, A. C., and Gelfand, E. W. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. *Proc. Natl. Acad. Sci. USA*, 91: 11477-11481, 1994.
85. Jefferies, H. B., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., and Thomas, G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. *EMBO J.*, 16: 3693-3704, 1997.
86. Beretta, L., Gingras, A. C., Svitkin, Y. V., Hall, M. N., and Sonenberg, N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. *EMBO J.*, 15: 658-664, 1996.
87. Hidalgo, M., and Rowinsky, E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. *Oncogene*, 19: 6680-6686, 2000.
88. Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., Germain, G. S., Abraham, R. T., and Houghton, P. J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. *Cancer Res.*, 59: 886-894, 1999.
89. Huang, S., and Houghton, P. J. Resistance to rapamycin: a novel anticancer drug. *Cancer Metastasis Rev.*, 20: 69-78, 2001.
90. Georger, B., Kerr, K., Tang, C. B., Fung, K. M., Powell, B., Sutton, L. N., Phillips, P. C., and Janss, A. J. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. *Cancer Res.*, 61: 1527-1532, 2001.
91. Gibbons, J. J., Discafani, C., Peterson, R., Hernandez, R., Skotnicki, J., and Frost, P. The effect of CCI-779, a novel macroide anti-tumor agent, on the growth of human tumor cells *in vitro* and in nude mouse xenografts *in vivo*. *Proc. Am. Assoc. Cancer Res.*, 40: 301, 1999.
92. Hidalgo, M., Rowinsky, E., Erllichman, C., Marshall, B., Marks, R., Edwards, T., and Buckner, J. J. A Phase I and pharmacological study of CCI-779 cycle inhibitor. *Ann. Oncol.*, 11 (Suppl. 4): 133, 2001.
93. Alexandre, J., Raymond, E., Depenbrock, H., Mekhaldi, S., Angevin, E., Paillet, C., Hanauska, A., Frisch, J., Feussner, A., and Armand, J. P. CCI-779, a new rapamycin analog, has antitumor activity at doses inducing only mild cutaneous effects and mucositis: early results of an ongoing Phase I study. *Proceedings of the 1999 AACR-NCI-EORTC International Conference, Clin. Cancer Res.*, 5 (Suppl.): 3730s, 1999.
94. Chan, S., Johnston, S., Scheulen, M. E., Moss, K., Morant, A., Lahr, A., Feussner, A., Berger, M., and Kirsch, T. First report: a Phase 2 study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy. *Proc. Am. Soc. Clin. Oncol.*, 21: 44a, 2002.
95. Atkins, M. B., Hidalgo, M., Stadler, W., Logan, T., Dutcher, J. P., Hudes, G., Park, Y., Marshall, B., Boni, J., and Dukart, G. A randomized double-blind Phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. *Proc. Am. Soc. Clin. Oncol.*, 21: 10a, 2002.
96. Smith, S. G., Trinh, C. M., Inge, L. J., Thomas, G., Cloughsey, T. F., Sawyers, C. L., and Mischak, P. S. PTEN expression status predicts glioblastoma cell sensitivity to CCI-779. *Proc. Am. Assoc. Cancer Res.*, 43: 335, 2002.
97. Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., and Gibbons, J. J. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. *Endocr. Relat. Cancer*, 8: 249-258, 2001.
98. Dilling, M. B., Germain, G. S., Dudkin, L., Jayaraman, A. L., Zhang, X., Harwood, F. C., and Houghton, P. J. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are downregulated in cells with acquired or intrinsic resistance to rapamycin. *J. Biol. Chem.*, 277: 13907-13917, 2002.
99. Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., Jauch, K. W., and Gellssler, E. K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. *Nat. Med.*, 8: 128-135, 2002.
100. Lane, H. A., Schell, C., Theuer, A., O'Reilly, T., and Wood, J. Anti-angiogenic activity of RAD001, an orally active anticancer agent. *Proc. Am. Assoc. Cancer Res.*, 43: 184, 2002.
101. Maeshima, Y., Sudhakar, A., Lively, J. C., Ueki, K., Kharbanda, S., Kahn, C. R., Sonenberg, N., Hynes, R. O., and Kalluri, R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. *Science (Wash. DC)*, 295: 140-143, 2002.
102. Caygill, C. P., Charlett, A., and Hill, M. J. Fat, fish, fish oil and cancer. *Br. J. Cancer*, 74: 159-164, 1996.
103. Falconer, J. S., Ross, J. A., Fearon, K. C., Hawkins, R. A., O'Riordan, M. G., and Carter, D. C. Effect of elcosapentanoic acid and other fatty acids on the growth *in vitro* of human pancreatic cancer cell lines. *Br. J. Cancer*, 69: 826-832, 1994.
104. Noguchi, M., Minami, M., Yagasaki, R., Knoshta, K., Earashi, M., Kitagawa, H., Taniya, T., and Miyazaki, I. Chemoprevention of DMBA-induced mammary carcinogenesis in rats by low-dose EPA and DHA. *Br. J. Cancer*, 75: 348-353, 1997.
105. Palakurthi, S. S., Fluckiger, R., Aktas, H., Changoikar, A. K., Shah-safaei, A., Harmit, S., Kili, E., and Halperin, J. A. Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid elcosapentanoic acid. *Cancer Res.*, 60: 2919-2925, 2000.
106. Aktas, H., Fluckiger, R., Acosta, J. A., Savage, J. M., Palakurthi, S. S., and Halperin, J. A. Depletion of intracellular Ca^{2+} stores, phosphorylation of eIF2 α , and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. *Proc. Natl. Acad. Sci. USA*, 95: 8280-8285, 1998.
107. Mhashilkar, A. M., Schrock, R. D., Hindi, M., Liao, J., Sliger, K., Kourouma, F., Zou-Yang, X. H., Onishi, E., Takh, O., Vedvick, T. S., Fanger, G., Stewart, L., Watson, G. J., Snary, D., Fisher, P. B., Seelk, T., Roth, J. A., Ramesh, R., and Chada, S. Melanoma differentiation associated gene-7 (*mda-7*): a novel anti-tumor gene for cancer gene therapy. *Mol. Med.*, 7: 271-282, 2001.
108. Su, Z. Z., Madireddi, M. T., Lin, J. J., Young, C. S., Kitada, S., Reed, J. C., Goldstein, N. I., and Fisher, P. B. The cancer growth suppressor gene *mda-7* selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. *Proc. Natl. Acad. Sci. USA*, 95: 14400-14405, 1998.
109. Saeki, T., Mhashilkar, A., Chada, S., Branch, C., Roth, J. A., and Ramesh, R. Tumor-suppressive effects by adenovirus-mediated *mda-7* gene transfer in non-small cell lung cancer cell *in vitro*. *Gene Ther.*, 7: 2051-2057, 2000.
110. Pataer, A., Vorburger, S. A., Barber, G. N., Chada, S., Mhashilkar, A. M., Zou-Yang, H., Stewart, A. L., Balachandran, S., Roth, J. A., Hunt, K. K., and Swisher, S. G. Adenoviral transfer of the melanoma differentiation-associated gene 7 (*mda-7*) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). *Cancer Res.*, 62: 2239-2243, 2002.
111. Ito, T., Warnken, S. P., and May, W. S. Protein synthesis inhibition by flavonoids: roles of eukaryotic initiation factor 2 α kinases. *Biochem. Biophys. Res. Commun.*, 265: 589-594, 1999.
112. Eberle, J., Fecker, L. F., Bittner, J. U., Orfanos, C. E., and Geilen, C. C. Decreased proliferation of human melanoma cell lines caused by antisense RNA against translation factor eIF-4A1. *Br. J. Cancer*, 86: 1957-1962, 2002.
113. Polunovsky, V. A., Gingras, A. C., Sonenberg, N., Peterson, M., Tan, A., Rubins, J. B., Manivel, J. C., and Bitterman, P. B. Translational control of the antiapoptotic function of Bax. *J. Biol. Chem.*, 275: 24776-24780, 2000.
114. D'Cunha, J., Kratzke, M. G., Alter, M. D., Polunovsky, V. A., Bitterman, P. B., and Kratzke, R. A. Over-expression of the translational repressor 4E-BP1 inhibits NSCLC tumorigenicity *in vivo*. *Proc. Am. Assoc. Cancer Res.*, 43: 818-817, 2002.
115. DeFatta, R. J., Nathan, C. A., and De Benedetti, A. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. *Laryngoscope*, 110: 928-933, 2000.
116. Herbert, T. P., Fahraeus, R., Prescott, A., Lane, D. P., and Proud, C. G. Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. *Curr. Biol.*, 10: 793-798, 2000.
117. DeFatta, R. J., Li, Y., and De Benedetti, A. Selective killing of cancer cells based on translational control of a suicide gene. *Cancer Gene Ther.*, 9: 573-578, 2002.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.